WorldWideScience

Sample records for cancer institute nih

  1. Selected National Cancer Institute Breast Cancer Research Topics | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Find Out More MedlinePlus: Breast Cancer medlineplus.gov/breastcancer.html National Cancer Institute, NIH, HHS Phone Number(s): ( ... Treatment-Research-Studies MedlinePlus tutorial medlineplus.gov/tutorials/breastcancer/htm/index.htm NIH Senior Health http://nihseniorhealth. ...

  2. NIH Research Leads to Cervical Cancer Vaccine

    Science.gov (United States)

    ... NIH researchers Drs. Douglas Lowy (left) and John Schiller developed the vaccine to prevent HPV infection in ... But thanks to Drs. Douglas Lowy and John Schiller, senior research scientists at NIH's National Cancer Institute, ...

  3. NCI QuitPal, an App from the National Cancer Institute | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn Javascript on. NCI QuitPal, an App from the National Cancer Institute Past Issues / Winter ... a cigarette? NCI QuitPal is a free, interactive app for iPhone or iPad that uses proven quit ...

  4. 75 FR 20370 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-04-19

    ...@mail.nih.gov . Name of Committee: National Cancer Institute Special Emphasis Panel, Breast Cancer... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings... clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute...

  5. NIH Roadmap & the Common Fund - Cancer Imaging Program

    Science.gov (United States)

    The NIH Roadmap for Medical Research is a series of high impact, trans-NIH programs supported by the NIH Common Fund. These programs address challenges that are priorities for the NIH and medical research but are issues that require the cooperation of more than one NIH institute to address.

  6. Support for National Institutes of Health (NIH) Implementation of the Revised Public Access Policy

    OpenAIRE

    Richard K Johnson

    2008-01-01

    Comments submitted by SPARC (Scholarly Publishing and Academic Resources Coalition) in response to the U.S. National Institutes of Health (NIH) “Request for Information: NIH Public Access Policy” issued on March 31, 2008 (73 Federal Register 16881).

  7. 76 FR 9353 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2011-02-17

    ....nih.gov . Name of Committee: National Cancer Institute Special Emphasis Panel; Prostate Imaging..., Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  8. NIH scientists provide new insight into rare kidney cancer

    Science.gov (United States)

    NIH scientists have discovered a unique feature of a rare, hereditary form of kidney cancer that may provide a better understanding of its progression and metastasis, possibly laying the foundation for the development of new targeted therapies.

  9. DCP Leading NIH Glycoscience Common Fund Program; Funding Opportunities Open | Division of Cancer Prevention

    Science.gov (United States)

    NCI's Division of Cancer Prevention is a leading participant for a key initiative in the National Institutes of Health (NIH) Glycoscience Common Fund program. This program supports development of accessible and affordable new tools and technologies for studying the role complex carbohydrates in health and disease. |

  10. NIH researchers complete whole-exome sequencing of skin cancer

    Science.gov (United States)

    A team led by researchers at NIH is the first to systematically survey the landscape of the melanoma genome, the DNA code of the deadliest form of skin cancer. The researchers have made surprising new discoveries using whole-exome sequencing, an approach that decodes the 1-2 percent of the genome that contains protein-coding genes.

  11. 78 FR 44136 - Submission for OMB review; 30-day Comment Request: National Cancer Institute (NCI) Cancer...

    Science.gov (United States)

    2013-07-23

    ... HUMAN SERVICES National Institutes of Health Submission for OMB review; 30-day Comment Request: National Cancer Institute (NCI) Cancer Nanotechnology Platform Partnership Scientific Progress Reports SUMMARY... Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request for...

  12. NIH scientists identify molecular link between metabolism and breast cancer

    Science.gov (United States)

    A protein associated with conditions of metabolic imbalance, such as diabetes and obesity, may play a role in the development of aggressive forms of breast cancer, according to new findings by researchers at the National Cancer Institute (NCI), part of th

  13. Intakes of Fruit, Vegetables, and Specific Botanical Groups in Relation to Lung Cancer Risk in the NIH-AARP Diet and Health Study

    OpenAIRE

    Wright, Margaret E.; Park, Yikyung; Subar, Amy F; Neal D Freedman; Albanes, Demetrius; Hollenbeck, Albert; Leitzmann, Michael F.; Schatzkin, Arthur

    2008-01-01

    Increased fruit and vegetable consumption may protect against lung cancer, although epidemiologic findings are inconclusive. The authors prospectively examined associations between lung cancer risk and intakes of fruit, vegetables, and botanical subgroups in 472,081 participants aged 50–71 years in the National Institutes of Health (NIH)-AARP Diet and Health Study. Diet was assessed at baseline (1995–1996) with a 124-item dietary questionnaire. A total of 6,035 incident lung cancer cases were...

  14. NIH study confirms risk factors for male breast cancer

    Science.gov (United States)

    Pooled data from studies of about 2,400 men with breast cancer and 52,000 men without breast cancer confirmed that risk factors for male breast cancer include obesity, a rare genetic condition called Klinefelter syndrome, and gynecomastia.

  15. The NIH-NIAID Schistosomiasis Resource Center at the Biomedical Research Institute: Molecular Redux

    Science.gov (United States)

    Cody, James J.; Ittiprasert, Wannaporn; Miller, André N.; Henein, Lucie; Mentink-Kane, Margaret M.; Hsieh, Michael H.

    2016-01-01

    Schistosomiasis remains a health burden in many parts of the world. The complex life cycle of Schistosoma parasites and the economic and societal conditions present in endemic areas make the prospect of eradication unlikely in the foreseeable future. Continued and vigorous research efforts must therefore be directed at this disease, particularly since only a single World Health Organization (WHO)-approved drug is available for treatment. The National Institutes of Health (NIH)–National Institute of Allergy and Infectious Diseases (NIAID) Schistosomiasis Resource Center (SRC) at the Biomedical Research Institute provides investigators with the critical raw materials needed to carry out this important research. The SRC makes available, free of charge (including international shipping costs), not only infected host organisms but also a wide array of molecular reagents derived from all life stages of each of the three main human schistosome parasites. As the field of schistosomiasis research rapidly advances, it is likely to become increasingly reliant on omics, transgenics, epigenetics, and microbiome-related research approaches. The SRC has and will continue to monitor and contribute to advances in the field in order to support these research efforts with an expanding array of molecular reagents. In addition to providing investigators with source materials, the SRC has expanded its educational mission by offering a molecular techniques training course and has recently organized an international schistosomiasis-focused meeting. This review provides an overview of the materials and services that are available at the SRC for schistosomiasis researchers, with a focus on updates that have occurred since the original overview in 2008. PMID:27764112

  16. National Cancer Institute

    Science.gov (United States)

    ... Español 1-800-4-CANCER Live Chat Publications Dictionary Menu Contact Dictionary Search About Cancer Causes and Prevention Risk Factors ... Contacts Other Funding Find NCI funding for small business innovation, technology transfer, and contracts Training Cancer Training ...

  17. Lung Cancer: Early Detection is the Key | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Early Detection is the Key Past Issues / Winter ... that can cause lung cancer." The 2011 National Cancer Institute's National Lung Screening Trial showed the importance of detecting lung ...

  18. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study.

    Science.gov (United States)

    Park, Yikyung; Mitrou, Panagiota N; Kipnis, Victor; Hollenbeck, Albert; Schatzkin, Arthur; Leitzmann, Michael F

    2007-12-01

    Calcium and dairy foods in relation to prostate cancer were examined in the National Institutes of Health (NIH)-AARP (formerly known as the American Association of Retired Persons) Diet and Health Study (1995/1996-2001). Diet was assessed with a food frequency questionnaire at baseline. Multivariate relative risks and 95% confidence intervals were estimated by Cox regression. During up to 6 years of follow-up (n = 293,888), the authors identified 10,180 total prostate cancer cases (8,754 nonadvanced, 1,426 advanced, and 178 fatal cases). Total and supplemental calcium were unrelated to total and nonadvanced prostate cancer. However, a statistically nonsignificant positive association with total calcium was observed for advanced (> or = 2,000 vs. 500- or = 1,000 vs. 500-dairy foods, was associated with increased risk of advanced prostate cancer (> or = 2 vs. zero servings/day: RR = 1.23, 95% CI: 0.99, 1.54; p(trend) = 0.01). In contrast, calcium from nondairy foods was associated with lower risk of nonadvanced prostate cancer (> or = 600 vs. dairy foods increase prostate cancer risk.

  19. Trends in Research on Energy Balance Supported by the National Cancer Institute

    OpenAIRE

    Ballard-Barbash, Rachel; Siddiqi, Sameer M.; Berrigan, David A.; Ross, Sharon A.; Nebeling, Linda C.; Dowling, Emily C.

    2013-01-01

    Over the past decade, the body of research linking energy balance to the incidence, development, progression and treatment of cancer has grown substantially. No prior NIH portfolio analyses have focused on energy balance within one institute. This portfolio analysis describes the growth of National Cancer Institute (NCI) grant research on energy balance–related conditions and behaviors from 2004 to 2010 following the release of an NCI research priority statement in 2003 on energy balance and ...

  20. 75 FR 46945 - Proposed Collection; Comment Request; the Drug Accountability Record (Form NIH 2564) (NCI)

    Science.gov (United States)

    2010-08-04

    ... collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget... Respondents: Investigators, pharmacists, nurses, pharmacy technicians, and data managers. The...

  1. NIH mouse study finds gut microorganisms may determine cancer treatment outcome

    Science.gov (United States)

    An intact gut commensal microbiota, which is a population of microorganisms living in the intestine, is required for optimal response to cancer therapy, according to a mouse study by scientists at the National Cancer Institute (NCI)

  2. ICMIC Institutions - Cancer Imaging Program

    Science.gov (United States)

    ICMIC grants facilitate interaction among scientists from a variety of fields to conduct multidisciplinary research on cellular and molecular imaging related to cancer. Pre-ICMIC planning grants have provided time and funds for investigators and institutions to prepare themselves, organizationally and scientifically, to establish ICMICs.

  3. NIH study finds regular aspirin use may reduce ovarian cancer risk

    Science.gov (United States)

    Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, according to a study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health. However, further research is needed before clinical r

  4. Sleep Duration and Cancer in the NIH-AARP Diet and Health Study Cohort

    Science.gov (United States)

    Gu, Fangyi; Xiao, Qian; Chu, Lisa W.; Yu, Kai; Matthews, Charles E.; Hsing, Ann W.; Caporaso, Neil E.

    2016-01-01

    Background Very few studies have examined sleep duration in relation to cancer incidence with the exception of breast cancer. Methods We assessed the associations between sleep duration and incidences of total and 18 site-specific cancers in the NIH-AARP Health and Diet Study cohort, with 173,327 men and 123,858 women aged 51–72 years at baseline. Self-reported sleep duration categories were assessed via questionnaire. We used multivariable Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI), using 7–8 hours/night as the reference. Results We observed a significantly increased risk of stomach cancer among male short sleepers (multivariable HR5-6 vs. 7–8 hours = 1.29; 95%CI: 1.05, 1.59; Ptrend = 0.03). We also observed suggestive associations in either short or long sleepers, which did not reach overall significance (Ptrend >0.05), including increased risks in male short sleepers for cancers of head and neck (HRcancer risk (HRcancer risk (HRcancer risk (HR≥ 9 vs. 7–8 hours = 0.50; 95%CI:0.26–0.97) and an increased NHL risk (HR≥ 9 vs. 7–8 hours = 1.45; 95%CI:1.00–2.11) were observed among long sleepers. Conclusion In an older population, we observed an increased stomach cancer risk in male short sleepers and suggestive associations with short or long sleep duration for many cancer risks in both genders. PMID:27611440

  5. 75 FR 61763 - Submission of OMB Review; Comment Request; Drug Accountability Record (Form NIH 2564) (NCI)

    Science.gov (United States)

    2010-10-06

    ... collection projects, the National Cancer Institute, the National Cancer Institute (NIH) has submitted to the..., 2010 (75 FR 46945) and allowed 60 days for public comment. No public comments were received. The... institutions. Type of Respondents: Investigators, pharmacists, nurses, pharmacy technicians, and data...

  6. Mitochondrial DNA from colorectal cancer cells induces the mutation of NIH3T3 cells%大肠癌线粒体DNA诱导NIH3T3细胞D-环突变

    Institute of Scientific and Technical Information of China (English)

    姬宏莉; 姬宏娟; 宋卫兵; 马永全; 杜芳; 王辉; 肖冰

    2011-01-01

    Objective To investigate the mtDNA mutation in NIH3T3 cell, which was transfected with mutated mtDNA from colorectal cancer cell line. Methods Recombinant eukaryotic vector, expressing plasmid of the mutated mtDNA, was transfected into NIH3T3 cell using Lipofection 2000 TM and screened by G418. The mutated mtDNA of transfected NIH3T3 cell was detected by PCR. Results Mutation and polymorphism was observed in NIH3T3 cell transfected with mutated mtDNA. Conclusion MtDNA mutations in colorectal cancer cell affects NIH3T3 cell mtDNA loci, though further study is required.%目的 观察突变的大肠癌细胞线粒体DNA(mtDNA)转染 NIH3T3 细胞后转染细胞mtDNA D-环突变特性.方法 通过脂质体法(Lipofection 2000TM) 将大肠癌细胞突变的 mtDNA 真核表达载体转染 NIH3T3细胞,利用 G418 抗性筛选克隆细胞;用PCR法检测转染细胞线粒体突变情况.结果 突变mtDNA 导致转染细胞 mtDNA 的突变和多态性变化.结论 突变的大肠癌 mtDNA可致NIH3T3细胞mtDNA位点变化,但具体的机制和过程有待于进一步研究.

  7. NIH's National Institute of General Medical Sciences celebrates 45 years of Discovery for Health

    Science.gov (United States)

    ... applications. In recognition of the significance of their work, a number of NIGMS grantees have received the Nobel Prize and other high scientific honors. The Institute's research training programs help provide the next generation of scientists. " ...

  8. 11th Annual NIH Pain Consortium Symposium on Advances in Pain Research | Division of Cancer Prevention

    Science.gov (United States)

    The NIH Pain Consortium will convene the 11th Annual NIH Pain Consortium Symposium on Advances in Pain Research, featuring keynote speakers and expert panel sessions on Innovative Models and Methods. The first keynote address will be delivered by David J. Clark, MD, PhD, Stanford University entitled “Challenges of Translational Pain Research: What Makes a Good Model?” |

  9. Five Decades of Discovery: National Institute of General Medical Sciences | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... to treat cancer and prevent blood clots. Shedding light on the critical functions of carbohydrates, sugar molecules found on all living cells that are vital to fertilization, inflammation, blood clotting, and viral infection. Modeling infectious disease outbreaks and the impact of interventions ...

  10. Intakes of fruit, vegetables, and specific botanical groups in relation to lung cancer risk in the NIH-AARP Diet and Health Study.

    Science.gov (United States)

    Wright, Margaret E; Park, Yikyung; Subar, Amy F; Freedman, Neal D; Albanes, Demetrius; Hollenbeck, Albert; Leitzmann, Michael F; Schatzkin, Arthur

    2008-11-01

    Increased fruit and vegetable consumption may protect against lung cancer, although epidemiologic findings are inconclusive. The authors prospectively examined associations between lung cancer risk and intakes of fruit, vegetables, and botanical subgroups in 472,081 participants aged 50-71 years in the National Institutes of Health (NIH)-AARP Diet and Health Study. Diet was assessed at baseline (1995-1996) with a 124-item dietary questionnaire. A total of 6,035 incident lung cancer cases were identified between 1995 and 2003. Total fruit and vegetable intake was unrelated to lung cancer risk in both men and women. Higher consumption of several botanical subgroups, however, was significantly inversely associated with risk, but only in men. For example, the relative risks of lung cancer among men in the highest versus lowest quintiles of intake of rosaceae, convolvulaceae, and umbelliferae were 0.82 (95% confidence interval (CI): 0.73, 0.91), 0.86 (95% CI: 0.75, 0.96), and 0.86 (95% CI: 0.78, 0.96), respectively; corresponding relative risks in women were 0.97 (95% CI: 0.85, 1.12), 0.95 (95% CI: 0.83, 1.09), and 0.92 (95% CI: 0.80, 1.06). These results provide support for a protective role of specific botanical subgroups of fruits and vegetables in lung cancer prevention in men, although the findings could also be due to residual confounding by smoking or chance.

  11. American Institute for Cancer Research

    Science.gov (United States)

    ... Our Blog: How to make kid-friendly, tasty fruit leather with 4 ingredients Study: Now is the Lowest Weight You’ll Be All Year Cancer Research Our Cancer Research Cancer Sites Research Conference ...

  12. Evaluation of institutional cancer registries in Colombia.

    Science.gov (United States)

    Cuervo, L G; Roca, S; Rodríguez, M N; Stein, J; Izquierdo, J; Trujillo, A; Mora, M

    1999-09-01

    The four primary objectives of this descriptive study were to: 1) design a quality-measurement instrument for institutional cancer registries (ICRs), 2) evaluate the existing ICRs in Colombia with the designed instrument, 3) categorize the different registries according to their quality and prioritize efforts that will efficiently promote better registries with the limited resources available, and 4) determine the institution with the greatest likelihood of successfully establishing Colombia's second population-based cancer registry. In 1990 the National Cancer Institute of Colombia developed 13 institution-based cancer registries in different Colombian cities in order to promote the collection of data from a large group of cancer diagnostic and treatment centers. During the first half of 1997, this evaluation reviewed 12 registries; one of the original 13 no longer existed. All of the Colombian institutions (hospitals) that maintain institution-based cancer registries were included in the study. At each institution, a brief survey was administered to the hospital director, the registry coordinator, and the registrar (data manager). Researchers investigated the institutions by looking at six domains that are in standard use internationally. Within each domain, questions were developed and selected through the Delphi method. Each domain and each question were assigned weights through a consensus process. In most cases, two interviewers went to each site to collect the information. The university hospitals in Cali, Pereira, and Medellín had substantially higher scores, reflecting a good level of performance. Four of the 12 institutions had almost no cancer registry work going on. Five of the 12 hospital directors considered that the information provided by the cancer registries influenced their administrative decisions. Three of the registries had patient survival data. Four of the institutions allocated specific resources to operate their cancer registries; in the

  13. 76 FR 40736 - NIH State-of-the-Science Conference on the Role of Active Surveillance in the Management of Men...

    Science.gov (United States)

    2011-07-11

    ... HUMAN SERVICES National Institutes of Health NIH State-of-the-Science Conference on the Role of Active Surveillance in the Management of Men With Localized Prostate Cancer ACTION: Notice. Notice is hereby given of the National Institutes of Health (NIH), ``State-of-the-Science Conference on the Role of...

  14. NIH Study Finds Regular Aspirin Use May Reduce Ovarian Cancer Risk

    Science.gov (United States)

    ... NIGMS NIMH NIMHD NINDS NINR NLM CC CIT CSR FIC NCATS NCCIH OD About NIH Who We ... limited treatment options and poor prognoses, making preventive strategies potentially important for controlling this disease. Chronic or ...

  15. Single Institution Feasibility Trials - Cancer Imaging Program

    Science.gov (United States)

    Within the CIP program, the current R21 mechanism provides potential funding for small, single institution feasibility trials. The current announcement is titled In Vivo Cancer Imaging Exploratory/Developmental Grants.

  16. 75 FR 16816 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-02

    ... Committee: National Cancer Institute Special Emphasis Panel, NCI SPORE in Skin and Prostate Cancers. Date..., Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  17. 78 FR 20118 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-04-03

    ... Committee: National Cancer Institute Special Emphasis Panel; Cancer Biology and Therapy. Date: April 17... Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  18. 78 FR 25459 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-05-01

    ... Committee: National Cancer Institute Special Emphasis Panel; Cancer Therapy (Omnibus). Date: June 27-28....395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  19. 75 FR 67379 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-11-02

    ... Committee: National Cancer Institute Special Emphasis Panel; SPORE in Prostate, Skin, Pancreatic and other.... 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  20. 77 FR 67015 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-11-08

    ... Committee: National Cancer Institute Special Emphasis Panel NCI Omnibus and Cancer Therapy. Date: November... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  1. 78 FR 8157 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-02-05

    ... Committee: National Cancer Institute Special Emphasis Panel; Provocative Questions: Cancer Therapy and... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  2. 78 FR 36200 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-06-17

    ... Committee: National Cancer Institute Special Emphasis Panel; Cancer Biology and Therapy. Date: June 24, 2013... Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  3. Breast Cancer: Surgery at the South Egypt Cancer Institute

    OpenAIRE

    Salem, Ahmed A.S.; Mohamed Abou Elmagd Salem; Hamza Abbass

    2010-01-01

    Breast cancer is the most frequent malignant tumor in women worldwide. In Egypt, it is the most common cancer among women, representing 18.9% of total cancer cases (35.1% in women and 2.2% in men) among the Egypt National Cancer Institute’s (NCI) series of 10,556 patients during the year 2001, with an age-adjusted rate of 49.6 per 100,000 people. In this study, the data of all breast cancer patients presented to the surgical department of the South Egypt cancer Institute (SECI) hospital durin...

  4. NIH study finds two doses of HPV vaccine may be as protective as full course | Division of Cancer Prevention

    Science.gov (United States)

    Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up, according to researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues. The results of the study, based on data from a community-based clinical trial of Cervarix in Costa Rica, appeared online Sept.9, 2011, in the Journal of the National Cancer Institute. |

  5. 77 FR 5029 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2012-02-01

    ... 1 p.m. Agenda: 2/29--Drug Shortage--A Critical Challenge for the Cancer Community; Cancer Drug..., Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant...

  6. Cancer Survivor Eric Dishman Is On a Precision Medicine Mission | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... 19. That was the power of precision medicine.” PMI Cohort Program The PMI Cohort Program seeks to extend precision medicine to ... Thought Leader In naming Dishman director of the PMI Cohort Program, NIH Director Collins noted Dishman’s unique ...

  7. Doing business with the NIH

    Science.gov (United States)

    Ben-Menachem, Gil; Ferguson, Steven M; Balakrishnan, Krishna

    2009-01-01

    Young biotech startups can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur. PMID:16475248

  8. NIH Quickfinder and NIH MedlinePlus Advisory Group - Winter 2010 | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... 1-800-352-9424 National Institute of Nursing Research (NINR) www.ninr.nih.gov (301) 496-0207 Centers & Offices Center for Information Technology (CIT) www.cit.nih.gov (301) 594-6248 Center for Scientific Review (CSR) www.csr.nih.gov (301) 435-1115 Fogarty ...

  9. 78 FR 55750 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-11

    ... Cancer Institute Special Emphasis Panel; NCI Omnibus--Drug and Gene Delivery. Date: November 7, 2013... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  10. 77 FR 24969 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-04-26

    ... . Name of Committee: National Cancer Institute Special Emphasis Panel; SPORE in Breast, Prostate and... Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  11. 78 FR 27408 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-10

    ... Committee: National Cancer Institute Special Emphasis Panel; SBIR Topic 304 ``Development of Blood-based Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients. Date: June 4, 2013... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  12. 78 FR 41939 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-07-12

    ... Committee: National Cancer Institute Special Emphasis Panel; NCI Omnibus Review, Cancer Etiology/Genetics... Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and...

  13. Lung Cancer:Symptoms, Diagnosis, Treatments & Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Lung Cancer: Symptoms, Diagnosis, Treatments & Research Past Issues / Winter 2013 ... lung cancer are given intravenously or by mouth. Lung Cancer Research The large-scale National Lung Screening Trial, ...

  14. Lung Cancer, Questions to Ask Your Health Professional | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Questions to Ask Your Health Professional Past Issues / ... answer questions about cancer at 1-800-4-CANCER. The NCI Lung Cancer Home Page provides up-to-date information ...

  15. Lung Cancer:Symptoms, Diagnosis, Treatments & Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Lung Cancer: Symptoms, Diagnosis, Treatments & Research Past Issues / Winter ... lung cancer are given intravenously or by mouth. Lung Cancer Research The large-scale National Lung Screening ...

  16. 78 FR 58321 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-23

    ... Emphasis Panel, Provocative Questions: Cancer Therapy & Outcomes. Date: November 7-8, 2013. Time: 8:00 a.m..., Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  17. 77 FR 31030 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2012-05-24

    ...: June 27, 2012--Drug User Fee Programs, Generic Cancer Drug Shortages: Continuing the Dialogue, The Role..., Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant...

  18. Institutional shared resources and translational cancer research

    Directory of Open Access Journals (Sweden)

    De Paoli Paolo

    2009-06-01

    Full Text Available Abstract The development and maintenance of adequate shared infrastructures is considered a major goal for academic centers promoting translational research programs. Among infrastructures favoring translational research, centralized facilities characterized by shared, multidisciplinary use of expensive laboratory instrumentation, or by complex computer hardware and software and/or by high professional skills are necessary to maintain or improve institutional scientific competitiveness. The success or failure of a shared resource program also depends on the choice of appropriate institutional policies and requires an effective institutional governance regarding decisions on staffing, existence and composition of advisory committees, policies and of defined mechanisms of reporting, budgeting and financial support of each resource. Shared Resources represent a widely diffused model to sustain cancer research; in fact, web sites from an impressive number of research Institutes and Universities in the U.S. contain pages dedicated to the SR that have been established in each Center, making a complete view of the situation impossible. However, a nation-wide overview of how Cancer Centers develop SR programs is available on the web site for NCI-designated Cancer Centers in the U.S., while in Europe, information is available for individual Cancer centers. This article will briefly summarize the institutional policies, the organizational needs, the characteristics, scientific aims, and future developments of SRs necessary to develop effective translational research programs in oncology. In fact, the physical build-up of SRs per se is not sufficient for the successful translation of biomedical research. Appropriate policies to improve the academic culture in collaboration, the availability of educational programs for translational investigators, the existence of administrative facilitations for translational research and an efficient organization

  19. Smoking and Lung Cancer: It's Never Too Late To Quit | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn Javascript on. Feature: Lung Cancer Smoking and Lung Cancer: It's Never Too Late to ... getting another cancer. To get help with quitting smoking... Go online to smokefree.gov. (See this issue's ...

  20. Breast Cancer Basics and You: Staging and Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Staging and Treatment Past ... Table of Contents Staging The extent (stage) of breast cancer needs to be determined to help choose ...

  1. Breast Cancer Basics and You: Introduction | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Introduction Past Issues / Spring - ... women, although male breast cancer is rare. The Breasts Inside a woman's breast are 15 to 20 ...

  2. Breast Cancer Basics and You | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Screening For Breast Cancer Breast Cancer Basics and You Past Issues / Summer 2014 ... women, although male breast cancer is rare. The Breasts Inside a woman's breast are 15 to 20 ...

  3. Lung Cancer, Questions to Ask Your Health Professional | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Questions to Ask Your Health Professional Past Issues / ... 2013 Table of Contents Tests What type of lung cancer do I have? Has the cancer spread from ...

  4. Skin Cancer: Biology, Risk Factors & Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Skin Cancer Skin Cancer: Biology, Risk Factors & Treatment Past Issues / Summer 2013 ... Factors When you're told that you have skin cancer, it's natural to wonder what may have caused ...

  5. Skin Cancer Can Strike Anyone | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Skin Cancer Skin Cancer Can Strike Anyone Past Issues / Summer 2013 Table ... removed. That is the most common form of skin cancer and not as dangerous as melanoma. Photo: Corbis ...

  6. 75 FR 2552 - NIH State-of-the-Science Conference: Enhancing Use and Quality of Colorectal Cancer Screening

    Science.gov (United States)

    2010-01-15

    ..., including a systematic literature review commissioned through the Agency for Healthcare Research and Quality... States, the National Cancer Institute and the Office of Medical Applications of Research of the National... colorectal cancer screening? What research is needed to make the most progress and have the greatest...

  7. 78 FR 28235 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-14

    ... Diagnostic Assay to Detect Basal- like Breast Cancer. Date: June 13, 2013. Time: 12:00 p.m. to 1:00 p.m... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings... Committee: National Cancer Institute Special Emphasis Panel, Novel Imaging Agents to Expand the...

  8. 75 FR 3239 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-01-20

    ... Special Emphasis Panel, Basal-like Breast Cancer Assay. Date: March 10, 2010. Time: 8 a.m. to 7 p.m... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings... clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute...

  9. 75 FR 21002 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-04-22

    ... Panel, SPORE in Lymphoma and Breast Cancer. Date: June 15-16, 2010. Time: 5 p.m. to 5 p.m. Agenda: To... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings... Committee: National Cancer Institute Special Emphasis Panel, Drug Discovery, Chemoprevention and...

  10. 75 FR 16488 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-01

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes...

  11. 77 FR 15782 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2012-03-16

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes...

  12. 76 FR 76981 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2011-12-09

    ... Emphasis Panel, NCI SPORE in Prostate and Gastrointestinal Cancers. Date: February 15-16, 2012. Time: 8 a.m... Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  13. 78 FR 14099 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-03-04

    ... Treatment for Prostate Cancer. Date: March 28, 2013. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and... Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  14. 75 FR 54161 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-09-03

    ... Sarcoma, Brain, Liver, Lung, and Prostate Cancers. Date: September 29-30, 2010. Time: 8 a.m. to 5 p.m... Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  15. NIH Quickfinder and NIH MedlinePlus Advisory Group - Winter 2011

    Science.gov (United States)

    ... 1-800-352-9424 National Institute of Nursing Research (NINR) www.ninr.nih.gov (301) 496-0207 Centers & Offices Center for Information Technology (CIT) www.cit.nih.gov (301) 594-6248 Center for Scientific Review (CSR) www.csr.nih.gov (301) 435-1115 Fogarty ...

  16. 77 FR 54584 - Final Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH...

    Science.gov (United States)

    2012-09-05

    ... in the Federal Register (74 FR 9411) to revise the NIH Guidelines in two regards. The first was to..., NIH/OBA revised the proposal and published a notice for comment on April 22, 2010 (75 FR 21008... Involving Recombinant DNA Molecules (NIH Guidelines) SUMMARY: On March 4, 2009, the National Institutes...

  17. Braving Breast Cancer: Just Do It! | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Feature: Breast Cancer Braving Breast Cancer: Just Do It! Past Issues / Spring - Summer 2010 Table of Contents ... Photo: Jana Brightwell Jana Brightwell says, "Just Do It!" Examine your breasts every month. If you don' ...

  18. Breast Cancer Basics and You: Detection and Diagnosis | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Detection and Diagnosis Past ... healthcare provider when they have a concern." Clinical Breast Exam During a clinical breast exam, your healthcare ...

  19. Lung Cancer: Early Detection is the Key | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Early Detection is the Key Past Issues / Winter 2013 Table of Contents Lung cancer survivor Dusty Donaldson helps to spread the word ...

  20. 75 FR 60132 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-09-29

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI...; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395..., Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: September...

  1. 75 FR 71712 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-11-24

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI...; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395..., Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: November...

  2. 77 FR 43098 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2012-07-23

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93....398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated:...

  3. NIH Precision Medicine Initiative: Implications for Diabetes Research.

    Science.gov (United States)

    Fradkin, Judith E; Hanlon, Mary C; Rodgers, Griffin P

    2016-07-01

    In his January 2015 State of the Union address, President Barack Obama announced a new Precision Medicine Initiative (PMI) to personalize approaches toward improving health and treating disease (www.whitehouse.gov/precision-medicine). He stated that the goal of such an initiative was "to bring us closer to curing diseases like cancer and diabetes, and to give all of us access to the personalized information we need to keep ourselves and our families healthier." Since that time, the National Institutes of Health (NIH) has taken a leadership role in implementing the President's vision related to biomedical research (www.nih.gov/precisionmedicine). Here, we discuss the NIH component of the PMI, related ongoing diabetes research, and near-term research that could position the diabetes field to take full advantage of the opportunities that stem from the PMI. PMID:27289128

  4. 76 FR 64090 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2011-10-17

    ..., Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116....) Contact Person: Timothy C. Meeker, MD, PhD, Scientific Review Officer, Resources and Training Review... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  5. 78 FR 64507 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-10-29

    ... hereby given of meetings of the Board of Scientific Counselors for Clinical Sciences and Epidemiology National Cancer Institute and the Board of Scientific Counselors for Basic Sciences National Cancer... Counselors for Clinical Sciences and Epidemiology National Cancer Institute. Date: November 12, 2013. Time:...

  6. 78 FR 50064 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2013-08-16

    ...: 8:30 a.m. to 3:30 p.m. Agenda: Cancer Communication for Prevention: In the Digital Commons... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to... a meeting of the President's Cancer Panel. The meeting will be open to the public, with...

  7. 78 FR 69432 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2013-11-19

    ...:30 a.m. to 4:00 p.m. Agenda: Cancer Communication in the Digital Era: Opportunities and Challenges... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to... a meeting of the President's Cancer Panel. The meeting will be open to the public, with...

  8. 78 FR 53154 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-08-28

    ... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93... Emphasis Panel NCI Experimental Therapeutics--Clinical Trials Network with Phase 1 Emphasis. Date: November... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  9. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer

    Science.gov (United States)

    Scientists have mapped the genetic changes that drive tumors in rhabdomyosarcoma, a pediatric soft-tissue cancer, and found that the disease is characterized by two distinct genotypes. The genetic alterations identified in this malignancy could be useful

  10. Breast Cancer:Detection and Diagnosis | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Screening For Breast Cancer Detection and Diagnosis Past Issues / Summer 2014 ... treatment is more likely to work well. Clinical Breast Exam During a clinical breast exam, your health ...

  11. NIH study finds high cancer risk for U.S. organ transplant recipients

    Science.gov (United States)

    Organ transplant recipients in the United States have a high risk of developing 32 different types of cancer, according to a new study of transplant recipients which fully describes the range of malignancies that occur.

  12. Breast Cancer: Staging and Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... to remove or destroy cancer in the breast. Systemic Therapy Hormone therapy, chemotherapy, and targeted therapy are types of systemic therapy. They enter the bloodstream and destroy or control ...

  13. 76 FR 41273 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-07-13

    ...: Gail J Bryant, MD, Medical Officer, Resources and Training Review Branch, Division of Extramural... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  14. 78 FR 41072 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-07-09

    ... therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93..., Cancer Control, National Institutes of Health, HHS) Dated: July 2, 2013. David Clary, Program...

  15. 78 FR 66370 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-11-05

    ... therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93..., Cancer Control, National Institutes of Health, HHS). Dated: October 30, 2013. Melanie J. Gray,...

  16. 77 FR 12318 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2012-02-29

    ... outcome of the evaluation will provide information for consideration by an internal NCI committee that... Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93....398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)...

  17. 77 FR 70170 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2012-11-23

    ... therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93..., Cancer Control, National Institutes of Health, HHS) Dated: November 16, 2012. Melanie J. Gray,...

  18. NIH-supported trial drug shows benefit in children with previously treated cancers

    Science.gov (United States)

    Young patients with some types of advanced cancer, for whom standard treatment had failed, had their tumors disappear during treatment with a drug that both targets and blocks a protein associated with their disease. These findings are from a Phase I, mul

  19. NIH-funded study shows increased prostate cancer risk from vitamin E supplements | Division of Cancer Prevention

    Science.gov (United States)

    Men who took 400 international units (I.U.) of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The findings showed that, per 1,000 men, there were 76 prostate cancers in men who took only vitamin E supplements, vs. |

  20. 75 FR 7489 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-02-19

    ... Special Emphasis Panel, Portable e-Technology Diet and Physical Activity Tools for Consumers. Date: April... Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute... Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd.,...

  1. 77 FR 19024 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-03-29

    ... SPORE in Lymphoma, Leukemia, Brain, Esophageal and Gastrointestinal Cancers. Date: May 23-24, 2012. Time...., Scientific Review Officer, National Cancer Institute, Division of Extramural Activities, Research Programs... Development of Emerging Technologies for Cancer Research (R33). Date: June 14, 2012. Time: 8 a.m. to 6...

  2. 76 FR 42719 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-07-19

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel, NCI Experimental Therapeutics...

  3. 76 FR 10381 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-02-24

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  4. 75 FR 33817 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-06-15

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  5. 76 FR 66733 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-10-27

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel, NCI Experimental Therapeutics...

  6. 78 FR 15021 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-03-08

    ... therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal... Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396... Control, National Institutes of Health, HHS) Dated: March 4, 2013. Melanie J. Gray, Program...

  7. The association between selenium and other micronutrients and thyroid cancer incidence in the NIH-AARP Diet and Health Study.

    Directory of Open Access Journals (Sweden)

    Thomas J O'Grady

    Full Text Available BACKGROUND: Selenium is an essential trace element that is important for thyroid hormone metabolism and has antioxidant properties which protect the thyroid gland from oxidative stress. The association of selenium, as well as intake of other micronutrients, with thyroid cancer is unclear. METHODS: We evaluated associations of dietary selenium, beta-carotene, calcium, vitamin D, vitamin C, vitamin E, folate, magnesium, and zinc intake with thyroid cancer risk in the National Institutes of Health - American Association of Retired Persons Diet and Health Study, a large prospective cohort of 566,398 men and women aged 50-71 years in 1995-1996. Multivariable-adjusted Cox proportional hazards regression was used to examine associations between dietary intake of micronutrients, assessed using a food frequency questionnaire, and thyroid cancer cases, ascertained by linkage to state cancer registries and the National Death Index. RESULTS: With the exception of vitamin C, which was associated with an increased risk of thyroid cancer (HR(Q5 vs Q1, 1.34; 95% CI, 1.02-1.76; P(trend, <0.01, we observed no evidence of an association between quintile of selenium (HR(Q5 vs Q1, 1.23; 95% CI, 0.92-1.65; P(trend, 0.26 or other micronutrient intake and thyroid cancer. CONCLUSION: Our study does not suggest strong evidence for an association between dietary intake of selenium or other micronutrients and thyroid cancer risk. More studies are needed to clarify the role of selenium and other micronutrients in thyroid carcinogenesis.

  8. The Association between Selenium and Other Micronutrients and Thyroid Cancer Incidence in the NIH-AARP Diet and Health Study

    Science.gov (United States)

    O’Grady, Thomas J.; Kitahara, Cari M.; DiRienzo, A. Gregory; Gates, Margaret A.

    2014-01-01

    Background Selenium is an essential trace element that is important for thyroid hormone metabolism and has antioxidant properties which protect the thyroid gland from oxidative stress. The association of selenium, as well as intake of other micronutrients, with thyroid cancer is unclear. Methods We evaluated associations of dietary selenium, beta-carotene, calcium, vitamin D, vitamin C, vitamin E, folate, magnesium, and zinc intake with thyroid cancer risk in the National Institutes of Health – American Association of Retired Persons Diet and Health Study, a large prospective cohort of 566,398 men and women aged 50–71 years in 1995–1996. Multivariable-adjusted Cox proportional hazards regression was used to examine associations between dietary intake of micronutrients, assessed using a food frequency questionnaire, and thyroid cancer cases, ascertained by linkage to state cancer registries and the National Death Index. Results With the exception of vitamin C, which was associated with an increased risk of thyroid cancer (HRQ5 vs Q1, 1.34; 95% CI, 1.02–1.76; Ptrend, <0.01), we observed no evidence of an association between quintile of selenium (HRQ5 vs Q1, 1.23; 95% CI, 0.92–1.65; Ptrend, 0.26) or other micronutrient intake and thyroid cancer. Conclusion Our study does not suggest strong evidence for an association between dietary intake of selenium or other micronutrients and thyroid cancer risk. More studies are needed to clarify the role of selenium and other micronutrients in thyroid carcinogenesis. PMID:25329812

  9. How to Write an NIH R13 Conference Grant Application

    Science.gov (United States)

    Sonis, Jeffrey H.; Triffleman, Elisa; King, Lynda; King, Daniel

    2009-01-01

    Objective: The purpose of this article is to provide recommendations for writing a successful R13 conference grant proposal for the National Institutes of Health (NIH). Methods: The authors reviewed successful NIH conference grant proposal abstracts. They also reflect on their own experience in writing an NIH conference grant proposal and…

  10. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study.

    Directory of Open Access Journals (Sweden)

    Fatma M Shebl

    Full Text Available BACKGROUND: Chronic inflammation has been linked to cancers, and use of non-steroidal anti-inflammatory drugs (NSAIDs has been associated with reduced risk of several cancers. To further refine the magnitude of NSAID-related associations, in particular for cancers related to inflammation, such as alcohol-, infection-, obesity-, and smoking-related cancers, as well as for less common cancers, we evaluated the use of NSAIDs and cancer risk in a very large cohort. We used propensity scores to account for potential selection bias and hypothesized that NSAID use is associated with decreased cancer incidence. METHODS: We conducted a prospective study among 314,522 participants in the NIH-AARP Diet and Health Study. Individuals who completed the lifestyle questionnaire, which included NSAID use, in 1996-1997 were followed through 2006. Information on cancer incidence was ascertained by linking to cancer registries and vital status databases. FINDINGS: During 2,715,994 person-years of follow-up (median 10.1 person-years, there were 51,894 incident cancers. Compared with non-users of NSAIDs, individuals who reported use in the 12 months prior to interview had a significantly lower risk of all inflammation-related cancer, alcohol-related, infection-related, obesity-related, and smoking-related cancers [hazard ratio (HR (95% CI 0.90 (0.87-0.93, 0.80 (0.74-0.85, 0.82 (0.78-0.87, 0.88 (0.84-0.92, and 0.88 (0.85-0.92 respectively]. CONCLUSIONS: After accounting for potential selection bias, our data showed an inverse association between NSAID use and alcohol-related, infection-related, obesity-related, and smoking-related cancers and support the hypothesis that inflammation is related to an increased risk of certain cancers.

  11. Licensing Opportunities for NIH, CDC & FDA Technologies

    Data.gov (United States)

    U.S. Department of Health & Human Services — This dataset represents all technologies available for licensing from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the...

  12. NIH/NSF accelerate biomedical research innovations

    Science.gov (United States)

    A collaboration between the National Science Foundation and the National Institutes of Health will give NIH-funded researchers training to help them evaluate their scientific discoveries for commercial potential, with the aim of accelerating biomedical in

  13. Welcome to NIH MedlinePlus magazine!

    Science.gov (United States)

    ... Current Issue Past Issues Welcome to NIH MedlinePlus magazine! Past Issues / Winter 2009 Table of Contents For ... Produced by the National Institutes of Health, the magazine and its companion Web site medlineplus.gov are ...

  14. Survey of Community Engagement in NIH-Funded Research

    OpenAIRE

    Hood, Nancy E.; Brewer, Tracy; Jackson, Rebecca; Wewers, Mary Ellen

    2010-01-01

    Community engagement is an innovative and required component for Clinical and Translational Science Awards (CTSAs) funded by the National Institutes of Health (NIH). However, the extent of community engagement in NIH-funded research has not been previously examined. This study assessed baseline prevalence of community engagement activities among NIH-funded studies at a large Midwestern university with a CTSA. An online survey was e-mailed to principal investigators of recent NIH-funded studie...

  15. Monsanto may bypass NIH in microbe test.

    Science.gov (United States)

    Sun, Marjorie

    1985-01-11

    The Monsanto Company is planning to ask the Environmental Protection Agency for clearance to field test a genetically engineered microbial pesticide, bypassing the traditional approval process of the National Institutes of Health. Although only federally funded institutions are required to obtain NIH approval for genetic engineering tests, Monsanto is the first company to bypass the NIH regulatory process, which has become mired in a lawsuit brought by Jeremy Rifkin.

  16. 75 FR 42114 - Office of Biotechnology Activities; Recombinant DNA Research: Proposed Action Under the NIH...

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA Research: Proposed Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH... transgenic rodents by recombinant DNA technology must be registered with the Institutional...

  17. 76 FR 1625 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-01-11

    ... Committee: National Cancer Institute Initial Review Group; Subcommittee I--Career Development, Career Development. Date: February 22-23, 2011. Time: February 22, 2011, 8 a.m. to 6 p.m. Agenda: To review...

  18. 75 FR 48699 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-08-11

    ... Committee: National Cancer Institute Initial Review Group, Subcommittee I--Career Development, NCI-I Career Development. Date: September 21, 2010. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate...

  19. 78 FR 50065 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-08-16

    ... Roberson, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural... Rockville Pike, Rockville, MD 20852. Contact Person: Robert Bird, Ph.D., Chief, Resources and Training... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  20. 78 FR 30933 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-23

    ...: Robert Bird, Ph.D., Chief, Resources and Training Review Branch, Division of Extramural Activities... Person: Timothy C. Meeker, MD, Ph.D., Scientific Review Officer, Resources and Training Review Branch... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  1. Dana-Farber Cancer Institute | Office of Cancer Genomics

    Science.gov (United States)

    Functional Annotation of Cancer Genomes Principal Investigator: William C. Hahn, M.D., Ph.D. The comprehensive characterization of cancer genomes has and will continue to provide an increasingly complete catalog of genetic alterations in specific cancers. However, most epithelial cancers harbor hundreds of genetic alterations as a consequence of genomic instability. Therefore, the functional consequences of the majority of mutations remain unclear.

  2. NIH Quickfinder and NIH MedlinePlus Advisory Group - Summer 2009

    Science.gov (United States)

    ... Current Issue Past Issues NIH Quickfinder Past Issues / Summer 2009 Table of Contents For an enhanced version ... Institute of Arthritis and Musculoskeletal and Skin Diseases Summer 2009 Issue: Volume 4 Number 3 Page 29

  3. Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP Diet and Health Study

    International Nuclear Information System (INIS)

    Despite strong evidence of an inverse association of physical activity with postmenopausal breast cancer risk, whether a certain intensity or time of life of physical activity is most effective for lowering breast cancer risk is not known. In 118,899 postmenopausal women in the prospective NIH-AARP Diet and Health Study, we examined the relations of light and moderate-to-vigorous intensity physical activity during four periods of life ('historical': ages 15-18, 19-29, 35-39 years; 'recent': past 10 years) to postmenopausal breast cancer risk. Physical activity was assessed by self-report at baseline, and 4287 incident breast cancers were identified over 6.6 years of follow-up. In age-adjusted and multivariate Cox regression models, >7 hours/week of moderate-to-vigorous activity during the past 10 years was associated with 16% reduced risk of postmenopausal breast cancer (RR:0.84; 95%CI:0.76,0.93) compared with inactivity. The association remained statistically significant after adjustment for BMI (RR:0.87; 95%CI:0.78,0.96). Neither moderate-to-vigorous activity during other periods of life nor light intensity activity during any period of life was related to breast cancer risk, and associations did not vary by tumor characteristics. A high level of recent, but not historical, physical activity of moderate-to-vigorous intensity is associated with reduced postmenopausal breast cancer risk. More precise recall of recent physical activity than activity in the distant past is one possible explanation for our findings

  4. Altered gene expression profiles of NIH3T3 cells regulated by human lung cancer associated gene CT120

    Institute of Scientific and Technical Information of China (English)

    Xiang Huo HE; Jin Jun LI; Yi Hu XIE; Yun Tian TANG; Gen Fu YAO; Wen Xin QIN; Da Fang WAN; Jian Ren GU

    2004-01-01

    CT120, a novel membrane-associated gene implicated in lung carcinogenesis, was previously identified from chromosome 17p13.3 locus, a hot mutation spot involved in human malignancies. In the present study, we further determined that CT120 ectopic expression could promote cell proliferation activity of NIH3T3 cells using MTS assay, and monitored the downstream effects of CT120 in NIH3T3 cells with Atlas mouse cDNA expression arrays. Among 588known genes, 133 genes were found to be upregulated or downregulated by CT120. Two major signaling pathways involved in cell proliferation, cell survival and anti-apoptosis were overexpressed and activated in response to CT120:One is the Raf/MEK/Erk signal cascades and the other is the PI3K/Akt signal cascades, suggesting that CT120 might contribute, at least in part, to the constitutively activation of Erk and Akt in human lung caner cells. In addition, some tumor metastasis associated genes cathepsin B, cathepsin D, cathepsin L, MMP-2/TIMP-2 were also upregulated by CT120, upon which CT120 might be involved in tumor invasiveness and metastasis. In addition, CT120 might play an important role in tumor progression through modulating the expression of some candidate "Lung Tumor Progression"genes including B-Raf, Rab-2, BAX, BAG-1, YB-1, and Cdc42.

  5. We Can! | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... was entitled "Staying Healthy Together." NIH Promotes Healthier Children We Can! is a national childhood obesity prevention program sponsored by the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Eunice Kennedy ...

  6. NIH funding for disease categories related to neurodegenerative diseases

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    @@ Introduction The National Institutes of Health (NIH), a part of the U.S.Department of Health and Human Services, is the nation's medical research agency-making important discoveries that improve health and save lives.Thanks in large part to NIH-funded medical research, Americans today are living longer and healthier.The NIH invests over $31.2* billion annually in medical research for the American people.More than 80% of the NIH's funding is awarded through almost 50 000 competitive grants to more than 325 000 researchers at over 3 000 universities, medical schools, and other research institutions in every state and around the world.

  7. Adolescent and mid-life diet and subsequent risk of thyroid cancer in the NIH-AARP diet and health study.

    Science.gov (United States)

    Braganza, Melissa Z; Potischman, Nancy; Park, Yikyung; Thompson, Frances E; Hollenbeck, Albert R; Kitahara, Cari M

    2015-11-15

    Although thyroid cancer is suspected to have a nutritional etiology, prospective studies examining the relationship between diet and thyroid cancer are lacking. During 1996-1997, NIH-AARP Diet and Health Study participants, ages 51-72 years, completed a 37-item food frequency questionnaire about diet at ages 12-13 years (adolescence) and 10 years before baseline (mid-life). Over a median 10 years of follow-up, 325 individuals (143 men and 182 women) were diagnosed with thyroid cancer. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for intakes of foods and food groups comparing the highest to the lowest quartiles. Adolescent intakes of chicken/turkey (HR = 1.59, 95% CI: 0.97-2.60; ptrend  diet, mid-life intake of sweet baked goods was nonsignificantly associated with an increased risk of thyroid cancer (HR = 1.39, 95% CI: 0.96-2.00; ptrend  = 0.11), but intake of butter/margarine was inversely associated with risk (HR = 0.66, 95% CI: 0.46-0.95; ptrend  = 0.03). Among men, higher adolescent consumption of canned tuna was positively associated with risk of thyroid cancer (HR = 1.69, 95% CI: 1.01-2.83; ptrend  = 0.03), and greater mid-life intake of broccoli was associated with a twofold increased risk (HR = 2.13, 95% CI: 1.13-3.99; ptrend  diet, including iodine-rich foods and goitrogens, may influence thyroid cancer risk.

  8. The Regina Elena National Cancer Institute process of accreditation according to the standards of the Organisation of European Cancer Institutes.

    Science.gov (United States)

    Canitano, Stefano; Di Turi, Annunziata; Caolo, Giuseppina; Pignatelli, Adriana C; Papa, Elena; Branca, Marta; Cerimele, Marina; De Maria, Ruggero

    2015-01-01

    The accreditation process is, on the one hand, a tool used to homogenize procedures, rendering comparable and standardized processes of care, and on the other, a methodology employed to develop a culture of quality improvement. Although not yet proven by evidence-based studies that health outcomes improve as a result of an accreditation to excellence, it is undeniable that better control of healthcare processes results in better quality and safety of diagnostic and therapeutic pathways. The Regina Elena National Cancer Institute underwent the accreditation process in accordance with the standards criteria set by the Organisation of European Cancer Institutes (OECI), and it has recently completed the process, acquiring its designation as a Comprehensive Cancer Center (CCC). This was an invaluable opportunity for the Regina Elena Institute to create a more cohesive environment, to widely establish a culture of quality, to implement an institutional information system, and to accelerate the process of patient involvement in strategic decisions. The steps of the process allowed us to evaluate the performance and the organization of the institute and put amendments in place designed to be adopted through 26 improvement actions. These actions regarded several aspects of the institute, including quality culture, information communication technology system, care, clinical trials unit, disease management team, nursing, and patient empowerment and involvement. Each area has a timeline. We chose to present the following 3 improvement actions: clinical trial center, computerized ambulatory medical record, and centrality of patient and humanization of clinical pathway.

  9. 78 FR 69858 - National Cancer Institute; Amended Notice of Meeting

    Science.gov (United States)

    2013-11-21

    ... following agenda topics will be discussed: Proposed organizational change: DEA, Biomedical Cloud Technology, Optimizing Big Data to Advance Research, and Advocate and Organizational Engagement. Dated: November 15, 2013... is hereby given of a change in the meeting of the National Cancer Institute Director's...

  10. New Hires at the National Cancer Institute at Frederick | Poster

    Science.gov (United States)

    Fifty-one people joined the facility in November and December 2013. The National Cancer Institute welcomes… Emily Boward Emad Darvishi Shuo Gu Sanath Kumar Janaka Robert Kortum Yasmin Lachir Jinbian Liu Yang Liu Eric Ramirez Salazar Brett Shelley Li Xia Jaeho Yoon

  11. Gastrointestinal Tumor Board: An Evolving Experience in Tehran Cancer Institute

    Directory of Open Access Journals (Sweden)

    Peiman Haddad

    2013-04-01

    Full Text Available Gastrointestinal (GI cancers are a significant source of morbidity and mortality in Iran, with stomach adenocarcinoma as the most common cancer in men and the second common cancer in women. Also, some parts of Northern Iran have one of the highest incidences of esophageal cancer in the world. Multi-disciplinary organ-based joint clinics and tumor boards are a well-recognized necessity for modern treatment of cancer and are routinely utilized in developed countries, especially in major academic centres. But this concept is relatively new in developing countries, where cancer treatment centres are burdened by huge loads of patients and have to cope with a suboptimum availability of resources and facilities. Cancer Institute of Tehran University of Medical Sciences is the oldest and the only comprehensive cancer treatment centre in Iran, with a long tradition of a general tumor board for all cancers. But with the requirements of modern oncology, there has been a very welcome attention to sub-specialized organ-based tumor boards and joint clinics here in the past few years. Considering this, we started a multi-disciplinary tumor board for GI cancers in our institute in early 2010 as the first such endeavor here. We hereby review this 2-year evolving experience. The process of establishment of a GI tumor board, participations from different oncology disciplines and related specialties, the cancers presented and discussed in the 2 years of this tumor board, the general intents of treatment for the decisions made and the development of interest in this tumor board among the Tehran oncology community will be reviewed. The GI tumor board of Tehran Cancer Institute started its work in January 2010, with routine weekly sessions. A core group of 2 physicians from each surgical, radiation and medical oncology departments plus one gastroenterologist, GI pathologist and radiologist was formed, but participation from all interested physicians was encouraged. An

  12. New Cancer Prevention and Control Central Institutional Review Board Established | Division of Cancer Prevention

    Science.gov (United States)

    The NCI Central Institutional Review Board (CIRB) Initiative announced the establishment of the Cancer Prevention and Control (CPC) CIRB January 14, extending the benefits of centralized review to investigators participating in clinical trials sponsored by the Division of Cancer Prevention (DCP). |

  13. Cancer Genome Anatomy Project | Office of Cancer Genomics

    Science.gov (United States)

    The National Cancer Institute (NCI) Cancer Genome Anatomy Project (CGAP) is an online resource designed to provide the research community access to biological tissue characterization data. Request a free copy of the CGAP Website Virtual Tour CD from ocg@mail.nih.gov.

  14. 75 FR 63494 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2010-10-15

    ... Report: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentations; Reports... entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will...

  15. 76 FR 72956 - Submission for OMB Review; Comment Request; Cancer Risk in U.S. Radiologic Technologists: Fourth...

    Science.gov (United States)

    2011-11-28

    ... HUMAN SERVICES National Institutes of Health Submission for OMB Review; Comment Request; Cancer Risk in...)(1)(D) of the Paperwork Reduction Act of 1995, the National Cancer Institute, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review...

  16. 78 FR 76311 - Submission for OMB Review; 30-Day Comment Request: Outcomes Evaluation of the National Cancer...

    Science.gov (United States)

    2013-12-17

    ... HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request: Outcomes Evaluation of the National Cancer Institute (NCI) Cancer Prevention Fellowship Program (CPFP) SUMMARY: Under... Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request to...

  17. Northeast Regional Cancer Institute's Cancer Surveillance and Risk Factor Program

    Energy Technology Data Exchange (ETDEWEB)

    Lesko, Samuel M.

    2007-07-31

    OBJECTIVES The Northeast Regional Cancer Institute is conducting a program of ongoing epidemiologic research to address cancer disparities in northeast Pennsylvania. Of particular concern are disparities in the incidence of, stage at diagnosis, and mortality from colorectal cancer. In northeast Pennsylvania, age-adjusted incidence and mortality rates for colorectal cancer are higher, and a significantly smaller proportion of new colorectal cancer cases are diagnosed with local stage disease than is observed in comparable national data. Further, estimates of the prevalence of colorectal cancer screening in northeast Pennsylvania are lower than the US average. The Northeast Regional Cancer Institute’s research program supports surveillance of common cancers, investigations of cancer risk factors and screening behaviors, and the development of resources to further cancer research in this community. This project has the following specific objectives: I. To conduct cancer surveillance in northeast Pennsylvania. a. To monitor incidence and mortality for all common cancers, and colorectal cancer, in particular, and b. To document changes in the stage at diagnosis of colorectal cancer in this high-risk, underserved community. II. To conduct a population-based study of cancer risk factors and screening behavior in a six county region of northeast Pennsylvania. a. To monitor and document changes in colorectal cancer screening rates, and b. To document the prevalence of cancer risk factors (especially factors that increase the risk of colorectal cancer) and to identify those risk factors that are unusually common in this community. APPROACH Cancer surveillance was conducted using data from the Northeast Regional Cancer Institute’s population-based Regional Cancer Registry, the Pennsylvania Cancer Registry, and NCI’s SEER program. For common cancers, incidence and mortality were examined by county within the region and compared to data for similar populations in the US

  18. 75 FR 28811 - Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH...

    Science.gov (United States)

    2010-05-24

    ... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH... DNA Advisory Committee and approved by the NIH Director (Section III-A-1). Such research involves...

  19. Cooperative research and development opportunities with the National Cancer Institute

    Science.gov (United States)

    Sybert, Kathleen

    1991-01-01

    The Office of Technology Development (OTD) of the National Cancer Institute (NCI) is responsible for negotiating Cooperative Research and Development Agreements (CRADAs), whereby the knowledge resulting from NCI investigators' government-sponsored research is developed in collaboration with universities and/or industry into new products of importance for the diagnosis and treatment of cancer and acquired immunodeficiency syndrome (AIDS). The NCI has recently executed a unique 'clinical trials' CRADA and is developing a model agreement based upon it for the development and commercialization of products for the diagnosis and treatment of cancer and AIDS. NCI drug screening, preclinical testing, clinical trials, and AIDS program capabilities form the basis for this new technology development/technology transfer vehicle. NCI's extensive drug screening program and 'designer foods' program serve as potential sources of investigational new drugs (INDs) and cancer preventatives. Collaborations between NCI and pharmaceutical companies having the facilities, experience, and expertise necessary to develop INDs into approved drugs available to the public are being encouraged where the companies have proprietary rights to INDs, or where NCI has proprietary rights to INDs and invites companies to respond to a collaborator announcement published in the Federal Register. The joint efforts of the NCI and the chosen collaborator are designed to generate the data necessary to obtain pharmaceutic regulatory approval from the Food and Drug Administration (FDA) to market the drugs developed, and thereby make them available to health care providers for the diagnosis and treatment of cancer and AIDS.

  20. NIH Data Sharing Repositories

    Data.gov (United States)

    U.S. Department of Health & Human Services — A list of NIH-supported repositories that accept submissions of appropriate scientific research data from biomedical researchers. It includes resources that...

  1. NIH Clinical Centers

    Data.gov (United States)

    Federal Laboratory Consortium — The NIH Clinical Center consists of two main facilities: The Mark O. Hatfield Clinical Research Center, which opened in 2005, houses inpatient units, day hospitals,...

  2. Cooperative Research and Development Agreement (CRADA) Opportunities from NIH

    Data.gov (United States)

    U.S. Department of Health & Human Services — This RSS Feed represents all Collaborative Research and Development (CRADA) opportunities available from the National Institutes of Health (NIH).The intent of...

  3. Treating Alcohol Problems | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... in NIAAA's Rethinking Drinking, an easy-to-use website and publication. A new resource from NIH's National Institute on Alcohol Abuse and Alcoholism (NIAAA), Treatment for Alcohol Problems: Finding and Getting Help , will help individuals and ...

  4. Cancer complementary and alternative medicine research at the US National Cancer Institute.

    Science.gov (United States)

    Jia, Libin

    2012-05-01

    The United States National Cancer Institute (NCI) supports complementary and alternative medicine (CAM) research which includes different methods and practices (such as nutrition therapies) and other medical systems (such as Chinese medicine). In recent years, NCI has spent around $120 million each year on various CAM-related research projects on cancer prevention, treatment, symptom/side effect management and epidemiology. The categories of CAM research involved include nutritional therapeutics, pharmacological and biological treatments, mind-body interventions, manipulative and body based methods, alternative medical systems, exercise therapies, spiritual therapies and energy therapies on a range of types of cancer. The NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) supports various intramural and extramural cancer CAM research projects. Examples of these cancer CAM projects are presented and discussed. In addition, OCCAM also supports international research projects.

  5. 75 FR 51830 - National Cancer Institute's Best Practices for Biospecimen Resources

    Science.gov (United States)

    2010-08-23

    ... HUMAN SERVICES National Institutes of Health National Cancer Institute's Best Practices for Biospecimen... best practices, the National Cancer Institute (NCI) is seeking public comment on a revised version of the NCI Best Practices for Biospecimen Resources. This revised version of the NCI Best Practices...

  6. 75 FR 63489 - Proposed Collection; Comment Request; NIH Office of Intramural Training & Education Application

    Science.gov (United States)

    2010-10-15

    ... educational level individuals into the National Institutes of Health Intramural Research Program (NIH-IRP) to..., resume ] components, employment history, employment interests, dissertation research details, letters...

  7. 76 FR 5181 - Proposed Collection; Comment Request; NIH Office of Intramural Training & Education Application

    Science.gov (United States)

    2011-01-28

    ... educational level individuals into the National Institutes of Health Intramural Research Program (NIH-IRP) to..., resume components, employment history, employment interests, dissertation research details, letters...

  8. Estimating the NIH efficient frontier.

    Directory of Open Access Journals (Sweden)

    Dimitrios Bisias

    Full Text Available BACKGROUND: The National Institutes of Health (NIH is among the world's largest investors in biomedical research, with a mandate to: "…lengthen life, and reduce the burdens of illness and disability." Its funding decisions have been criticized as insufficiently focused on disease burden. We hypothesize that modern portfolio theory can create a closer link between basic research and outcome, and offer insight into basic-science related improvements in public health. We propose portfolio theory as a systematic framework for making biomedical funding allocation decisions-one that is directly tied to the risk/reward trade-off of burden-of-disease outcomes. METHODS AND FINDINGS: Using data from 1965 to 2007, we provide estimates of the NIH "efficient frontier", the set of funding allocations across 7 groups of disease-oriented NIH institutes that yield the greatest expected return on investment for a given level of risk, where return on investment is measured by subsequent impact on U.S. years of life lost (YLL. The results suggest that NIH may be actively managing its research risk, given that the volatility of its current allocation is 17% less than that of an equal-allocation portfolio with similar expected returns. The estimated efficient frontier suggests that further improvements in expected return (89% to 119% vs. current or reduction in risk (22% to 35% vs. current are available holding risk or expected return, respectively, constant, and that 28% to 89% greater decrease in average years-of-life-lost per unit risk may be achievable. However, these results also reflect the imprecision of YLL as a measure of disease burden, the noisy statistical link between basic research and YLL, and other known limitations of portfolio theory itself. CONCLUSIONS: Our analysis is intended to serve as a proof-of-concept and starting point for applying quantitative methods to allocating biomedical research funding that are objective, systematic, transparent

  9. CPTAC Establishes Formal Relationships with Two Academic Institutions in Taiwan - Office of Cancer Clinical Proteomics Research

    Science.gov (United States)

    The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) has entered into memorandum of understandings (MOUs) with Chang Gung University and Academia Sinica, in Taipei, Taiwan.

  10. Cancer immunotherapy out of the gate: the 22nd annual Cancer Research Institute International Immunotherapy Symposium.

    Science.gov (United States)

    Tontonoz, Matthew; Gee, Connie E

    2015-05-01

    The 22nd annual Cancer Research Institute (CRI) International Immunotherapy Symposium was held from October 5-8, 2014, in New York City. Titled "Cancer Immunotherapy: Out of the Gate," the symposium began with a Cancer Immunotherapy Consortium satellite meeting focused on issues in immunotherapy drug development, followed by five speaker sessions and a poster session devoted to basic and clinical cancer immunology research. The second annual William B. Coley lecture was delivered by Lieping Chen, one of the four recipients of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology; the other three recipients were Gordon Freeman, Tasuku Honjo, and Arlene Sharpe. Prominent themes of the conference were the use of genomic technologies to identify neoantigens and the emergence of new immune modulatory molecules, beyond CTLA-4 and PD-1/PD-L1, as new therapeutic targets for immunotherapy. PMID:25941356

  11. Cancer immunotherapy out of the gate: the 22nd annual Cancer Research Institute International Immunotherapy Symposium.

    Science.gov (United States)

    Tontonoz, Matthew; Gee, Connie E

    2015-05-01

    The 22nd annual Cancer Research Institute (CRI) International Immunotherapy Symposium was held from October 5-8, 2014, in New York City. Titled "Cancer Immunotherapy: Out of the Gate," the symposium began with a Cancer Immunotherapy Consortium satellite meeting focused on issues in immunotherapy drug development, followed by five speaker sessions and a poster session devoted to basic and clinical cancer immunology research. The second annual William B. Coley lecture was delivered by Lieping Chen, one of the four recipients of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology; the other three recipients were Gordon Freeman, Tasuku Honjo, and Arlene Sharpe. Prominent themes of the conference were the use of genomic technologies to identify neoantigens and the emergence of new immune modulatory molecules, beyond CTLA-4 and PD-1/PD-L1, as new therapeutic targets for immunotherapy.

  12. ISS-NIH Collaborative Programme: final report of the projects

    International Nuclear Information System (INIS)

    In July 2003, the National Institutes of Health (NIH) of the United States of America and the Istituto Superiore di Sanita (ISS) of Italy signed an agreement aimed at strengthening the ongoing research cooperation between USA and Italy. Over the years, the programme was able to create new partnerships and to foster the establishment of innovative synergies, the exchange of young researcher, and the merging of the best available skills, talents and know-how in different fields of biomedical sciences. This book contains the final report of the projects of the scientific cooperation between the two Countries. The report consists of two parts (in Italian and English) divided into four sections: Cancer, Neuroscience, Cardiovascular diseases, Infectious diseases

  13. Contact | Office of Cancer Genomics

    Science.gov (United States)

    For more information about the Office of Cancer Genomics, please contact: Office of Cancer Genomics National Cancer Institute 31 Center Drive, 10A07 Bethesda, Maryland 20892-2580 Phone: (301) 451-8027 Fax: (301) 480-4368 Email: ocg@mail.nih.gov *Please note that this site will not function properly in Internet Explorer unless you completely turn off the Compatibility View*

  14. 77 FR 41191 - Proposed Collection; Comment Request: Effectiveness of the NIH Curriculum Supplements Programs

    Science.gov (United States)

    2012-07-12

    ... teach science by featuring the latest NIH research and utilized research-based instructional methods. A... collection projects, the Office of Science Education, the National Institutes of Health (NIH), will publish... collection of information, contact Lisa Strauss, Office of Science Education, National Institutes of...

  15. The national cancer institute (NCI) and cancer biology in a 'post genome world'

    International Nuclear Information System (INIS)

    The National Cancer Institute (NCI) exists to reduce the burden of all cancers through research and discovery. Extensive restructuring of the NCI over the past year has been aimed at assuring that the institution functions in all ways to promote opportunities for discovery in the laboratory, in the clinic, and in the community. To do this well requires the difficult and almost paradoxical problem of planning for scientific discovery which, in turn is based on the freedom to pursue the unanticipated. The intellectual and structural landscape of science is changing and it places new challenges, new demands and new opportunities for facilitating discovery. The nature of cancer as a disease of genomic instability and of accumulated genetic change, coupled with a possibility of the development of new technologies for reading, utilizing, interpreting and manipulating the genome of single cells, provides unprecedented opportunities for a new type of high through-put biology that will change the nature of discovery, cancer detection, diagnosis, prognosis, therapeutic decision-making and therapeutic discovery. To capture these new opportunities will require attention to be paid to integrate the development of technology and new scientific discoveries with the ability to apply advances rapidly and efficiently through clinical trials

  16. NIH Exported Research Portfolio Online Reporting Tools: Expenditures and Results (ExPORTER)

    Data.gov (United States)

    National Institutes of Health, Department of Health and Human Services — Research projects funded by the National Institutes of Health (NIH), other DHHS Operating Divisions (AHRQ, CDC, FDA, HRSA, SAMHSA), and the Department of Veterans...

  17. NIH Health Disparities Strategic Plan, Fiscal Years 2004-2008

    Science.gov (United States)

    National Human Genome Research Institute, 2008

    2008-01-01

    The National Human Genome Research Institute (NHGRI) led the National Institutes of Health's (NIH) contribution to the International Human Genome Project, whose primary goal was the sequencing of the human genome. This project was successfully completed in April 2003. Now, the NHGRI's mission is focused on a broad range of studies aimed at…

  18. 75 FR 992 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2010-01-07

    ... personal privacy. Name of Committee: National Cancer Advisory Board; Ad Hoc Subcommittee on Experimental Therapeutics. Open: February 8, 2010, 6:30 p.m. to 8 p.m. Agenda: Discussion on cancer experimental... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research;...

  19. Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers.

    Science.gov (United States)

    Deriu, Pier Luigi; La Pietra, Leonardo; Pierotti, Marco; Collazzo, Raffaele; Paradiso, Angelo; Belardelli, Filippo; De Paoli, Paolo; Nigro, Aldo; Lacalamita, Rosanna; Ferrarini, Manlio; Pelicci, Piergiuseppe; Pierotti, Marco; Roli, Anna; Ciliberto, Gennaro; Scala, Stefania; Amadori, Alberto; Chiusole, Daniela; Musto, Pellegrino; Fusco, Vincenzo; Storto, Giovanni; De Maria, Ruggero; Canitano, Stefano; Apolone, Giovanni; Ravelli, Maria; Mazzini, Elisa; Amadori, Dino; Bernabini, Marna; Ancarani, Valentina; Lombardo, Claudio

    2013-01-01

    A panel of experts from Italian Comprehensive Cancer Centers defines the recommendations for external quality control programs aimed to accreditation to excellence of these institutes. After definition of the process as a systematic, periodic evaluation performed by an external agency to verify whether a health organization possesses certain prerequisites regarding structural, organizational and operational conditions that are thought to affect health care quality, the panel reviews models internationally available and makes final recommendations on aspects considered of main interest. This position paper has been produced within a special project of the Ministry of Health of the Italian Government aimed to accredit, according to OECI model, 11 Italian cancer centers in the period 2012-2014. The Project represents the effort undertaken by this network of Comprehensive Cancer Centers to find a common denominator for the experience of all Institutes in external quality control programs. Fourteen shared "statements" are put forth, designed to offer some indications on the main aspects of this subject, based on literature evidence or expert opinions. They deal with the need for "accountability" and involvement of the entire organization, the effectiveness of self-evaluation, the temporal continuity and the educational value of the experience, the use of indicators and measurement tools, additionally for intra- and inter-organization comparison, the system of evaluation models used, the provision for specific requisites for oncology, and the opportunity for mutual exchange of evaluation experiences. PMID:24503807

  20. Intake of Fruits and Vegetables, and Risk of Endometrial Cancer in Women in the NIH-AARP Diet and Health Study

    OpenAIRE

    Kabat, Geoffrey C; Park, Yikyung; Hollenbeck, Albert R.; Schatzkin, Arthur; Rohan, Thomas E.

    2010-01-01

    Fruits and vegetables contain a wide variety of phytochemicals which may have anti-carcinogenic effects. Although the results of case-control studies have suggested a possible protective effect of fruit and vegetable intake on the risk of endometrial carcinoma, few cohort studies have examined this association. We used data from the NIH-AARP Diet and Health Study to assess the association of fruit and vegetable consumption, as well as intake of specific botanical groupings of fruits and veget...

  1. Prevalence of bone marrow necrosis in Egyptian cancer patients referring to the National Cancer Institute

    International Nuclear Information System (INIS)

    Bone marrow necrosis; Egyptian cancer patients Abstract Background: Bone marrow necrosis is a relatively rare entity which has been associated with a poor prognosis. It is most commonly found in patients with neoplastic disorders and severe infections. Methods: study comprised examination of 5043 bone marrow biopsy specimens performed at the National Cancer Institute, Cairo University, over 7 years period (March 2004-March 2011). It included 5 years retrospective (2867 archived samples) and 2 years prospective (2176 samples). Results: Bone marrow necrosis was diagnosed in fifteen out of 5043 examined specimens with a percentage of 0.3% and ranged from mild to massive according to semiquantitative estimation. Prognosis of all patients was poor with survival not exceeding 6 months from the date of marrow necrosis diagnosis. Conclusion: In Egyptian patients, bone marrow necrosis in association with malignancy is a rare disorder which is accompanied by a poor outcome

  2. [Cancer between infection and heredity: genes, viruses and mice at National Cancer Institute (1937-1977)].

    Science.gov (United States)

    Gaudillière, J P

    1994-01-01

    After World War II, in the United States,viral explanation of cancer replaced a vision of the disease emphasizing genetic factors. From the mid 1950s onwards, experimental oncologists favored the notion that cancer was initiated by infectious agents passed from one generation to the next. In order to analyze this displacement, the present paper focuses on the part played by new experimental systems, i.e. mice showing tumors induced by viruses. Since animal models are agencies which "represent" human diseases, and mediate between different social worlds, their uses often result in opposing views. Mouse models thus provided tractable resources which favored the alternation between heredity and infection. The paper describes the emergence, in the late 1930s, at the Jackson Memorial Laboratory, of an agent enhancing the formation of mammary tumors in mice. This laboratory was then involved in the production of marketable inbred mice as well as in research concerned with genetic factors that may cause cancer. After World War II, loose theories and conflicting results helped turn the agent into a virus. At the National Cancer Institute, the virus was associated with a whole range of particles causing leukemia in mice. Owing to the Virus Cancer Program, the value of mouse tumor viruses increased in the late 1960s. This research effort then aimed at finding human tumor viruses, and at crafting cancer vaccines. It was modeled after the experience of the NCI chemotherapy program stemming from war research. In addition to the fact that biomedical research became a state enterprise, the study emphasizes three parameters. First, loose practices--both theoretical and experimental--helped manage the variability of animal models. Secondly, the standardization and mass production of animals and reagents encouraged the stabilization of research programs. Thirdly, private biotechnology companies working under NCI contracts implemented preclinical work, and mediated between virology

  3. The relationship between National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI)and serum high sensitivity C-reactive protein (Hs-CRP) level in Fangchengang area male residents%广西防城港地区男性居民慢性前列腺炎症状指数和血清 Hs-CRP 的关系

    Institute of Scientific and Technical Information of China (English)

    牛得草; 米华; 陶佳意; 余小祥; 莫曾南

    2016-01-01

    目的:探讨广西防城港地区男性居民的美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)和血清超敏C 反应蛋白(Hs-CRP)水平的关系。方法对广西防城港地区男性居民进行大型横断面健康调查。采用标准设计生活方式的调查问卷采集试验数据,包括 NIH-CPSI 总评分、社会人口学资料、生活方式等基本信息。并采集静脉血标本进行 Hs-CRP 检测。根据 NIH-CPSI 评分将参与者分为前列腺炎样症状组和正常组。结果前列腺炎样症状患病率为6.69%。血清 Hs-CRP 水平在前列腺炎样症状组和正常组的均值分别是(1.38±2.78)mg/L 和(1.60±4.27)mg/L,差异无统计学意义。Logistic 回归模型提示血清 Hs-CRP 水平与前列腺炎样症状的发生、NIH-CPSI 评分中的疼痛评分和 CPSI 总评分无相关性。结论血清 Hs-CRP 与 CPSI 评分无关系。慢性前列腺炎的诊断和疗效评估应采用其它方法。%Objective To investigate the relationship between National Institute of Health Chronic Prosta-titis Symptom Index (NIH - CPSI)and serum high sensitivity C - reactive protein (Hs - CRP )level in Fangchengang area male residents. Methods A large cross sectional study was performed for Fangchengang area male residents.A standard questionnaire and basic data were collected including total score of NIH-CP-SI,demographic information and lifestyle risk factors.The vein blood was drawn to measure the serum Hs-CRP level.According to the NIH-CPSI score,the participants were divided into a prostatitis-like symptoms group and a healthy group. Results According to NIH-CPSI total score,the prevalence of prostatitis-like symptoms was 6.70%.The mean values of serum Hs-CRP were (1.38 ±2.78)mg/L and (1.604±4.274) mg/L in the prostatitis-like symptom group and the healthy group respectively,and there was no statistically significant difference.By applying Logistic regression model,we found that there was no significant

  4. 75 FR 8373 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2010-02-24

    ... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville..., Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience...

  5. 77 FR 63847 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2012-10-17

    ... Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6148...: National Institutes of Health, Neuroscience Center, 6001 Executive ] Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive...

  6. 75 FR 57044 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2010-09-17

    ... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville..., Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive...

  7. 76 FR 11801 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2011-03-03

    ... of Committee: National Institute of Mental Health Special Emphasis Panel; Behavioral Mechanisms In..., Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001..., National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC...

  8. 76 FR 576 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2011-01-05

    ... Emphasis Panel; SPORE in Mesothelioma, Lung, Breast and Ovarian Cancers. Date: February 2-3, 2011. Time: 8... Molecular Diagnostics Assay to Detect Basal- like Breast Cancer. Date: February 15, 2011. Time: 12 p.m. to 5...-Therapy Breast Cancer Patients. Date: March 3, 2011. Time: 12 p.m. to 5 p.m. Agenda: To review...

  9. 75 FR 26267 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2010-05-11

    ... personal privacy. Name of Committee: National Cancer Advisory Board Ad hoc Subcommittee on Experimental Therapeutics. Open: June 21, 2010, 6:30 p.m. to 8 p.m. Agenda: Discussion on Experimental Therapeutics. Place... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research;...

  10. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... NIH researchers report promising results in prevention and treatment of Ebola virus disease (from left) NIH Director Dr. Francis Collins, NIAID Director Dr. Anthony Fauci, and NIH Clinical Center Director Dr. John Gallin exit the Clinical Center ...

  11. Cancer in human immunodeficiency virus-infected children : A case series from the Children's Cancer Group and the National Cancer Institute

    NARCIS (Netherlands)

    Granovsky, MO; Mueller, BU; Nicholson, HS; Rosenberg, PS; Rabkin, CS

    1998-01-01

    Purpose: To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors. Methods: We retrospectively surveyed the Children's Cancer Group (CCG) and the National Cancer institute (NCI) for cases of cancer that oc

  12. Adherence to the World Cancer Research Fund/American Institute for Cancer Research lifestyle recommendations in colorectal cancer survivors : Results of the PROFILES registry

    NARCIS (Netherlands)

    Winkels, Renate M; van Lee, Linde; Beijer, Sandra; Bours, Martijn J; van Duijnhoven, Fränzel J B; Geelen, Anouk; Hoedjes, Meeke; Mols, F.; de Vries, Jeanne; Weijenberg, Matty P; Kampman, Ellen

    2016-01-01

    We examined adherence to the eight The World Cancer Research Foundation/American Institute for Cancer Research (WCRF/AICR) recommendations on diet, physical activity, and body weight among colorectal cancer survivors, and whether adherence was associated with intention to eat healthy and with the ne

  13. 78 FR 57400 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2013-09-18

    ...: Biomedical Cloud Technology; Electronic Health Records; Advocate and Organizational Engagement; and Proposed Organizational Change: Division of Extramural Activities. Place: National Institutes of Health, Building 31,...

  14. Treatment of Prostate Cancer using Anti-androgen Small Molecules | NCI Technology Transfer Center | TTC

    Science.gov (United States)

    The National Cancer Institute seeks parties interested in collaborative research to co-develop and commercialize a new class of small molecules for the treatment of prostate cancer. General information on co-development research collaborations, can be found on our web site (http://ttc.nci.nih.gov/forms).

  15. 78 FR 19496 - Submission for OMB Review; 30-day Comment Request; The National Cancer Institute (NCI...

    Science.gov (United States)

    2013-04-01

    ... HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-day Comment Request; The National Cancer Institute (NCI) SmokefreeTXT Program Evaluation SUMMARY: Under the provisions of Section... submitted ] to the Office of Management and Budget (OMB) a request to review and approve the...

  16. Learning about Prostate Cancer

    Science.gov (United States)

    ... of Information on Prostate Cancer What is prostate cancer? Prostate cancer is the most common cancer in American ... of page Additional Resources of Information on Prostate Cancer Prostate Cancer [nlm.nih.gov] From Medline Plus Medical ...

  17. Gazelles, unicorns, and dragons battle cancer through the Nanotechnology Startup Challenge

    OpenAIRE

    Truman, Rosemarie; Locke, Cody J.

    2016-01-01

    On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of the Nanotechnology Startup Challenge in Cancer (NSC 2 ). This innovation-development model is a partnership among our company, the Center for Advancing Innovation (CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes at the National Institutes of Health (NIH). NSC 2 “crowdsources” talent from around the world to launch startups with near-term, commercially viable cancer nanotechnolo...

  18. 76 FR 3150 - Office of Biotechnology Activities; Recombinant DNA Research: Action Under the NIH Guidelines for...

    Science.gov (United States)

    2011-01-19

    ...). On July 20, 2010 the NIH Office of Biotechnology Activities (OBA) published a proposed action (75 FR... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... contact OBA by e- mail at oba@od.nih.gov , telephone, 301-496-9838 or mail to the Office of...

  19. 75 FR 43535 - NIH Consensus Development Conference on Inhaled Nitric Oxide Therapy for Premature Infants

    Science.gov (United States)

    2010-07-26

    ... Oxide Therapy for Premature Infants Notice Notice is hereby given of the National Institutes of Health (NIH) ``NIH Consensus Development Conference on Inhaled Nitric Oxide Therapy for Premature Infants'' to... premature infants who still require supplemental oxygen 36 weeks after conception are diagnosed...

  20. 77 FR 38844 - Notice of NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus

    Science.gov (United States)

    2012-06-29

    ... Gestational Diabetes Mellitus SUMMARY: The National Institutes of Health (NIH) is holding a conference titled ``Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus.'' The conference will be open to... http://prevention.nih.gov/cdp . SUPPLEMENTARY INFORMATION: Gestational diabetes mellitus (GDM) is...

  1. A clinicoepidemiological study of esophageal cancer patients at the National Cancer Institute, Cairo University, Egypt

    Institute of Scientific and Technical Information of China (English)

    Soumaya Ezzat; Hisham El Hossieny; Mohamed Abd Alla; Azza Nasr; Nagwan Anter; Ahmed Adel

    2016-01-01

    Objective The purposes of this study were to (1) assess the clinicoepidemiological characteristics of esopha-geal cancer patients, (2) analyze the prognostic factors determining treatment failure and survival, and (3) evaluate the results of various treatment modalities for locoregional and disseminated disease and their ef ect on disease-free survival and overal survival (OS). Methods Clinicoepidemiological retrospective data from 81 esophageal cancer patients treated at the Na-tional Cancer Institute of Cairo between 2007 and 2011 were evaluated. Results The study showed that patients with esophageal cancer commonly present with local y advanced disease (87.7% had T-stage 3 and 12.3% had T-stage 4). There was a significant correlation between surgery and survival; patients who received radical surgery and postoperative radiation had a better median survival than patients who received radical radiotherapy (20 months vs. 16 months, respectively; P = 0.04). There was also a significant statistical correlation between radical concomitant chemoradiotherapy (NCRT) and pal iative treatment. Patients who received radical NCRT had a better median survival than patients who received pal-liative radiotherapy (16 months vs. 10 months, respectively; P = 0.001). The median fol ow-up period for al patients was 7 months. The median OS of the whole group was 12 months. The OS after 1 and 2 years was 57.8% and 15%, respectively. Conclusion High-dose NCRT is an acceptable alternative for patients unfit for surgery or with inoperable disease. High-dose radiation is more ef ective than low-dose radiation in terms of local control, time to relapse, and OS. Further study using a larger series of patients and introducing new treatment protocols is necessary for a final evaluation.

  2. 78 FR 59362 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-26

    ... Boulevard, Gaithersburg, MD 20878. Contact Person: Caron A. Lyman, Ph.D., Chief, Research Programs Review... B: Exploratory Grants. Date: November 18, 2013. Time: 7:30 a.m. to 5:00 p.m. Agenda: To review and... Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research;...

  3. 78 FR 4422 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-01-22

    ... Prevention and Etiology. Date: February 27, 2013. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and... Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and...

  4. NIH disease funding levels and burden of disease.

    Directory of Open Access Journals (Sweden)

    Leslie A Gillum

    Full Text Available BACKGROUND: An analysis of NIH funding in 1996 found that the strongest predictor of funding, disability-adjusted life-years (DALYs, explained only 39% of the variance in funding. In 1998, Congress requested that the Institute of Medicine (IOM evaluate priority-setting criteria for NIH funding; the IOM recommended greater consideration of disease burden. We examined whether the association between current burden and funding has changed since that time. METHODS: We analyzed public data on 2006 NIH funding for 29 common conditions. Measures of US disease burden in 2004 were obtained from the World Health Organization's Global Burden of Disease study and national databases. We assessed the relationship between disease burden and NIH funding dollars in univariate and multivariable log-linear models that evaluated all measures of disease burden. Sensitivity analyses examined associations with future US burden, current and future measures of world disease burden, and a newly standardized NIH accounting method. RESULTS: In univariate and multivariable analyses, disease-specific NIH funding levels increased with burden of disease measured in DALYs (p = 0.001, which accounted for 33% of funding level variation. No other factor predicted funding in multivariable models. Conditions receiving the most funding greater than expected based on disease burden were AIDS ($2474 M, diabetes mellitus ($390 M, and perinatal conditions ($297 M. Depression ($719 M, injuries ($691 M, and chronic obstructive pulmonary disease ($613 M were the most underfunded. Results were similar using estimates of future US burden, current and future world disease burden, and alternate NIH accounting methods. CONCLUSIONS: Current levels of NIH disease-specific research funding correlate modestly with US disease burden, and correlation has not improved in the last decade.

  5. 75 FR 62547 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-10-12

    ... consideration of personnel qualifications and performance, and the competence of individual investigators, the... performance, and competence of individual investigators. Place: Double Tree Hotel, 8120 Wisconsin Avenue... qualifications and performance, and competence of individual investigators. Place: National Institutes of...

  6. 75 FR 62552 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-10-12

    ... Institute, including consideration of personnel qualifications and performance, and the competence of... personal qualifications and performance, and competence of individual investigators. Place: National... performance, and competence of individual investigators. Place: Double Tree Hotel, 8120 Wisconsin...

  7. 75 FR 79010 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-12-17

    ... Special Emphasis Panel. SPORE in Glioma, Head and Neck, Lymphoma, Myeloid Leukemia, and Myeloma. Date... Program for Cancer Epidemiology. Date: April 28-29, 2011. Time: 8:30 a.m. to 5 p.m. Agenda: To review...

  8. Protecting yourself from cancer scams

    Science.gov (United States)

    ... at: nccih.nih.gov/sites/nccam.nih.gov/files/CAM_Basics_Cancer_and_CHA_0.pdf . Accessed August 25, 2015. U.S. Food and Drug Administration. Beware of Online Cancer Fraud. January 2014. Available ...

  9. The National Cancer Institute's Physical Sciences - Oncology Network

    Science.gov (United States)

    Espey, Michael Graham

    In 2009, the NCI launched the Physical Sciences - Oncology Centers (PS-OC) initiative with 12 Centers (U54) funded through 2014. The current phase of the Program includes U54 funded Centers with the added feature of soliciting new Physical Science - Oncology Projects (PS-OP) U01 grant applications through 2017; see NCI PAR-15-021. The PS-OPs, individually and along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OCs), comprise the Physical Sciences-Oncology Network (PS-ON). The foundation of the Physical Sciences-Oncology initiative is a high-risk, high-reward program that promotes a `physical sciences perspective' of cancer and fosters the convergence of physical science and cancer research by forming transdisciplinary teams of physical scientists (e.g., physicists, mathematicians, chemists, engineers, computer scientists) and cancer researchers (e.g., cancer biologists, oncologists, pathologists) who work closely together to advance our understanding of cancer. The collaborative PS-ON structure catalyzes transformative science through increased exchange of people, ideas, and approaches. PS-ON resources are leveraged to fund Trans-Network pilot projects to enable synergy and cross-testing of experimental and/or theoretical concepts. This session will include a brief PS-ON overview followed by a strategic discussion with the APS community to exchange perspectives on the progression of trans-disciplinary physical sciences in cancer research.

  10. NIH Peer Review: Scored Review Criteria and Overall Impact

    Science.gov (United States)

    Lindner, Mark D.; Vancea, Adrian; Chen, Mei-Ching; Chacko, George

    2016-01-01

    The National Institutes of Health (NIH) is the largest source of funding for biomedical research in the world. Funding decisions are made largely based on the outcome of a peer review process that is intended to provide a fair, equitable, timely, and unbiased review of the quality, scientific merit, and potential impact of the research. There have…

  11. NIH Mulls Ways to Lure Back Veteran Peer Reviewers

    Science.gov (United States)

    Brainard, Jeffrey

    2008-01-01

    Not long ago, academic scientists welcomed calls from the National Institutes of Health (NIH) asking them to volunteer as peer reviewers. Many were glad for the opportunity to help distribute billions of dollars in federal biomedical-research grants even though the service required a big time commitment--the equivalent of one month a year to…

  12. Memory and Forgetfulness: NIH Research

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Memory & Forgetfulness NIH Research Past Issues / Summer 2013 Table ... agency for research on Alzheimer's disease and related memory research. An analysis funded by the NIA finds ...

  13. NIH Common Data Elements Repository

    Data.gov (United States)

    U.S. Department of Health & Human Services — The NIH Common Data Elements (CDE) Repository has been designed to provide access to structured human and machine-readable definitions of data elements that have...

  14. 75 FR 26266 - National Cancer Institute (NCI); National Institute of Allergy and Infectious Diseases (NIAID...

    Science.gov (United States)

    2010-05-11

    ... Allergy and Infectious Diseases (NIAID); National Institute of Arthritis and Musculoskeletal and Skin...: From Mouse Models to Human Disease and Treatment.'' Dates: September 2-3, 2010. Location: Lister Hill... treatment. It is hoped that one consequence of this meeting might be some consensus as to what is...

  15. Bone Cancer

    Science.gov (United States)

    ... cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National ...

  16. Depression in Early Pregnancy Linked to Gestational Diabetes, NIH Study Finds

    Science.gov (United States)

    ... News Releases News Release Monday, September 19, 2016 Depression in early pregnancy linked to gestational diabetes, NIH ... Women with gestational diabetes at risk for postpartum depression. Researchers at the National Institutes of Health have ...

  17. NIH Exported Research Portfolio Online Reporting Tools: Expenditures and Results (ExPORTER)

    Data.gov (United States)

    U.S. Department of Health & Human Services — Research projects funded by the National Institutes of Health (NIH), other DHHS Operating Divisions (AHRQ, CDC, FDA, HRSA, SAMHSA), and the Department of Veterans...

  18. Application of log-linear models to cancer patients: a case study of data from the National Cancer Institute.

    Science.gov (United States)

    Tiensuwan, Montip; Yimprayoon, Pornpis; Lenbury, Yongwimon

    2005-09-01

    Cancer is a noninfectious disease which is on the increase throughout the world and has become a serious problem for public health in many countries, including Thailand. In Thailand, cancer has risen significantly to become a leading cause of death and most patients are admitted to the National Cancer Institute. The objective of this study is to identify the associated factors between personal, cancer/clinical variables of cancer patients using log-linear models. Tests of independence are used (chi-square and Cramer's V-value tests) to find out the relationships between any two variables. In addition two- and three-dimensional log-linear models are used to obtain estimated parameters and expected frequencies for these models. Amongst the models fitted, the best are chosen based on the analysis of deviance. The results of this study show that most paired variables of personal, cancer/clinical variables are significantly related at p-value value. Moreover, the site of cancer also affects the method of diagnostic evidence and treatment. Since the site of cancer in each sex is different, prevention for various sites of cancer should be considered for each specific sex. In addition, for male and female patients, treatment is related to the site of cancer. Consequently, physicians may consider these factors before selecting the appropriate method of treatment. PMID:16438159

  19. Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

    OpenAIRE

    Adela Castelló; Miguel Martín; Amparo Ruiz; Casas, Ana M.; Baena-Cañada, Jose M; Virginia Lope; Silvia Antolín; Pedro Sánchez; Manuel Ramos; Antonio Antón; Montserrat Muñoz; Begoña Bermejo; Ana De Juan-Ferré; Carlos Jara; José I Chacón

    2015-01-01

    Background According to the “World Cancer Research Fund” and the “American Institute of Cancer Research” (WCRF/AICR) one in four cancer cases could be prevented through a healthy diet, weight control and physical activity. Objective To explore the association between the WCRF/AICR recommendations and risk of breast cancer. Methods During the period 2006 to 2011 we recruited 973 incident cases of breast cancer and 973 controls from 17 Spanish Regions. We constructed a score based on 9 of the W...

  20. The Match of Her Life | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... answer questions for this issue of NIH MedlinePlus magazine about her breast cancer. You discovered you had ... way of healing. As this issue of the magazine went to press, Navratilova was receiving radiation therapy ...

  1. Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

    OpenAIRE

    Hirasawa Naoki; Itoh Yoshiyuki; Naganawa Shinji; Ishihara Shunichi; Suzuki Kazunori; Koyama Kazuyuki; Murao Takayuki; Asano Akiko; Nomoto Yoshihito; Horikawa Yoshimi; Sasaoka Masahiro; Obata Yasunori

    2012-01-01

    Abstract Background The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan. Methods Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplet...

  2. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.

    OpenAIRE

    Desai, S J; Barr, R D; Andrew, M.; deVeber, L L; Pai, M K

    1989-01-01

    There is ample evidence of the value of intensive therapeutic strategies in the management of acute lymphoblastic leukemia (ALL), the commonest form of malignant disease in children. Such a program, devised at the Dana-Farber Cancer Institute (DFCI), Boston, and incorporating high-dose L-asparaginase, was adopted in 1984 by the Children's Hospital at Chedoke-McMaster, Hamilton, Ont., and the Children's Hospital of Western Ontario, London. We describe the experience of these institutions in th...

  3. 75 FR 6675 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2010-02-10

    ... Activities, National Institute of ] Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6151... Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call... Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6154, MSC 9609,...

  4. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

    OpenAIRE

    Zuber, Simon; Weiß, Susan; Baaske, Dieter; Schöpe, Michael; Stevens, Simon; Bodis, Stephan; Zwahlen, Daniel R.

    2015-01-01

    Purpose We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution. Material and methods Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexual fu...

  5. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

    OpenAIRE

    Zuber, Simon; Weiß, Susan; Baaske, Dieter; Schöpe, Michael; Stevens, Simon; Bodis, Stephan; Zwahlen, Daniel R.

    2015-01-01

    PURPOSE: We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution. MATERIAL AND METHODS: Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexu...

  6. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience

    Science.gov (United States)

    Coelho, Rafael Corrêa; Reinert, Tomás; Campos, Franz; Peixoto, Fábio Affonso; de Andrade, Carlos Augusto; Castro, Thalita; Herchenhorn, Daniel

    2016-01-01

    ABSTRACT Purpose: The aim of this study was to assess the impact of sunitinib treatment in a non-screened group of patients with metastatic renal cell cancer (mRCC) treated by the Brazilian Unified Health System (SUS) at a single reference institution. Material and Methods: Retrospective cohort study, which evaluated patients with mRCC who received sunitinib between May 2010 and December 2013. Results: Fifty-eight patients were eligible. Most patients were male 41 (71%), with a median age of 58 years. Nephrectomy was performed in 41 (71%) patients with a median interval of 16 months between the surgery and initiation of sunitinib. The most prevalent histological subtype was clear cell carcinoma, present in 52 (91.2%) patients. In 50 patients (86%), sunitinib was the first line of systemic treatment. The main adverse effects were fatigue (57%), hypothyroidism (43%), mucositis (33%) and diarrhea (29%). Grade 3 and 4 adverse effects were infrequent: fatigue (12%), hypertension (12%), thrombocytopenia (7%), neutropenia (5%) and hand-foot syndrome (5%). Forty percent of patients achieved a partial response and 35% stable disease, with a disease control rate of 75%. Median progression free survival was 7.6 months and median overall survival was 14.1 months. Conclusion: Sunitinib treatment was active in the majority of patients, especially those with low and intermediate risk by MSKCC score, with manageable toxicity. Survival rates were inferior in this non-screened population with mRCC treated in the SUS. PMID:27564279

  7. National Institutes of Health Funding for disease categories related to Neural Regeneration Research

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    @@ Introduction The National Institutes of Health (NIH), a part of the U.S.Department of Health and Human Services, is the nation's medical research agency-making important discoveries that improve health and save lives.Thanks in large part to NIH-funded medical research, Americans today are living longer and healthier.Life expectancy in the United States has jumped from 47 years in 1900 to 78 years as reported in 2009, and disability in people over age 65 has dropped dramatically in the past 3 decades.In recent years, nationwide rates of new diagnoses and deaths from all cancers combined have fallen significantly.

  8. Intraoperative Radiotherapy for Parotid Cancer: A Single-Institution Experience

    Energy Technology Data Exchange (ETDEWEB)

    Zeidan, Youssef H., E-mail: youssefzaidan@gmail.com [Department of Radiation Oncology, Methodist Hospital, Indianapolis, IN (United States); Shiue, Kevin; Weed, Daniel [Department of Radiation Oncology, Methodist Hospital, Indianapolis, IN (United States); Johnstone, Peter A. [Department of Radiation Oncology, Indiana University, Indianapolis, IN (United States); Terry, Colin [Methodist Research Institute, Methodist Hospital, Indianapolis, IN (United States); Freeman, Stephen; Krowiak, Edward; Borrowdale, Robert; Huntley, Tod [CENTA Otolaryngology, Indianapolis, IN (United States); Yeh, Alex [Department of Radiation Oncology, Methodist Hospital, Indianapolis, IN (United States)

    2012-04-01

    Purpose: Our practice policy has been to provide intraoperative radiotherapy (IORT) at resection to patients with head-and-neck malignancies considered to be at high risk of recurrence. The purpose of the present study was to review our experience with the use of IORT for primary or recurrent cancer of the parotid gland. Methods and Materials: Between 1982 and 2007, 96 patients were treated with gross total resection and IORT for primary or recurrent cancer of the parotid gland. The median age was 62.9 years (range, 14.3-88.1). Of the 96 patients, 33 had previously undergone external beam radiotherapy as a component of definitive therapy. Also, 34 patients had positive margins after surgery, and 40 had perineural invasion. IORT was administered as a single fraction of 15 or 20 Gy with 4-6-MeV electrons. The median follow-up period was 5.6 years. Results: Only 1 patient experienced local recurrence, 19 developed regional recurrence, and 12 distant recurrence. The recurrence-free survival rate at 1, 3, and 5 years was 82.0%, 68.5%, and 65.2%, respectively. The 1-, 3-, and 5-year overall survival rate after surgery and IORT was 88.4%, 66.1%, and 56.2%, respectively. No perioperative fatalities occurred. Complications developed in 26 patients and included vascular complications in 7, trismus in 6, fistulas in 4, radiation osteonecrosis in 4, flap necrosis in 2, wound dehiscence in 2, and neuropathy in 1. Of these 26 patients, 12 had recurrent disease, and 8 had undergone external beam radiotherapy before IORT. Conclusions: IORT results in effective local disease control at acceptable levels of toxicity and should be considered for patients with primary or recurrent cancer of the parotid gland.

  9. Intraoperative Radiotherapy for Parotid Cancer: A Single-Institution Experience

    International Nuclear Information System (INIS)

    Purpose: Our practice policy has been to provide intraoperative radiotherapy (IORT) at resection to patients with head-and-neck malignancies considered to be at high risk of recurrence. The purpose of the present study was to review our experience with the use of IORT for primary or recurrent cancer of the parotid gland. Methods and Materials: Between 1982 and 2007, 96 patients were treated with gross total resection and IORT for primary or recurrent cancer of the parotid gland. The median age was 62.9 years (range, 14.3–88.1). Of the 96 patients, 33 had previously undergone external beam radiotherapy as a component of definitive therapy. Also, 34 patients had positive margins after surgery, and 40 had perineural invasion. IORT was administered as a single fraction of 15 or 20 Gy with 4–6-MeV electrons. The median follow-up period was 5.6 years. Results: Only 1 patient experienced local recurrence, 19 developed regional recurrence, and 12 distant recurrence. The recurrence-free survival rate at 1, 3, and 5 years was 82.0%, 68.5%, and 65.2%, respectively. The 1-, 3-, and 5-year overall survival rate after surgery and IORT was 88.4%, 66.1%, and 56.2%, respectively. No perioperative fatalities occurred. Complications developed in 26 patients and included vascular complications in 7, trismus in 6, fistulas in 4, radiation osteonecrosis in 4, flap necrosis in 2, wound dehiscence in 2, and neuropathy in 1. Of these 26 patients, 12 had recurrent disease, and 8 had undergone external beam radiotherapy before IORT. Conclusions: IORT results in effective local disease control at acceptable levels of toxicity and should be considered for patients with primary or recurrent cancer of the parotid gland.

  10. Outcome and treatment strategy in female lung cancer: a single institution experience

    International Nuclear Information System (INIS)

    Purpose: To assess the survival rate of female lung cancer treated at the Institute of Oncology of the Vilnius University, Lithuania during the period between 1996-2005. Materials and Methods: During the period between 1996-2005, 471 women diagnosed with lung cancer were treated at the Department of Thoracic Surgery and Oncology of the Institute of Oncology, Vilnius University. Data on morphology, stage and treatment was collected from the medical records. All lung cancer cases by histology were classified in two groups: non-small cell lung cancer (includes squamous cell carcinoma, large cell carcinoma, adenocarcinoma and other less common types) and small cell lung cancer. The vital status of the study group was assessed as of December 31, 2007, by passive follow-up, using data from the population registry. It was found that 411 (87.3%) of the patients had died. Survival was estimated according to the Kaplan-Meier method. Results: The median survival of female lung cancer diagnosed during 1996-2005 in Lithuania show to be 8.7 months (8.4 (95% CI 7.2-10.8) months with non-small cell lung cancer and 9.3 (95% CI 6.3-13.0) months with small-cell lung cancer). Survival was more than 20 months in resectable non-small cell lung cancer (stages I, II, IIIA). Non-small cell lung cancer survival in advanced stages was less than 7 months. Small-cell lung cancer patients median survival at limited and extended stages of the disease were 9.5 (95% CI 2.9-18.4) compared to 9.2 (95% CI 6.2-13.7) months. Non-small cell lung cancer patients most frequently were treated by surgery (27.0%), surgery and chemotherapy or radiotherapy (19.6%). Small cell lung cancer patient treatment included chemo and radiotherapy (27.0%), chemotherapy (19.0%), radiotherapy (17.5%), surgery (27.9%). Conclusions: The single center study of female lung cancer diagnosed during 1996-2005 in Lithuania show a significantly better chance of survival in resectable non-small cell lung cancer. Advanced stages of

  11. Integrated oncology and palliative care: five years experience at the National Cancer Institute of Mexico.

    Science.gov (United States)

    Allende-Pérez, Silvia; Verástegui-Avilés, Emma; Mohar-Betancourt, Alejandro; Meneses-García, Abelardo; Herrera-Gómez, Angel

    2016-04-01

    Under the national plan for addressing cancer, prevention and detection play important roles. However, the cost of treatments and late diagnosis represent a significant burden on health services. At the National Cancer Institute, more than half of patients present with tumors in advanced stages, and approximately 10% of patients seen for the first time exhibit terminal-stage malignancies, where there are no feasible cancer treatment options, and the patients are instead admitted to the hospital exclusively for palliative symptomatic management. In 2010, the National Cancer Plan began implementing a model of integrative management of palliative care in oncology that has gradually come to include symptomatic palliative care, involving ambulatory, distant and hospitalized management of patients with cancer, in its final stages and, more recently, in earlier stages. PMID:27557392

  12. Epidemiology of epithelial ovarian cancer, a single institution-based study in India

    Directory of Open Access Journals (Sweden)

    Surendra Kumar Saini

    2016-01-01

    Full Text Available Background: Ovarian cancer is the leading cause of mortality among all cancers of female genital tract in countries where effective cervical cancer screening program exists. As the world's population ages, remarkable increase in the total number of ovarian cancer cases are expected. This is preliminary epidemiological study to decide priorities in ovarian cancer research. Materials and Methods: A retrospective study was conducted with primary epithelial ovarian cancer cases registered in J. K. Cancer Institute, Kanpur (Uttar Pradesh, from 2007 to 2009. Patients' age at diagnosis, clinical feature, parity of patients, tumor histological type, Federation of Gynecology and Obstetrics stage, chemotherapy regimens, and overall survival data were collected and analyzed. Results: One hundred and sixty-three cases of primary ovarian epithelial cancer were analyzed. Patients' mean age at diagnosis was 55.98 ± 9.24 (median = 55. Serous adenocarcinoma (49.69% was the most prevalent type of histopathology followed by endometroid (19.1%, mucinous (10.42% and clear cell (4.29%. Combination of taxane and platin was most commonly used first line regimen in newly diagnosed as well as in relapsed patients post 1 year. Survival was not significantly different in various histopathology (log-rank P = 0.7406, but advancing stage demonstrated gradually poor survival (log-rank P < 0.05 when compared with early stage disease. Conclusion: Research efforts should be in the direction to find early diagnostic and effective screening tools as well as better therapeutic approaches for advanced epithelial ovarian cancer.

  13. I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data.

    Science.gov (United States)

    Weintraub, Sandra; Bauer, Patricia J; Zelazo, Philip David; Wallner-Allen, Kathleen; Dikmen, Sureyya S; Heaton, Robert K; Tulsky, David S; Slotkin, Jerry; Blitz, David L; Carlozzi, Noelle E; Havlik, Richard J; Beaumont, Jennifer L; Mungas, Dan; Manly, Jennifer J; Borosh, Beth G; Nowinski, Cindy J; Gershon, Richard C

    2013-08-01

    This monograph presents the pediatric portion of the National Institutes of Health (NIH) Toolbox Cognition Battery (CB) of the NIH Toolbox for the Assessment of Neurological and Behavioral Function. The NIH Toolbox is an initiative of the Neuroscience Blueprint, a collaborative framework through which 16 NIH Institutes, Centers, and Offices jointly support neuroscience-related research, to accelerate discoveries and reduce the burden of nervous system disorders. The CB is one of four modules that measure cognitive, emotional, sensory, and motor health across the lifespan. The CB is unique in its continuity across childhood, adolescence, early adulthood, and old age, and in order to help create a common currency among disparate studies, it is also available at low cost to researchers for use in large-scale longitudinal and epidemiologic studies. This chapter describes the evolution of the CB; methods for selecting cognitive subdomains and instruments; the rationale for test design; and a validation study in children and adolescents, ages 3-15 years. Subsequent chapters feature detailed discussions of each test measure and its psychometric properties (Chapters 2-6), the factor structure of the test battery (Chapter 7), the effects of age and education on composite test scores (Chapter 8), and a final summary and discussion (Chapter 9). As the chapters in this monograph demonstrate, the CB has excellent psychometric properties, and the validation study provided evidence for the increasing differentiation of cognitive abilities with age. PMID:23952199

  14. NIH Researchers Identify OCD Risk Gene

    Science.gov (United States)

    ... News From NIH NIH Researchers Identify OCD Risk Gene Past Issues / Summer 2006 Table of Contents For ... and Alcoholism (NIAAA) have identified a previously unknown gene variant that doubles an individual's risk for obsessive- ...

  15. ZADOVOLJSTVO UPORABNIKOV TURISTIČNIH STORITEV

    OpenAIRE

    Stanonik, Tana

    2015-01-01

    Zadovoljstvo uporabnikov turističnih storitev je eden ključnih dejavnikov za uspešno poslovanje ponudnikov turističnih storitev. V teoretičnem delu diplomske naloge smo na kratko razjasnili glavna pojma turizem ter zadovoljstvo. Opisali smo nekaj dejavnikov, ki vplivajo na zadovoljstvo uporabnikov turističnih storitev. Govorimo o kakovosti storitev v turizmu, nakupnem vedenju turistov ter o lojalnosti turistov. Opisali smo tudi samo merjenje zadovoljstva turistov ter razjasnili kako se v ...

  16. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

    International Nuclear Information System (INIS)

    Gonadotropin releasing hormone (GNRH1) triggers the release of follicle stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones. We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3). We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases. Resulting single nucleotide polymorphisms (SNPs) were genotyped and used to identify haplotype-tagging SNPs (htSNPS) in a panel of 349 healthy women. The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II), European Prospective Investigation on Cancer and Nutrition (EPIC), Multiethnic Cohort (MEC), Nurses' Health Study (NHS), and Women's Health Study (WHS). Circulating levels of sex steroids (androstenedione, estradiol, estrone and testosterone) were also measured in 4713 study subjects. Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors. Polymorphisms in these two genes were not strongly associated with circulating hormone levels. Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians

  17. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3

    Directory of Open Access Journals (Sweden)

    Lund Eiliv

    2009-07-01

    Full Text Available Abstract Background Gonadotropin releasing hormone (GNRH1 triggers the release of follicle stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones. We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3. Methods We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases. Resulting single nucleotide polymorphisms (SNPs were genotyped and used to identify haplotype-tagging SNPs (htSNPS in a panel of 349 healthy women. The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II, European Prospective Investigation on Cancer and Nutrition (EPIC, Multiethnic Cohort (MEC, Nurses' Health Study (NHS, and Women's Health Study (WHS. Circulating levels of sex steroids (androstenedione, estradiol, estrone and testosterone were also measured in 4713 study subjects. Results Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors. Polymorphisms in these two genes were not strongly associated with circulating hormone levels. Conclusion Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.

  18. Back Cover: NIH MedlinePlus Salud

    Science.gov (United States)

    ... la revista NIH MedlinePlus Salud, visite medlineplus.gov/spanish/ magazine . Para obtener una subscripición gratis de la versión ... NIH MedlinePlus Salud magazine online, visit medlineplus.gov /spanish/magazine . For your free print subscription to NIH MedlinePlus ...

  19. 75 FR 3243 - NIH State-of-the-Science Conference: Preventing Alzheimer's Disease and Cognitive Decline; Notice

    Science.gov (United States)

    2010-01-20

    ... HUMAN SERVICES National Institutes of Health NIH State-of-the-Science Conference: Preventing Alzheimer's... the ``NIH State-of-the-Science Conference: Preventing Alzheimer's Disease and Cognitive Decline'' to... state of cognitive impairment or into various forms of dementia, including Alzheimer's disease....

  20. 75 FR 11889 - Request for Comments on Proposed NIH, AHRQ and CDC Process Change for Electronic Submission of...

    Science.gov (United States)

    2010-03-12

    ... HUMAN SERVICES Request for Comments on Proposed NIH, AHRQ and CDC Process Change for Electronic Submission of Grant Applications AGENCY: Department of Health and Human Services. ACTION: Process change. SUMMARY: The National Institutes of Health (NIH), the Agency for Healthcare Research and Quality...

  1. The National Cancer Informatics Program (NCIP) Annotation and Image Markup (AIM) Foundation Model

    OpenAIRE

    Mongkolwat, Pattanasak; Kleper, Vladimir; Talbot, Skip; Rubin, Daniel

    2014-01-01

    Knowledge contained within in vivo imaging annotated by human experts or computer programs is typically stored as unstructured text and separated from other associated information. The National Cancer Informatics Program (NCIP) Annotation and Image Markup (AIM) Foundation information model is an evolution of the National Institute of Health’s (NIH) National Cancer Institute’s (NCI) Cancer Bioinformatics Grid (caBIG®) AIM model. The model applies to various image types created by various techn...

  2. NIH Pathways to Prevention (P2P) Workshop: Role of Opioids in the Treatment of Chronic Pain | Division of Cancer Prevention

    Science.gov (United States)

    Chronic pain is a major public health problem, which is estimated to affect more than 100 million people in the United States and about 20–30% of the population worldwide. The prevalence of persistent pain is expected to rise in the near future as the incidence of associated diseases (including diabetes, obesity, cardiovascular disorders, arthritis, and cancer) increases in the aging U.S. population. |

  3. New Memorandum of Understanding in Clinical Proteogenomics Between the United States and Australia - Office of Cancer Clinical Proteomics Research

    Science.gov (United States)

    The White House Office of the Vice President has announced the signing of three Memoranda of Understanding (MOUs) that will make available an unprecedented international dataset to advance cancer research and care. An MOU between the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the United States, and Macquarie University (MU), Children's Medical Research Institute (CMRI), Garvan Institute of Medical Research (GIMR), and Bioplatforms Australia Limited (BPA) in Australia will facilitate scientific collaborations in the field of clinical proteogenomic studies and their translation to cancer care.

  4. A comparative study of breast cancer mass screening using ultrasonography and mammography at a single institution

    International Nuclear Information System (INIS)

    In order to evaluate the effectiveness of ultrasonic screening for breast cancer (US group) in comparison with mammographic screening (MMG group), we analyzed 78,214 breast screening examinees presenting between 2007 and 2008 at our institution. The cancer detection rate in the US group was lower than that in the MMG group. However, the average age in the US group was significantly younger than that in the MMG group, and the rate of annual screening was significantly higher in the former than in the latter. In the US subgroup who underwent annual screening, the recall rate and the cancer detection rate were significantly lower, and the rate of detection of early breast cancers was significantly higher than that in the subgroup who underwent screening biennially or at longer intervals, and there was no significant inter-group difference in the cancer detection rate between women in their 40s and those aged 50 or above who underwent annual screening. The proportion of early breast cancers detected was almost the same in the both groups. In summary, US screening as well as MMG screening seems to be useful for detection of early breast cancer. Although a high recall rate for US screening has been reported previously, annual screening and sufficient quality control based on the guidelines proposed by the Japan Association of Breast and Thyroid Sonology (JABTS) are considered to reduce the recall rate. (author)

  5. Treatment Option Overview (Breast Cancer)

    Science.gov (United States)

    ... trials is available from the NCI website . Locally Advanced or Inflammatory Breast Cancer Treatment of locally advanced ... NIH). NIH is the federal government’s center of biomedical research. The PDQ summaries are based on an ...

  6. Some radiation protection problems in a cancer hospital and associated research institute

    International Nuclear Information System (INIS)

    Experience gained at the Royal Marsden Hospital and Institute of Cancer Research has shown that with attention to the design of facilities and procedures and an active personnel monitoring policy, relatively large scale radiation commitments can proceed with individual whole body doses to staff being held well below 15 mSv/annum. In spite of detailed attention to control of radiation work, traumatic radiation incidents may still occur. (H.K.)

  7. Architectural and engineering design work for the Nevada Cancer Institute facility

    International Nuclear Information System (INIS)

    The purpose of this project was to complete the architectural and engineering design, program planning, and other preliminary work necessary to construct the new Nevada Cancer Institute facility. These goals were accomplished with the construction of a new building of approximately 119,000 gross square feet. The facility houses the diagnostic and radio therapeutic treatment laboratories, radiation oncology treatment facility, physician offices, and clinical research areas

  8. 77 FR 47082 - National Institute of Mental Health; Notice of Closed Meeting

    Science.gov (United States)

    2012-08-07

    ... grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience...

  9. Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute.

    Directory of Open Access Journals (Sweden)

    Edamura,Kohei

    2005-10-01

    Full Text Available

    This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.

  10. Plant collecting program in Southeast Asia under the sponsorship of the United States National Cancer Institute (NCI) (1986-1991)

    OpenAIRE

    Soejarto, D. D.

    1992-01-01

    Under the funding from the United States National Cancer Institute (NCI)¹, a program was undertaken to collect plant samples in Southeast Asia to be tested for their cancer- and AIDS-arresting properties, for the period of September 1, 1986 through August 31, 1991. The program was implemented with the collaboration of the Arnold Arboretum and the Bishop Museum. Botanists from these and other institutions collaborated in the field work operation for the program, among others: J.S. BURLEY (A), ...

  11. The research for mitochondrial DNA inducing the D-loop mutation of NIH3T3 cells in colorectal cancer%大肠癌线粒体DNA 诱导NIH3T3细胞D-环突变的作用与机制

    Institute of Scientific and Technical Information of China (English)

    姬宏莉; 姬宏娟; 马永全; 杜芳; 王辉

    2011-01-01

    目的 观察突变的大肠癌细胞线粒体DNA(mtDNA)转导NIH3T3细胞后转染细胞mtDNA D-环突变特性.方法 通过脂质体法(Lipofection2000TM)将大肠癌细胞突变的mtDNA真核表达载体转染NIH3T3细胞,利用G418抗性筛选克隆细胞;用PCR法检测转染细胞线粒体突变情况.结果 突变mtDNA导致转染细胞mtDNA 的突变和多态性变化.结论 突变的大肠癌mtDNA可致NIH3T3细胞mtDNA位点变化,但具体的机制和过程有待于进一步研究.

  12. Asthma: NIH-Sponsored Research and Clinical Trials | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Asthma Asthma: NIH-Sponsored Research and Clinical Trials Past Issues / Fall 2011 Table of Contents NIH-Sponsored Research Asthma in the Inner City: Recognizing that asthma severity ...

  13. NIH Research: Advances In Parkinson's Disease | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... please turn JavaScript on. NIH Research: Advances in Parkinson's Disease Research Past Issues / Winter 2014 Table of Contents ... and Stroke. Photo courtesy of NIH Advances in Parkinson's Disease Research Story Landis, Ph.D., has been Director ...

  14. Plant collecting program in Southeast Asia under the sponsorship of the United States National Cancer Institute (NCI) (1986-1991)

    NARCIS (Netherlands)

    Soejarto, D.D.

    1992-01-01

    Under the funding from the United States National Cancer Institute (NCI)¹, a program was undertaken to collect plant samples in Southeast Asia to be tested for their cancer- and AIDS-arresting properties, for the period of September 1, 1986 through August 31, 1991. The program was implemented with t

  15. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and breast cancer risk.

    Science.gov (United States)

    Harris, Holly R; Bergkvist, Leif; Wolk, Alicja

    2016-06-01

    The World Cancer Research Fund/American Association for Cancer Research (WCRF/AICR) has published eight nutrition-related recommendations for the prevention of cancer. However, few prospective studies have examined these recommendations by breast cancer hormone receptor subtype and only one case-control study has included the dietary supplements recommendation in their evaluation. We investigated whether adherence to the WCRF/AICR cancer prevention recommendations was associated with breast cancer incidence, overall and by hormone receptor subtype, in the Swedish Mammography Cohort. Among 31,514 primarily postmenopausal women diet and lifestyle factors were assessed with a self-administered food frequency questionnaire. A score was constructed based on adherence to the recommendations for body fatness, physical activity, energy density, plant foods, animal foods, alcoholic drinks and dietary supplements (score range 0-7). Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). During 15 years of follow-up 1,388 cases of breast cancer were identified. Women who met six to seven recommendations had a 51% decreased risk of breast cancer compared to women meeting only zero to two recommendations (95% CI = 0.35-0.70). The association between each additional recommendation met and breast cancer risk was strongest for the ER-positive/PR-positive subtype (HR = 0.86; 95% CI = 0.79-0.94), while for the ER-negative/PR-negative subtype the individual recommendations regarding plant and animal foods were most strongly associated with reduced risk. Our findings support that adherence to the WCRF/AICR recommendations reduces breast cancer risk in a population of primarily postmenopausal women. Promoting these recommendations to the public could help reduce breast cancer incidence. PMID:26804371

  16. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and breast cancer risk.

    Science.gov (United States)

    Harris, Holly R; Bergkvist, Leif; Wolk, Alicja

    2016-06-01

    The World Cancer Research Fund/American Association for Cancer Research (WCRF/AICR) has published eight nutrition-related recommendations for the prevention of cancer. However, few prospective studies have examined these recommendations by breast cancer hormone receptor subtype and only one case-control study has included the dietary supplements recommendation in their evaluation. We investigated whether adherence to the WCRF/AICR cancer prevention recommendations was associated with breast cancer incidence, overall and by hormone receptor subtype, in the Swedish Mammography Cohort. Among 31,514 primarily postmenopausal women diet and lifestyle factors were assessed with a self-administered food frequency questionnaire. A score was constructed based on adherence to the recommendations for body fatness, physical activity, energy density, plant foods, animal foods, alcoholic drinks and dietary supplements (score range 0-7). Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). During 15 years of follow-up 1,388 cases of breast cancer were identified. Women who met six to seven recommendations had a 51% decreased risk of breast cancer compared to women meeting only zero to two recommendations (95% CI = 0.35-0.70). The association between each additional recommendation met and breast cancer risk was strongest for the ER-positive/PR-positive subtype (HR = 0.86; 95% CI = 0.79-0.94), while for the ER-negative/PR-negative subtype the individual recommendations regarding plant and animal foods were most strongly associated with reduced risk. Our findings support that adherence to the WCRF/AICR recommendations reduces breast cancer risk in a population of primarily postmenopausal women. Promoting these recommendations to the public could help reduce breast cancer incidence.

  17. Latest NIH Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Trials: Lung Cancer Prevention Check for trials about lung cancer prevention from NCI's List of Cancer Clinical Trials now accepting patients. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid=475994 Winter 2011 Issue: Volume 5 Number 4 Page 9

  18. Preliminary Analysis of Difficulty of Importing Pattern-Based Concepts into the National Cancer Institute Thesaurus.

    Science.gov (United States)

    He, Zhe; Geller, James

    2016-01-01

    Maintenance of biomedical ontologies is difficult. We have developed a pattern-based method for dealing with the problem of identifying missing concepts in the National Cancer Institute thesaurus (NCIt). Specifically, we are mining patterns connecting NCIt concepts with concepts in other ontologies to identify candidate missing concepts. However, the final decision about a concept insertion is always up to a human ontology curator. In this paper, we are estimating the difficulty of this task for a domain expert by counting possible choices for a pattern-based insertion. We conclude that even with support of our mining algorithm, the insertion task is challenging.

  19. Preliminary Analysis of Difficulty of Importing Pattern-Based Concepts into the National Cancer Institute Thesaurus.

    Science.gov (United States)

    He, Zhe; Geller, James

    2016-01-01

    Maintenance of biomedical ontologies is difficult. We have developed a pattern-based method for dealing with the problem of identifying missing concepts in the National Cancer Institute thesaurus (NCIt). Specifically, we are mining patterns connecting NCIt concepts with concepts in other ontologies to identify candidate missing concepts. However, the final decision about a concept insertion is always up to a human ontology curator. In this paper, we are estimating the difficulty of this task for a domain expert by counting possible choices for a pattern-based insertion. We conclude that even with support of our mining algorithm, the insertion task is challenging. PMID:27577410

  20. Male breast cancer: a report of 127 cases at a Moroccan institution

    Directory of Open Access Journals (Sweden)

    Tijami Fouad

    2011-06-01

    Full Text Available Abstract Background Male breast cancer (MBC is a rare disease representing less than 1% of all malignancies in men and only 1% of all incident breast cancers. Our study details clinico-pathological features, treatments and prognostic factors in a large Moroccan cohort. Findings One hundred and twenty-seven patients were collected from 1985 to 2007 at the National Institute of Oncology in Rabat, Morocco. Median age was 62 years and median time for consultation 28 months. The main clinical complaint was a mass beneath the areola in 93, 5% of the cases. Most patients have an advanced disease. Ninety-one percent of tumors were ductal carcinomas. Management consisted especially of radical mastectomy; followed by adjuvant radiotherapy and hormonal therapy with or without chemotherapy. The median of follow-up was 30 months. The evolution has been characterized by local recurrence; in twenty two cases (17% of all patients. Metastasis occurred in 41 cases (32% of all patients. The site of metastasis was the bone in twenty cases; lung in twelve cases; liver in seven case; liver and skin in one case and pleura and skin in one case. Conclusion Male breast cancer has many similarities to breast cancer in women, but there are distinct features that should be appreciated. Future research for better understanding of this disease at national or international level are needed to improve the management and prognosis of male patients.

  1. Mary Tyler Moore Helps Launch NIH MedlinePlus Magazine

    Science.gov (United States)

    ... Issues Mary Tyler Moore Helps Launch NIH MedlinePlus Magazine Past Issues / Winter 2007 Table of Contents For ... Javascript on. Among those attending the NIH MedlinePlus magazine launch on Capitol Hill were (l-r) NIH ...

  2. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

    Science.gov (United States)

    Mellman, Ira; Hubbard-Lucey, Vanessa M; Tontonoz, Matthew J; Kalos, Michael D; Chen, Daniel S; Allison, James P; Drake, Charles G; Levitsky, Hy; Lonberg, Nils; van der Burg, Sjoerd H; Fearon, Douglas T; Wherry, E John; Lowy, Israel; Vonderheide, Robert H; Hwu, Patrick

    2016-04-01

    With the recent FDA approvals of pembrolizumab and nivolumab, and a host of additional immunomodulatory agents entering clinical development each year, the field of cancer immunotherapy is changing rapidly. Strategies that can assist researchers in choosing the most promising drugs and drug combinations to move forward through clinical development are badly needed in order to reduce the likelihood of late-stage clinical trial failures. On October 5, 2014, the Cancer Immunotherapy Consortium of the Cancer Research Institute, a collaborative think tank composed of stakeholders from academia, industry, regulatory agencies, and patient interest groups, met to discuss strategies for de-risking immunotherapy development, with a focus on integrating preclinical and clinical studies, and conducting smarter early-phase trials, particularly for combination therapies. Several recommendations were made, including making better use of clinical data to inform preclinical research, obtaining adequate tissues for biomarker studies, and choosing appropriate clinical trial endpoints to identify promising drug candidates and combinations in nonrandomized early-phase trials.

  3. Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.

    Directory of Open Access Journals (Sweden)

    Adela Castelló

    Full Text Available According to the "World Cancer Research Fund" and the "American Institute of Cancer Research" (WCRF/AICR one in four cancer cases could be prevented through a healthy diet, weight control and physical activity.To explore the association between the WCRF/AICR recommendations and risk of breast cancer.During the period 2006 to 2011 we recruited 973 incident cases of breast cancer and 973 controls from 17 Spanish Regions. We constructed a score based on 9 of the WCRF/AICR recommendations for cancer prevention:: 1Maintain adequate body weight; 2Be physically active; 3Limit the intake of high density foods; 4Eat mostly plant foods; 5Limit the intake of animal foods; 6Limit alcohol intake; 7Limit salt and salt preserved food intake; 8Meet nutritional needs through diet; S1Breastfeed infants exclusively up to 6 months. We explored its association with BC by menopausal status and by intrinsic tumor subtypes (ER+/PR+ & HER2-; HER2+; ER&PR-&HER2- using conditional and multinomial logistic models respectively.Our results point to a linear association between the degree of noncompliance and breast cancer risk. Taking women who met 6 or more recommendations as reference, those meeting less than 3 showed a three-fold excess risk (OR=2.98(CI95%:1.59-5.59, especially for postmenopausal women (OR=3.60(CI95%:1.24;10.47 and ER+/PR+&HER2- (OR=3.60(CI95%:1.84;7.05 and HER2+ (OR=4.23(CI95%:1.66;10.78 tumors. Noncompliance of recommendations regarding the consumption of foods and drinks that promote weight gain in premenopausal women (OR=2.24(CI95%:1.18;4.28; p for interaction=0.014 and triple negative tumors (OR=2.93(CI95%:1.12-7.63; the intake of plant foods in postmenopausal women (OR=2.35(CI95%:1.24;4.44 and triple negative tumors (OR=3.48(CI95%:1.46-8.31; and the alcohol consumption in ER+/PR+&HER2- tumors (OR=1.52 (CI95%:1.06-2.19 showed the strongest associations.Breast cancer prevention might be possible by following the "World Cancer Research Fund" and the

  4. SPAJANJE IN MERITVE ZRAČNIH OPTIČNIH KABLOV V PRENOSTNIH ELEKTROENERGETSKIH SISTEMIH

    OpenAIRE

    Horvat, Dominik

    2010-01-01

    V nalogi smo predstavili spajanje in meritve zračnih optičnih kablov posebej v elektroenergetskih sistemih, pri čemer smo upoštevali ITU-T standarde za enorodovna optična vlakna. Podali smo predstavitev optičnih komunikacij, pri kateri smo opisali pomembne sestavne dele optične trase, kot so viri, prenosni mediji in detektorji. Posebej smo podali tipe zračnih optičnih kablov in spojk, ki se jih največkrat uporablja v elektroenergetskih sistemih, s poudarkom na OPGW kablih in kabelskih s...

  5. 2014 Awards Gala Event | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Grodzinski (left), Director of the NCI Alliance for Nanotechnology in Cancer at the National Cancer Institute, presented ... Library & Informatics Center, at the University of New Mexico. Good Morning America news anchor Amy Robach , who ...

  6. Environmental dose in the Nuclear Medicine Department of the National Institute of Cancer

    International Nuclear Information System (INIS)

    The dosimeters TLD-100 and TLD-900 were used to know the levels of environmental dose in areas of the Nuclear Medicine Department of the National Institute of Cancer. The dosimeters calibration was carried out in the Metrology Department of the National Institute of Nuclear Research. The radioisotopes used in the studied areas are 131I, 18F, 67Ga, 99mTc, 111In, 201Tl and 137Cs with gamma energies between 93 and 662 KeV. Dosimeters were placed during five months in the diagnostic, injection, waiting and PET rooms as well as hot room, waste room, enclosed corridors to patient rooms treated with 131I and 137Cs and witness dosimeters to know the bottom. The values found vary between 0.3 and 70 major times that those of bottom. The maximum doses were measured in the waste room and in the enclosed corridor to the patient rooms with cervical uterine cancer treated with 137Cs. (Author)

  7. 76 FR 60508 - National Institute of Mental Health Notice of Closed Meetings

    Science.gov (United States)

    2011-09-29

    ....282, Mental Health National Research Service Awards for Research Training, National Institutes of... HUMAN SERVICES National Institutes of Health National Institute of Mental Health Notice of Closed... of Committee: National Institute of Mental Health Special Emphasis Panel; NIH Summer...

  8. 75 FR 8372 - National Institute of Mental Health; Notice of Closed Meeting

    Science.gov (United States)

    2010-02-24

    ... HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed... of Committee: National Institute of Mental Health Special Emphasis Panel, HIV AIDS Training. Date... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001...

  9. 78 FR 18359 - National Institute of Environmental Health Sciences; Notice of Closed Meetings

    Science.gov (United States)

    2013-03-26

    ... HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice... personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis....nih.gov . Name of Committee: National Institute of Environmental Health Sciences Special...

  10. Quality of life among young women with breast cancer: Study from a tertiary cancer institute in south India

    Directory of Open Access Journals (Sweden)

    B Dubashi

    2010-01-01

    Full Text Available Background : The incidence of breast cancer in young patients less than 35 years is less than 1%. The physical and psychosocial morbidity may affect their ability to successfully function in their social roles. Hence we studied the quality of life (QOL issues in this subset. Materials and Methods :Younger women with age less than 35 years, diagnosed with non-metastatic breast cancer at our Institute, from 1995 to 2005, were included in the study. Quality of life issues were studied during the follow-up using EORTC QOL C30 and BR23. Descriptive and inferential statistics were used in order to analyze the data. Results : A total of 51 patients were included for the study. The mean age at diagnosis was 30 years. The effect of breast cancer on the occupation and marital status was minimal. The global health status and the functional scores were high, while the overall sexual function was lower. The global health status was higher in the mastectomy group. The arm symptoms (P = 0.027 and pain were higher in the Breast conservation surgery (BCS group. The sexual symptoms appeared to be higher in the ovary ablated group when compared to the ovary preserved group. The sexual functional scores (P = 0.02 and sexual enjoyment scores (P = 0.003 were better in the mastectomy group. Conclusion : The overall QOL in younger patients with breast cancer appeared to be good. The QOL and sexual function were marginally worse in the breast conservation group when compared to mastectomy group.

  11. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: results from the European Prospective Investigation into Nutrition and Cancer cohort study1,4

    NARCIS (Netherlands)

    Vergnaud, A.C.; Romaguera, D.; Peeters, P.H.M.; Gils, C.H. van; Chan, D.S.; Romieu, I.; Freisling, H.; Ferrari, P.; Clavel-Chapelon, F.; Fagherazzi, G.; Dartois, L.; Li, K.; Tikk, K.; Bergmann, M.M.; Boeing, H.; Tjonneland, A.; Olsen, A.; Overvad, K.; Dahm, C.C.; Redondo, M.L.; Agudo, A.; Sanchez, M.J.; Amiano, P.; Chirlaque, M.D.; Ardanaz, E.; Khaw, K.T.; Wareham, N.J.; Crowe, F.; Trichopoulou, A.; Orfanos, P.; Trichopoulos, D.; Masala, G.; Sieri, S.; Tumino, R.; Vineis, P.; Panico, S.; Bueno-De-Mesquita, H.B.; Ros, M.M.; May, A.; Wirfalt, E.; Sonestedt, E.; Johansson, I.; Hallmans, G.; Lund, E.; Weiderpass, E.; Parr, C.L.; Riboli, E.; Norat, T.

    2013-01-01

    BACKGROUND: In 2007, the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) issued recommendations on diet, physical activity, and weight management for cancer prevention on the basis of the most comprehensive collection of available evidence. OBJECTIVE: We inves

  12. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe : results from the European Prospective Investigation into Nutrition and Cancer cohort study

    NARCIS (Netherlands)

    Vergnaud, Anne-Claire; Romaguera, Dora; Peeters, Petra H.; van Gils, Carla H.; Chan, Doris S. M.; Romieu, Isabelle; Freisling, Heinz; Ferrari, Pietro; Clavel-Chapelon, Francoise; Fagherazzi, Guy; Dartois, Laureen; Li, Kuanrong; Tikk, Kaja; Bergmann, Manuela M.; Boeing, Heiner; Tjonneland, Anne; Olsen, Anja; Overvad, Kim; Dahm, Christina C.; Luisa Redondo, Maria; Agudo, Antonio; Sanchez, Maria-Jose; Amiano, Pilar; Chirlaque, Maria-Dolores; Ardanaz, Eva; Khaw, Kay-Tee; Wareham, Nick J.; Crowe, Francesca; Trichopoulou, Antonia; Orfanos, Philippos; Trichopoulos, Dimitrios; Masala, Giovanna; Sieri, Sabina; Tumino, Rosario; Vineis, Paolo; Panico, Salvatore; Bueno-de-Mesquita, H. Bas; Ros, Martine M.; May, Anne; Wirfalt, Elisabet; Sonestedt, Emily; Johansson, Ingegerd; Hallmans, Goeran; Lund, Eiliv; Weiderpass, Elisabete; Parr, Christine L.; Riboli, Elio; Norat, Teresa

    2013-01-01

    Background: In 2007, the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) issued recommendations on diet, physical activity, and weight management for cancer prevention on the basis of the most comprehensive collection of available evidence. Objective: We inves

  13. The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

    Science.gov (United States)

    Shoemaker, Robert H; Suen, Chen S; Holmes, Cathy A; Fay, Judith R; Steele, Vernon E

    2016-02-01

    The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a National Cancer Institute, Division of Cancer Prevention (NCI, DCP)-supported program whose primary goal is to bring new cancer preventive interventions (small molecules and vaccines) and biomarkers through preclinical development towards clinical trials by creating partnerships between the public sector (eg, academia, industry) and DCP. PREVENT has a formalized structure for moving interventions forward in the prevention pipeline using a stage-gate process with go/no go decision points along the critical path for development. This review describes the structure of the program, its focus areas, and provides examples of projects currently in the pipeline.

  14. The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

    Science.gov (United States)

    Shoemaker, Robert H; Suen, Chen S; Holmes, Cathy A; Fay, Judith R; Steele, Vernon E

    2016-02-01

    The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a National Cancer Institute, Division of Cancer Prevention (NCI, DCP)-supported program whose primary goal is to bring new cancer preventive interventions (small molecules and vaccines) and biomarkers through preclinical development towards clinical trials by creating partnerships between the public sector (eg, academia, industry) and DCP. PREVENT has a formalized structure for moving interventions forward in the prevention pipeline using a stage-gate process with go/no go decision points along the critical path for development. This review describes the structure of the program, its focus areas, and provides examples of projects currently in the pipeline. PMID:26970137

  15. Description of the National Institutes of Health

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    @@ Introduction The National Institutes of Health(NIH),apart of the U.S.Department of Health and Human Services,is the nation's medical research agency-making important discoveries that improve health and save lives.Thanks in large part to NIH-funded medical research,Americans today are living longer and healthier.

  16. 77 FR 57570 - National Institute On Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-18

    ... HUMAN SERVICES National Institutes of Health National Institute On Deafness and Other Communication..., Bethesda, MD 20892, 301-496-8683, sullivas@mail.nih.gov . Name of Committee: National Institute on Deafness...-8683, singhs@nidcd.nih.gov . Name of Committee: National Institute on Deafness and Other...

  17. 78 FR 40755 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-07-08

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Summer Research Experience Programs... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC...

  18. 78 FR 13362 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-02-27

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Pathway to Independence Award... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC...

  19. 77 FR 72366 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-12-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Pathway to Independence Award... Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245,...

  20. 78 FR 37835 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-06-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Summer Research Experience Programs... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  1. Cost comparison of curative therapies for localized prostate cancer in Japan. A single-institution experience

    International Nuclear Information System (INIS)

    In addition to open surgery, curative therapies for prostate cancer now include endoscopic surgery and radiation therapies. Because of the expansion and subdivision of treatment methods for prostate cancer, the medical fee point schedule in Japan was revised in fiscal year 2006. We examined changes in medical income and expenditure after this revision of the medical fee system. We studied income and expenditure, after institution of the new medical fee schedule, for the five types of therapies for prostate cancer performed at our hospital: two surgical therapies (radical retropubic prostatectomy and laparoscopic prostatectomy) and three radiation therapies (three-dimensional conformal radiation therapy, 192Ir high-dose-rate brachytherapy, and 125I low-dose-rate brachytherapy). Low-dose-rate brachytherapy was found to be associated with a profit of 199 yen per patient. Laparoscopic prostatectomy, a highly advanced medical treatment that the fee revision changed from a partially insured to an insured procedure, yielded a profit of 75672 yen per patient. However, high-dose-rate brachytherapy was associated with a loss of 654016 yen per patient. Given the loss in hospital income per patient undergoing high-dose-rate brachytherapy, the medical fee point system for this procedure should be reassessed. (author)

  2. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation.

    Directory of Open Access Journals (Sweden)

    Kazufumi Honda

    Full Text Available BACKGROUND: Among the more common human malignancies, invasive ductal carcinoma of the pancreas has the worst prognosis. The poor outcome seems to be attributable to difficulty in early detection. METHODS: We compared the plasma protein profiles of 112 pancreatic cancer patients with those of 103 sex- and age-matched healthy controls (Cohort 1 using a newly developed matrix-assisted laser desorption/ionization (oMALDI QqTOF (quadrupole time-of-flight mass spectrometry (MS system. RESULTS: We found that hemi-truncated apolipoprotein AII dimer (ApoAII-2; 17252 m/z, unglycosylated apolipoprotein CIII (ApoCIII-0; 8766 m/z, and their summed value were significantly decreased in the pancreatic cancer patients [P = 1.36×10(-21, P = 4.35×10(-14, and P = 1.83×10(-24 (Mann-Whitney U-test; area-under-curve values of 0.877, 0.798, and 0.903, respectively]. The significance was further validated in a total of 1099 plasma/serum samples, consisting of 2 retrospective cohorts [Cohort 2 (n = 103 and Cohort 3 (n = 163] and a prospective cohort [Cohort 4 (n = 833] collected from 8 medical institutions in Japan and Germany. CONCLUSIONS: We have constructed a robust quantitative MS profiling system and used it to validate alterations of modified apolipoproteins in multiple cohorts of patients with pancreatic cancer.

  3. Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution

    International Nuclear Information System (INIS)

    Pelvic exenteration (PE) continues to be the only curative option in selected patients with advanced or recurrent pelvic neoplasms. A current debate exists concerning the appropriate selection of patients for PE, with the most important factor being the absence of extrapelvic disease. To evaluate the outcome of patients submitted to exenterative surgery. A review of the clinical charts of patients with colorectal cancer who underwent PE between January 1994 and June 2010 at the Institute National of Cancerología in Mexico City was performed. We selected 59 patients, 53 of whom were females (90%), and six of whom were males (10%). Mean age at the time of diagnosis was 50 years (range, 21–77 years). A total of 51 patients underwent posterior PE (86%), and eight patients underwent total PE (14%). Operative mortality occurred in two cases (3%), and 29 patients developed complications (49%). Overall, 11 patients (19%) experienced local failure with mean disease-free survival time of 10.2 months. After a mean follow-up of 28.3 months, nine patients are still alive without evidence of the disease (15%). PE should be considered in advanced colorectal cancer without extrapelvic metastatic disease. PE is accompanied by considerable morbidity (49%) and mortality (3%), but local control is desirable. Overall survival justifies the use of this procedure in patients with primary or recurrent locally advanced rectal cancer

  4. Postoperative Survival Estimation of Gastric Cancer Patients in Cancer Institute of Tehran, Imam Khomeini Hospital and Its Relative Factors

    Directory of Open Access Journals (Sweden)

    A. Kazemnejad

    2010-10-01

    Full Text Available Introduction & Objective: Gastric Cancer (GC is one of the most common causes of death in the world. The most important cause of high death rate related to GC is late diagnosis of the disease. The main treatment of gastric cancer in its primary stage of is surgery, and radiotherapy and chemotherapy are supplementary treatments. There are some factors that affect survival after surgery. This study aimed to assess the survival of patients with GC under surgery and to determine the risk factors of this cancer. Materials & Methods: A total of 262 patients with GC under surgery were followed and included in the study from 21st of March 2003 to 21st of March 2007 in the cancer institute of Tehran, Imam Khomeini Hospital, . The staging of the disease before the surgery was based on CT-Scan and endosonography and after the surgery was based on the pathologic reports. The survival of the patients was determined by their periodical referrals and our telephone contacts with their relatives. The survival times were considered as the time from the diagnosis up to the death or the end of the study. The effect of the various risk factors including gender, age at diagnosis, tumor site, pathologic stage of the disease, type of treatment, metastases and relapse were evaluated. Kaplan-Miere approach was used to estimate survival and Log-rank test and proportional Cox model to evaluate the related factors. Data were analyzed using Spss16 statistical software. Results: 75.2% of patients were men and 34.4% cases of patients experienced death. The mean follow-up time was 19.317.4. The mean age at diagnosis was 5811.5 and survival mean and median were 49 and 27 months respectively. The one, three and five year survival of the patients were 0.85, 0.41 and 0.3 respectively. Gender, pathologic stage, age at diagnosis and weight-loss were significantly related to the survival in multivariate analysis. Conclusion: The diagnosis of the cancer in primary stages causes

  5. Locally advanced cervix cancer: chemotherapy prior to definitive surgery or radiotherapy. A single institutional experience

    International Nuclear Information System (INIS)

    Primary or neoadjuvant chemotherapy prior to definitive local therapy has potential advantages for locally advanced cervix cancer. It can down stage a cancer and allow definitive local therapy to be technically possible (surgery), or potentially more effective (radiotherapy). It can also eradicate subclinical systemic metastases. This report reviews a single institution's experience of neoadjuvant chemotherapy prior to definitive local therapy for cervix cancer over a 13-year period. One hundred and six patients were treated with this intent. The patients were analysed for their response to chemotherapy, treatment received, survival, relapse and toxicity. The chemotherapy was feasible and the majority of patients had a complete or partial response (58.5%). Eight patients did not proceed to local treatment. Forty-six patients had definitive surgery and 52 had definitive radiotherapy. The 5-year overall survival was 27% and the majority of patients died with disease. The first site of relapse was usually in the pelvis (46.2%). Late complications that required ongoing medical therapy (n = 6) or surgical intervention (n = 2) were recorded in eight patients (7.5%). On univariate analysis stage (P= 0.04), tumour size (P = 0.01), lymph node status (P=0.003), response to chemotherapy (P = 0.045) and treatment (P = 0.003) were all significant predictors of survival. On multivariate analysis, tumour size (P < 0.0001) and nodal status (P = 0.02) were significant predictors of survival. Despite the impressive responses to chemotherapy of advanced cervix cancer, there is evidence from randomized trials that it does not improve or compromise survival prior to radiotherapy. As its role prior to surgery remains unclear, it should not be used in this setting outside a prospective randomized trial. Copyright (2001) Blackwell Science Pty Ltd

  6. Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years

    Science.gov (United States)

    Hong, Ji Hyung; Ha, Kyung Sun; Jung, Yun Hwa; Won, Hye Sung; An, Ho Jung; Lee, Guk Jin; Kang, Donghoon; Park, Ji Chan; Park, Sarah; Byun, Jae Ho; Suh, Young Jin; Kim, Jeong Soo; Park, Woo Chan; Jung, Sang Seol; Park, Il Young; Chung, Su-Mi; Woo, In Sook

    2016-01-01

    Purpose Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC. Materials and Methods Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively. Results Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease. Conclusion Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted

  7. The Bone Marrow Transplantation Center of the National Cancer Institute - its resources to assist patients with bone marrow failure

    International Nuclear Information System (INIS)

    This paper describes the bone marrow transplantation center of the brazilian National Cancer Institute, which is responsible for the cancer control in Brazil. The document also describes the resources available in the Institute for assisting patients presenting bone marrow failures. The Center provides for allogeneic and autologous bone marrow transplants, peripheral stem cell transplants, umbilical cord collections and transplants, and a small experience with unrelated bone marrow transplants. The Center receives patient from all over the country and provides very sophisticated medical care at no direct cost to the patients

  8. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana:

    OpenAIRE

    Stanic, Karmen; Kovac, Viljem

    2010-01-01

    Background Prophylactic cranial irradiation (PCI) has been used in patients with small-cell lung cancer (SCLC) to reduce the incidence of brain metastases (BM) and thus increase overall survival. The aim of this retrospective study was to analyze the characteristics of patients with SCLC referred to the Institute of Oncology Ljubljana, their eligibility for PCI, patterns of dissemination, and survival. Patients and methods Medical charts of 357 patients with SCLC, referred to the Institute of...

  9. ANALIZA TRGA UPORABNIKOV KOZMETIČNIH STORITEV

    OpenAIRE

    Majcen, Maja

    2010-01-01

    Izhodiščni cilj diplomske naloge je raziskava in analiza trga uporabnikov kozmetičnih storitev. V uvodnem delu so podani opredelitev problema, metodologija ter hipoteze, kar je bilo v pomoč pri izvedbi tržne raziskave. V teoretičnem delu sta predstavljena kozmetična dejavnost skozi marketinški splet 7 x P ter ciljno trženje. Del naloge smo namenili tudi strategiji trženja kozmetičnih storitev ter kakovosti in ugotavljanju zadovoljstva uporabnikov kozmetičnih storitev. Prepoznavnost ...

  10. NIH Research to Results | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Results Past Issues / Summer 2013 Table of Contents Scientists are studying new ways of working with the immune system to fight cancer. This includes vaccines aimed at making a person immune to his or her skin cancer cells. Another method is to train a person's immune cells to ...

  11. 75 FR 2551 - NIH Consensus Development Conference: Lactose Intolerance and Health; Notice

    Science.gov (United States)

    2010-01-15

    ... HUMAN SERVICES National Institutes of Health NIH Consensus Development Conference: Lactose Intolerance... Consensus Development Conference: Lactose Intolerance and Health'' to be held February 22-24, 2010, in the.... Lactose intolerance is the inability to digest significant amounts of lactose, a sugar found in milk...

  12. 78 FR 12074 - Office of Biotechnology Activities; Recombinant DNA Research: Actions Under the NIH Guidelines...

    Science.gov (United States)

    2013-02-21

    ... containing an HA from the Goose/Guangdong/1/96 lineage should become an HHS Select Agent (77 FR 63783... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... recommendations of the RAC, the NIH Office of Biotechnology Activities (OBA) concluded that more specific...

  13. NIH funds Virginia Tech project to help senior citizens access health care

    OpenAIRE

    Benton, Netta

    2004-01-01

    The National Institutes of Health (NIH) has awarded funding to computer science researchers in the Virginia Tech College of Engineering for a project aimed at making it easier for senior citizens to access Virginia Department for the Aging (VDA) services on the World Wide Web.

  14. The NIH R03 Award: An Initial Funding Step for Social Work Researchers

    Science.gov (United States)

    Langhorst, Diane M.; Svikis, Dace S.

    2007-01-01

    Social workers in academic and agency settings have the opportunity to do funded research using the National Institutes of Health (NIH) R03 small grant mechanism designed for discrete, clearly defined projects that can be completed within a 1- to 2-year time period with limited funding. This article describes the R03 mechanism and provides a guide…

  15. 76 FR 69743 - Proposed Collection; Comment Request; Application for Collaboration With the NIH Center for...

    Science.gov (United States)

    2011-11-09

    ... drug project starting points and ongoing biological/disease expertise throughout the project. Frequency... more information on the proposed project or to obtain a copy of the data collection plans and... Branch, NIH Center for Translational Therapeutics, National Human Genome Research Institute,...

  16. "Bionic Man" Showcases Medical Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn JavaScript on. Feature: The Bionic Man Meet the Bionic Man Past Issues / Fall 2014 Table of Contents ... and medical imaging, visit www.nibib.nih.gov "Bionic Man" Showcases Medical Research The National Institute of ...

  17. Focus on Communication: NIH Research to Results

    Science.gov (United States)

    ... Current Issue Past Issues Special Section: Focus on Communication NIH Research to Results Past Issues / Fall 2008 ... grew new hair cells. Read More "Focus on Communication" Articles Living with Hearing Loss / Anatomy of the ...

  18. GENETIKA SINDROMA POLICISTIČNIH JAJNIKA

    OpenAIRE

    Geršak, Ksenija; Ferk, Polonca

    2007-01-01

    Prikazan je sindrom policističnih jajnika (PCOS) kao heterogena kompleksna bolest, uglavnom iz vidika njegove multifaktorske patogeneze. Genetska pozadina ovog sindroma i najvjerojatniji PCOS geni kandidati detaljno su obrazloženi.

  19. Health Lines | NIH Medlineplus the Magazine

    Science.gov (United States)

    ... Preliminary findings showed that those who were fast walkers were less likely to develop dementia than those ... other countries. Investigators with the University of North Carolina in Chapel Hill led the research. NIH's National ...

  20. From The NIH Director - Envisioning the Future

    Science.gov (United States)

    ... Past Issues From The NIH Director Envisioning the Future Past Issues / Winter 2008 Table of Contents For ... of biomedical imaging—a science that uses advanced technologies to capture, store, analyze, and display images of ...

  1. Bush favours research at Pentagon and NIH

    CERN Multimedia

    MacIlwain, C

    2001-01-01

    The first budget from George W. Bush increases funding for military research and the NIH, while environmental work is drastically cut. The rest of civilian science funding is essentially frozen (1 page).

  2. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons

    Science.gov (United States)

    Majithia, Neil; Temkin, Sarah M.; Ruddy, Kathryn J.; Beutler, Andreas S.; Hershman, Dawn L.; Loprinzi, Charles L.

    2016-01-01

    Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional—yet unsubstantiated—practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity. PMID:26686859

  3. Photodynamic Therapy in Gynecologic Malignancies: A Review of the Roswell Park Cancer Institute Experience

    Directory of Open Access Journals (Sweden)

    Paul C. Mayor

    2016-09-01

    Full Text Available Photodynamic therapy (PDT is a treatment modality used in the management of solid tumor malignancies that employs the use of a photosensitizing agent, a light source and oxygen in order to illicit a direct cytotoxic effect. Its use in gynecologic malignancies is somewhat novel and has been used for palliative and curative intent. At the Roswell Park Cancer Institute, the use of PDT in the management of gynecologic cancers began in the mid 1980s and since that time 35 patients have received PDT as a treatment for recurrent or metastatic cutaneous and vulvar, vaginal, anal, and cervical recurrences. In our experience, 85% patients with metastatic cutaneous lesions had a complete response. Twenty-seven percent of patients with metastatic vaginal, cervical or anal recurrences had a complete response to therapy with a median response time of 28 months. Side effects from the treatment included moderate to severe burning sensation, pain and edema at the treatment site requiring narcotic pain medication for symptom management in patients who underwent treatment to cutaneous lesions as well as lower genital tract recurrences. PDT should be considered an option in patients who are too frail to undergo the standard of care or decline the standard of care in lieu of a less invasive treatment modality.

  4. Photodynamic Therapy in Gynecologic Malignancies: A Review of the Roswell Park Cancer Institute Experience

    Science.gov (United States)

    Mayor, Paul C.; Lele, Shashikant

    2016-01-01

    Photodynamic therapy (PDT) is a treatment modality used in the management of solid tumor malignancies that employs the use of a photosensitizing agent, a light source and oxygen in order to illicit a direct cytotoxic effect. Its use in gynecologic malignancies is somewhat novel and has been used for palliative and curative intent. At the Roswell Park Cancer Institute, the use of PDT in the management of gynecologic cancers began in the mid 1980s and since that time 35 patients have received PDT as a treatment for recurrent or metastatic cutaneous and vulvar, vaginal, anal, and cervical recurrences. In our experience, 85% patients with metastatic cutaneous lesions had a complete response. Twenty-seven percent of patients with metastatic vaginal, cervical or anal recurrences had a complete response to therapy with a median response time of 28 months. Side effects from the treatment included moderate to severe burning sensation, pain and edema at the treatment site requiring narcotic pain medication for symptom management in patients who underwent treatment to cutaneous lesions as well as lower genital tract recurrences. PDT should be considered an option in patients who are too frail to undergo the standard of care or decline the standard of care in lieu of a less invasive treatment modality. PMID:27669307

  5. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

    Science.gov (United States)

    Takebe, Naoko; Ahmed, Mansoor M; Vikram, Bhadrasain; Bernhard, Eric J; Zwiebel, James; Norman Coleman, C; Kunos, Charles A

    2016-10-01

    A number of oncology phase II radiochemotherapy trials with promising results have been conducted late in the overall experimental therapeutic agent development process. Accelerated development and approval of experimental therapeutic agents have stimulated further interest in much earlier radiation-agent studies to increase the likelihood of success in phase III trials. To sustain this interest, more forward-thinking preclinical radiobiology experimental designs are needed to improve discovery of promising radiochemotherapy plus agent combinations for clinical trial testing. These experimental designs should better inform next-step radiation-agent clinical trial dose, schedule, exposure, and therapeutic effect. Recognizing the need for a better strategy to develop preclinical data supporting radiation-agent phase I or II trials, the National Cancer Institute (NCI)-Cancer Therapy Evaluation Program (CTEP) and the NCI-Molecular Radiation Therapeutics Branch of the Radiation Research Program have partnered to promote earlier radiobiology studies of CTEP portfolio agents. In this Seminars in Radiation Oncology article, four key components of this effort are discussed. First, we outline steps for accessing CTEP agents for preclinical testing. Second, we propose radiobiology studies that facilitate transition from preclinical testing to early phase trial activation. Third, we navigate steps that walk through CTEP agent strategic development paths available for radiation-agent testing. Fourth, we highlight a new NCI-sponsored cooperative agreement grant supporting in vitro and in vivo radiation-CTEP agent testing that informs early phase trial designs. Throughout the article, we include contemporary examples of successful radiation-agent development initiatives.

  6. Cognition assessment using the NIH Toolbox

    OpenAIRE

    Weintraub, Sandra; Dikmen, Sureyya S.; Heaton, Robert K.; Tulsky, David S.; Zelazo, Philip D.; Bauer, Patricia J.; Carlozzi, Noelle E.; Slotkin, Jerry; Blitz, David; Wallner-Allen, Kathleen; Fox, Nathan A.; Beaumont, Jennifer L.; Mungas, Dan; Nowinski, Cindy J.; Richler, Jennifer

    2013-01-01

    Cognition is 1 of 4 domains measured by the NIH Toolbox for the Assessment of Neurological and Behavioral Function (NIH-TB), and complements modules testing motor function, sensation, and emotion. On the basis of expert panels, the cognition subdomains identified as most important for health, success in school and work, and independence in daily functioning were Executive Function, Episodic Memory, Language, Processing Speed, Working Memory, and Attention. Seven measures were designed to tap ...

  7. NIH Quickfinder and NIH MedlinePlus Advisory Group

    Science.gov (United States)

    ... Chris Thomsen , National Center for Complementary & Alternative Medicine Larry Thompson , National Human Genome Research Institute Anne Thurn , Ph.D., Office of Dietary Supplements Summer 2006 Issue: Page 28

  8. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

    International Nuclear Information System (INIS)

    We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution. Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexual function, were measured, applying the International Prostate Symptom Score (IPSS), the 7-grade Quality of Life Scale (QoL) and medical status, the International Consultation on Incontinence Modular Questionnaire (ICIQ), the International Index of Erectile Function (IIEF-5) and the Common Terminology Criteria for Adverse Events (CTCAE v4.03). Seed migration and loss, dosimetric parameters and learning effects were also analyzed. Medium follow-up time was 50 months (range, 1–85 months). The five-year biochemical failure rate was 7%. Acute proctitis rates were 19% (grade 1) and 1% (grade 2), respectively. The overall incidence of incontinence was 19% (mild), 16% (moderate) and < 1% (severe). An increase in IPSS ≥ 5 points was detected in 59% of patients, with 38% regaining their baseline. Seed dislocation was found in 24% of patients and correlated with D90 and V100. A learning curve was found for seed migration, D90 and V100. QoL correlated with the general health condition of patient, incontinence symptoms and IPSS. BT for early stage prostate cancer offers excellent five-year biochemical control with low toxicities. QoL aspects are favorable. A learning curve was detected for procedural aspects but its impact on patient relevant endpoints remains inconclusive

  9. Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

    International Nuclear Information System (INIS)

    Purpose: The optimal locoregional therapy for stage IIIA non-small cell lung cancer (NSCLC) is controversial, with definitive chemoradiation therapy (CRT) and neoadjuvant therapy followed by surgery (NT-S) serving as competing strategies. In this study, we used the National Cancer Database to determine the prevalence and predictors of NT in a large, modern cohort of patients. Methods and Materials: Patients with stage IIIA NSCLC treated with CRT or NT-S between 2003 and 2010 at programs accredited by the Commission on Cancer were included. Predictors were categorized as clinical, time/geographic, socioeconomic, and institutional. In accord with the National Cancer Database, institutions were classified as academic/research program and as comprehensive and noncomprehensive community cancer centers. Logistic regression and random effects multilevel logistic regression were performed for univariable and multivariable analyses, respectively. Results: The cohort consisted of 18,581 patients, 3,087 (16.6%) of whom underwent NT-S (10.6% induction CRT, 6% induction chemotherapy). The prevalence of NT-S was constant over time, but there were significant relative 31% and 30% decreases in pneumonectomy and right-sided pneumonectomy, respectively, over time (P trend <.02). In addition to younger age, lower T stage, and favorable comorbidity score, indicators of higher socioeconomic status were strong independent predictors of NT-S, including white race, higher income, and private/managed insurance. The type of institution (academic/research program vs comprehensive or noncomprehensive community cancer centers, odds ratio 1.54 and 2.08, respectively) strongly predicted NT-S, but treatment volume did not. Conclusions: Neoadjuvant therapy followed by surgery was an uncommon treatment approach in Commission on Cancer programs, and the prevalence of postinduction pneumonectomy decreased over time. Higher socioeconomic status and treatment at academic institutions were significant

  10. Quality Improvement in the National Cancer Institute Community Cancer Centers Program: The Quality Oncology Practice Initiative Experience

    Science.gov (United States)

    Siegel, Robert D.; Castro, Kathleen M.; Eisenstein, Jana; Stallings, Holley; Hegedus, Patricia D.; Bryant, Donna M.; Kadlubek, Pam J.; Clauser, Steven B.

    2015-01-01

    Purpose: The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) began in 2007; it is a network of community-based hospitals funded by the NCI. Quality of care is an NCCCP priority, with participation in the American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) playing a fundamental role in quality assessment and quality improvement (QI) projects. Using QOPI methodology, performance on quality measures was analyzed two times per year over a 3-year period to enhance our implementation of quality standards at NCCCP hospitals. Methods: A data-sharing agreement allowed individual-practice QOPI data to be electronically sent to the NCI. Aggregated data with the other NCCCP QOPI participants were presented to the network via Webinars. The NCCCP Quality of Care Subcommittee selected areas in which to focus subsequent QI efforts, and high-performing practices shared voluntarily their QI best practices with the network. Results: QOPI results were compiled semiannually between fall 2010 and fall 2013. The network concentrated on measures with a quality score of ≤ 0.75 and planned voluntary group-wide QI interventions. We identified 13 measures in which the NCCCP fell at or below the designated quality score in fall 2010. After implementing a variety of QI initiatives, the network registered improvements in all parameters except one (use of treatment summaries). Conclusion: Using the NCCCP as a paradigm, QOPI metrics provide a useful platform for group-wide measurement of quality performance. In addition, these measurements can be used to assess the effectiveness of QI initiatives. PMID:25538082

  11. The NIH-NIAID Filariasis Research Reagent Resource Center.

    Directory of Open Access Journals (Sweden)

    Michelle L Michalski

    2011-11-01

    Full Text Available Filarial worms cause a variety of tropical diseases in humans; however, they are difficult to study because they have complex life cycles that require arthropod intermediate hosts and mammalian definitive hosts. Research efforts in industrialized countries are further complicated by the fact that some filarial nematodes that cause disease in humans are restricted in host specificity to humans alone. This potentially makes the commitment to research difficult, expensive, and restrictive. Over 40 years ago, the United States National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID established a resource from which investigators could obtain various filarial parasite species and life cycle stages without having to expend the effort and funds necessary to maintain the entire life cycles in their own laboratories. This centralized resource (The Filariasis Research Reagent Resource Center, or FR3 translated into cost savings to both NIH-NIAID and to principal investigators by freeing up personnel costs on grants and allowing investigators to divert more funds to targeted research goals. Many investigators, especially those new to the field of tropical medicine, are unaware of the scope of materials and support provided by the FR3. This review is intended to provide a short history of the contract, brief descriptions of the fiilarial species and molecular resources provided, and an estimate of the impact the resource has had on the research community, and describes some new additions and potential benefits the resource center might have for the ever-changing research interests of investigators.

  12. Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America.

    Science.gov (United States)

    Spinks, Tracy; Albright, Heidi W; Feeley, Thomas W; Walters, Ron; Burke, Thomas W; Aloia, Thomas; Bruera, Eduardo; Buzdar, Aman; Foxhall, Lewis; Hui, David; Summers, Barbara; Rodriguez, Alma; Dubois, Raymond; Shine, Kenneth I

    2012-05-15

    Responding to growing concerns regarding the safety, quality, and efficacy of cancer care in the United States, the Institute of Medicine (IOM) of the National Academy of Sciences commissioned a comprehensive review of cancer care delivery in the US health care system in the late 1990s. The National Cancer Policy Board (NCPB), a 20-member board with broad representation, performed this review. In its review, the NCPB focused on the state of cancer care delivery at that time, its shortcomings, and ways to measure and improve the quality of cancer care. The NCPB described an ideal cancer care system in which patients would have equitable access to coordinated, guideline-based care and novel therapies throughout the course of their disease. In 1999, the IOM published the results of this review in its influential report, Ensuring Quality Cancer Care. The report outlined 10 recommendations, which, when implemented, would: 1) improve the quality of cancer care, 2) increase the current understanding of quality cancer care, and 3) reduce or eliminate access barriers to quality cancer care. Despite the fervor generated by this report, there are lingering doubts regarding the safety and quality of cancer care in the United States today. Increased awareness of medical errors and barriers to quality care, coupled with escalating health care costs, has prompted national efforts to reform the health care system. These efforts by health care providers and policymakers should bridge the gap between the ideal state described in Ensuring Quality Cancer Care and the current state of cancer care in the United States.

  13. Institutional Repository Bibliography, Version 1

    OpenAIRE

    Bailey, Jr., Charles W.

    2009-01-01

    The Institutional Repository Bibliography (IRB) presents selected English-language articles, books, and other scholarly textual sources that are useful in understanding institutional repositories. Although institutional repositories intersect with a number of open access and scholarly communication topics, this bibliography only includes works that are primarily about institutional repositories. For example, an article dealing with the NIH open access policy would not be included, but one dea...

  14. FDG-PET scanning in patients with differentiated thyroid cancers. Institutional experience

    International Nuclear Information System (INIS)

    Full text: Patient with detectable serum thyroglobulin (Tg) and negative radioiodine whole body (RAI-WB) scan should have FDG-PET scan to locate tumor tissue. Sometimes scan fail to detect any pathologic accumulation of FDG. Some well-differentiated thyroid cancers do not accumulate FDG. In addition, tumor burden could be so small that imaging becomes impossible. To explore this possibility, several studies explored relationship between serum Tg level and result of FDG-PET scans. Results were inconclusive and it is not clear if there is some low level of serum Tg below which PET scanning is not cost effective. We examined all cases of thyroid cancer patients who underwent FDG-PET scanning in our institution (N-33) for relationship between Tg level and results of the scan. There were 16 females, 17 males. Age was 19-81 years. Follicular cancer was present in 2 patients while 31 had papillary cancer. 14 patients had PET scan while withdrawn from T4 therapy, and 19 patients were scanned while TSH was suppressed. Overall, 20 scans were considered positive, while 12 were negative. One patient was considered to have positive scan but after scan was repeated interpretation was changed into - positive uptake due to inflammation. In patients whose PET scan was positive, Tg level was in a range 6.6-7,108 ng/ml, while those with negative scan had Tg level in 1.7-36.5 ng/ml range. In group withdrawn from T4 therapy and positive scan Tg level ranged from 13.8-7,108 ng/ml, and with negative scan 2.8-36.5 ng/ml. In PET positive patients in euthyroid group Tg ranged 6.6-432 ng/ml and in negative 1.7-13.3 ng/ml. Conclusion: These results suggest that patients who have negative RAI scan and low Tg level may not benefit from PET scanning. In our study Tg level less than 6.6 ng/ml for the whole group, and below 13.8 ng/ml for patient withdrawn from T4 therapy did not result in positive FDG-PET scan result. Our group is small and more data need to be collected to clarify these

  15. 78 FR 70309 - Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed...

    Science.gov (United States)

    2013-11-25

    ... Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01... of Committee: National Institute of Child Health and Human Development Special Emphasis Panel... Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH,...

  16. 78 FR 66752 - Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed...

    Science.gov (United States)

    2013-11-06

    ..., Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100... funding cycle. Name of Committee: National Institute of Child Health and Human Development Initial Review... Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH,...

  17. Audition assessment using the NIH Toolbox.

    Science.gov (United States)

    Zecker, Steven G; Hoffman, Howard J; Frisina, Robert; Dubno, Judy R; Dhar, Sumitrajit; Wallhagen, Margaret; Kraus, Nina; Griffith, James W; Walton, Joseph P; Eddins, David A; Newman, Craig; Victorson, David; Warrier, Catherine M; Wilson, Richard H

    2013-03-12

    The NIH Toolbox project has assembled measurement tools to assess a wide range of human perception and ability across the lifespan. As part of this initiative, a small but comprehensive battery of auditory tests has been assembled. The main tool of this battery, pure-tone thresholds, measures the ability of people to hear at specific frequencies. Pure-tone thresholds have long been considered the "gold standard" of auditory testing, and are normally obtained in a clinical setting by highly trained audiologists. For the purposes of the Toolbox project, an automated procedure (NIH Toolbox Threshold Hearing Test) was developed that allows nonspecialists to administer the test reliably. Three supplemental auditory tests are also included in the Toolbox auditory test battery: assessment of middle-ear function (tympanometry), speech perception in noise (the NIH Toolbox Words-in-Noise Test), and self-assessment of hearing impairment (the NIH Toolbox Hearing Handicap Inventory Ages 18-64 and the NIH Toolbox Hearing Handicap Inventory Ages 64+). Tympanometry can help differentiate conductive from sensorineural pathology. The NIH Toolbox Words-in-Noise Test measures a listener's ability to perceive words in noisy situations. This ability is not necessarily predicted by a person's pure-tone thresholds; some people with normal hearing have difficulty extracting meaning from speech sounds heard in a noisy context. The NIH Toolbox Hearing Handicap Inventory focuses on how a person's perceived hearing status affects daily life. The test was constructed to include emotional and social/situational subscales, with specific questions about how hearing impairment may affect one's emotional state or limit participation in specific activities. The 4 auditory tests included in the Toolbox auditory test battery cover a range of auditory abilities and provide a snapshot of a participant's auditory capacity.

  18. Cancer - resources

    Science.gov (United States)

    Resources - cancer ... The following organizations are good resources for information on cancer : American Cancer Society -- www.cancer.org Cancer Care -- www.cancercare.org National Cancer Institute -- www.cancer.gov

  19. 76 FR 10380 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2011-02-24

    ... grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard,...

  20. 77 FR 64119 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2012-10-18

    ... grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard... Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience... review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center,...

  1. 75 FR 82408 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2010-12-30

    ...: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center... of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard,...

  2. 76 FR 55928 - National Institute of Mental Health Notice of Closed Meetings

    Science.gov (United States)

    2011-09-09

    .... Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd... review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center,...

  3. 78 FR 34662 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-06-10

    ... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard,...

  4. 76 FR 9586 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2011-02-18

    .... Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center/Room 6138/MSC 9608, 6001...: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD...

  5. 78 FR 38067 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-06-25

    ...: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone... Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room...

  6. 78 FR 9404 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-02-08

    ... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard,...

  7. 78 FR 72093 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-12-02

    .... Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd... evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001...

  8. 77 FR 16247 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

    Science.gov (United States)

    2012-03-20

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... Allergy and Infectious Diseases, including consideration of personnel qualifications and performance, and... of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Building 31,...

  9. 76 FR 66932 - The National Cancer Institute (NCI) Announces the Initiation of a Public Private Industry...

    Science.gov (United States)

    2011-10-28

    ... Initiation of a Public Private Industry Partnership on Translation of Nanotechnology in Cancer (TONIC) To Promote Translational Research and Development Opportunities of Nanotechnology-Based Cancer Solutions... industry partnership called TONIC (Translation Of Nanotechnology In Cancer) to promote...

  10. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

    Science.gov (United States)

    Takebe, Naoko; Ahmed, Mansoor M; Vikram, Bhadrasain; Bernhard, Eric J; Zwiebel, James; Norman Coleman, C; Kunos, Charles A

    2016-10-01

    A number of oncology phase II radiochemotherapy trials with promising results have been conducted late in the overall experimental therapeutic agent development process. Accelerated development and approval of experimental therapeutic agents have stimulated further interest in much earlier radiation-agent studies to increase the likelihood of success in phase III trials. To sustain this interest, more forward-thinking preclinical radiobiology experimental designs are needed to improve discovery of promising radiochemotherapy plus agent combinations for clinical trial testing. These experimental designs should better inform next-step radiation-agent clinical trial dose, schedule, exposure, and therapeutic effect. Recognizing the need for a better strategy to develop preclinical data supporting radiation-agent phase I or II trials, the National Cancer Institute (NCI)-Cancer Therapy Evaluation Program (CTEP) and the NCI-Molecular Radiation Therapeutics Branch of the Radiation Research Program have partnered to promote earlier radiobiology studies of CTEP portfolio agents. In this Seminars in Radiation Oncology article, four key components of this effort are discussed. First, we outline steps for accessing CTEP agents for preclinical testing. Second, we propose radiobiology studies that facilitate transition from preclinical testing to early phase trial activation. Third, we navigate steps that walk through CTEP agent strategic development paths available for radiation-agent testing. Fourth, we highlight a new NCI-sponsored cooperative agreement grant supporting in vitro and in vivo radiation-CTEP agent testing that informs early phase trial designs. Throughout the article, we include contemporary examples of successful radiation-agent development initiatives. PMID:27619249

  11. Tumor induction following intraoperative radiotherapy: Late results of the National Cancer Institute canine trials

    Energy Technology Data Exchange (ETDEWEB)

    Barnes, M.; Duray, P.; DeLuca, A.; Anderson, W.; Sindelar, W.; Kinsella, T. (Fox Chase Cancer Center, Philadelphia, PA (USA))

    1990-09-01

    Intraoperative radiotherapy has been employed in human cancer research for over a decade. Since 1979, trials to assess the acute and late toxicity of IORT have been carried out at the National Cancer Institute in an adult dog model in an attempt to establish dose tolerance guidelines for a variety of organs. Of the 170 animals entered on 12 studies with a minimum follow-up of 2 years, 148 dogs received IORT; 22 control animals received only surgery. Animals were sacrificed at designated intervals following IORT, usually at 1, 6, 12, 24, and 60 month intervals. 102 of 148 irradiated dogs were sacrificed less than 24 months; 46 dogs were followed greater than or equal to 24 months after IORT. To date, 34 of the 46 animals have been sacrificed; the 12 remaining animals are to be followed to 5 years. These 12 animals have minimum follow-up of 30 months. In the irradiated group followed for greater than or equal to 24 months, 10 tumors have arisen in 9 animals. One animal developed an incidental spontaneous breast carcinoma outside the IORT port, discovered only at scheduled post-mortem exam. The remaining nine tumors arose within IORT ports. Two tumors were benign neural tumors--a neuroma and a neurofibroma. One animal had a collision tumor comprised of grade I chondrosarcoma adjacent to grade III osteosarcoma arising in lumbar vertebrae. Two other grade III osteosarcomas, one grade III fibrosarcoma, and one grade III malignant fibrous histiocytoma arose in retroperitoneal/paravertebral sites. An embryonal rhabdomyosarcoma (sarcoma botryoides) arose within the irradiated urinary bladder of one animal. No sham irradiated controls nor IORT animals sacrificed less than 24 months have developed any spontaneous or radiation-induced tumors. The time range of diagnoses of tumors was 24-58 months. The IORT dose range associated with tumor development was 20-35 Gy.

  12. Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

    Directory of Open Access Journals (Sweden)

    Hirasawa Naoki

    2012-08-01

    Full Text Available Abstract Background The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC treated with radiotherapy (RT with or without chemotherapy at 10 institutions in the Tokai District, Japan. Methods Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p  0.05. Results For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016. The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage. Conclusions In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage.

  13. Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

    International Nuclear Information System (INIS)

    The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan. Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p < 0.05. For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT) was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016). The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage. In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage

  14. The Gray Cancer Institute X-ray microprobe and its radiobiological applications

    International Nuclear Information System (INIS)

    Radiation micro-beams represent a unique and powerful tool to study and quantify the effects of precise doses of radiation delivered with micron precision to selected biological samples. The Gray Cancer Institute has developed two independent but complementary micro-irradiation facilities, specifically developed for the targeted irradiation of cells and structured tissues; a charged-particle microbeam that uses collimated protons or helium ions and an ultra-soft X-ray microprobe. The ultra-soft X-ray facility employs a focused electron bombardments source to produce a near monochromatic CK X-ray beam. Highly efficient zone plates optimised for the appropriate wavelength are used to focus the characteristic X-rays into a sub-micron spot. The facility is also equipped with a three-axis micro-positioning stage, an epi-fluorescent UV microscope with intensified CCD camera coupled to a fast PC for a automatic, fast and accurate samples recognition and alignment with the probe. Recent experiments have been directed to investigate the bystander effect by irradiating only one cell within a population of V79 cells that are subsequently individually revisited for colony formation. A clear bystander effect has been detected (∼ 10 % reduction in survival) when a single cell has been irradiated. The effect is triggered by very low doses ((∼ 100 mGy) and it is largely dose independent. (authors)

  15. 76 FR 50235 - National Institute of Environmental Health Sciences; Notice of Meetings

    Science.gov (United States)

    2011-08-12

    ....), notice is hereby given of meetings of the Interagency Breast Cancer and Environmental Research... Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee. Date: October 11..., collman@niehs.nih.gov . Name of Committee: Interagency Breast Cancer and Environmental...

  16. 76 FR 24896 - National Institute of Environmental Health Sciences; Notice of Meetings

    Science.gov (United States)

    2011-05-03

    ....), notice is hereby given of meetings of the Interagency Breast Cancer and Environmental Research... Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee (IBCERC) Research...@niehs.nih.gov . Name of Committee: Interagency Breast Cancer and Environmental Research...

  17. NIH study shows increased risk for two types of myotonic muscular dystrophy

    Science.gov (United States)

    Adults with a form of muscular dystrophy called myotonic muscular dystrophy (MMD) may be at increased risk of developing cancer, according to a study by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health.

  18. Skin cancer profile in patients from Ceara Cancer Institute on the period of 2000 to 2003 - doi:10.5020/18061230.2007.p46

    Directory of Open Access Journals (Sweden)

    Ismael Leite Martins

    2012-01-01

    Full Text Available Studies on skin cancer fulfilled in places with geographical and/or population characteristics that predispose to this kind of disease have become more and more necessary, so that prevention may be performed effectively. This descriptive, retrospective and documental study had the aim of setting the skin cancer profile of the patients registered in the Ceara Cancer Institute (ICC in the period of January,2000 to December, 2003. During the referred period, 1153 skin cancer cases were identified, especially in men (n=612; 53.1%. Basal cell carcinoma (n=736; 63.8% and spin cell carcinoma (n=254; 22.0% were the main histological types of skin cancer observed, and the face (n=478; 41.5% was the most common affected site. There was a predominance of skin cancer in patients from 60s to 80s (n=547; 47.4% with white skin (n=635; 55.8%, and surgery was the usual treatment choice (n=591; 51.2%. By the analysis of the ICC patients’ skin cancer profile, it was disclosed that with the age, people with light-colored skin and blond hair, male with chronic exposure to the sunlight without protection have greater risk to develop pre-malignant and malignant cutaneous lesions, increasing the rate of surgeries as a way of treatment.

  19. Keep Trying! | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... SmokelessTobaccoAGuideforQuitting.htm National Institute on Drug Abuse: http://smoking.drugabuse.gov/ Includes information on treating tobacco use and nicotine addiction for adults and teens. Free Guide Helps You Quit The National Cancer ...

  20. NIH医学研究路线图(NIH roadmap)

    Institute of Scientific and Technical Information of China (English)

    徐高连; 赵冰海; 吕学诜

    2005-01-01

    多年来,国防和医疗领域一直是美国科技政策的重点。美国国立卫生研究院(national institutes of health,NIH)不仅是美国,也是世界上从事生命科学研究最重要的研究机构,它的一举一动无不对世界的科学研究,尤其是生命科学的发展有着巨大的影响。为提高医学研究能力,加速基础医学研究成果向临床应用的转化,NIH院长瑞尔霍尼(Elias A.Zerhouni)博士于2003年10月1日公布了NIH医学研究路线图(the NIH roadmap for medical research,NIH roadmap),这是一个通向生命科学未来的“中长期发展规划”,它将对21世纪全世界医学的发展产生重大影响。

  1. Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs

    OpenAIRE

    Jian Du; Xiaoli L Tang

    2014-01-01

    Objectives: To analyze multi-source data including awards, publications, patents and drugs, and try to draw the whole landscape of the research and development community in the area of natural products (NPs) against cancer. Materials and Methods: Awards, publications, patents and drugs data from National Institute of Health/Natural Science Foundation of China (NIH/NSFC), PubMed, Derwent Innovation Index and Cortellis were collected. Bibliometric methodologies and technology are used to in...

  2. Results of treatment of differentiated thyroid cancers using Iodine-131 at Sri Lanka's first private institution

    International Nuclear Information System (INIS)

    Full text: This department was started in order to meet the urgent demand of iodine-131 treatment in differentiated thyroid cancer (DTC), as the waiting list in government hospitals was unduly long. Data obtained revealed that 52% of the patients had iodine-131 therapy within 4 months, 31% in 4 to 8 months and 17% over 8 months time. Institute received license to order, stock and administer iodine-131 from the AEA-Sri Lanka as its facilities were according to IAEA standards. Facility included three 'single bedded en-suit toilet rooms' with storage capacity for iodine-131 capsules. 115 cases (male: female ratio 1:4) of DTC were treated during the past one and half year and each received 100 GBq of radioactivity. 89 (77.3%) comprised papillary carcinoma, 25 (21.7%) follicular carcinoma and 1 case of mixed carcinoma. 52% of males and 60.8% of females were in the 26-45 years age group. Sixty cases of papillary carcinoma were sub-typed and grouped to observe the distribution of metastases and response to iodine-131. They were follicular variant (FV) in 28 (46%), micropaillary (MP) in 10 (20%), encapsulated (EP) in 8 (13.3%), tall cell (TC) in 3 (5%) and diffuse sclerosis (DS) in 9 (15%). TSH and Tg values were measured before therapy and four months afterwards. Activity readings were measured 30 min after ingestion and 4 days later and discharged when the values were less than 20 μSv / hour. Six of the nine (66%) DS cancer patients had metastasis in lymph nodes and lungs when referred for iodine-131 treatment. In 8 of these patients, Tg levels were raised. 36% (8/9) of the FC patients also had raised Tg levels indicating metastases and 4/5 were found to have bony metastases. In post iodine-131 therapy whole body scans, 3.3% had metastases in the lungs in PC and 20% of FC in skeleton. With a single dose of iodine-131 over 90% had drop in Tg levels to less than I ng/ml except in DS (23% drop) and TC (33% drop). The study shows that sub-typing of PC was useful and TC and

  3. Definitive Radiotherapy for T1-2 Hypopharyngeal Cancer: A Single-Institution Experience

    Energy Technology Data Exchange (ETDEWEB)

    Nakajima, Aya, E-mail: anakajima-kyt@umin.ac.jp [Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (Japan); Nishiyama, Kinji; Morimoto, Masahiro; Nakamura, Satoaki; Suzuki, Osamu; Kawaguchi, Yoshifumi; Miyagi, Ken [Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (Japan); Fujii, Takashi; Yoshino, Kunitoshi [Department of Head and Neck Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (Japan)

    2012-02-01

    Purpose: To analyze the outcome in T1-2 hypopharyngeal cancer (HPC) patients treated with definitive radiotherapy (RT). Patients and Methods: A total of 103 patients with T1-2 hypopharyngeal squamous cell carcinoma treated with radical RT between March 2000 and June 2008 at our institution were analyzed. Pre-RT neck dissection (ND) was performed in 26 patients with advanced neck disease. Chemotherapy was used concurrently with RT in 14 patients. Sixty patients were associated with synchronous or metachronous malignancies. The median follow-up for surviving patients was 41 months. Results: The 3-year overall and cause-specific survival rates were 70% and 79%, respectively. The 3-year local control rates were 87% for T1 and 83% for T2 disease. The ultimate local control rate was 89%, including 7 patients in whom salvage was successful. The ultimate local control rate with laryngeal preservation was 82%. Tumors of the medial wall of the pyriform sinus tended to have lower control rates compared with tumors of the lateral or posterior pharyngeal wall. Among patients with N2b-3 disease, the 3-year regional control rates were 74% for patients with pre-RT ND and 40% for patients without ND. The 3-year locoregional control rates were as follows: Stage I, 100%; Stage II, 84%; Stage III, 67%; Stage IVA, 43%; Stage IVB, 67%. Forty-two patients developed disease recurrence, with 29 (70%) patients developing recurrence within the first year. Of the 103 patients, 6 developed late complications higher than or equal to Grade 3. Conclusions: Definitive RT accomplished a satisfactory local control rate and contributed to organ preservation.

  4. A pilot study to assess the level of depression and the coping strategies adopted by cancer patients receiving treatment in Mizoram State Cancer Institute, Aizawl

    Directory of Open Access Journals (Sweden)

    Gitumoni Konwar

    2015-01-01

    Full Text Available Background: Cancer, the second most common cause of death, has become a major health problem. Depression is the most common psychological problem encountered in patients with cancer. The coping skills adopted may affect the mental health of patients. Therefore, this research is undertaken to assess the level of depression and coping strategy adopted by the patients diagnosed with cancer. Materials and methods: A descriptive study to assess the level of depression and coping strategy adopted by cancer patients receiving treatment in Mizoram State Cancer Institute, Aizawl was carried out from April to May 2014 with 30 convenient samples. Depression was assessed by using Hospital Anxiety and Depression Scale (HADS developed by Zigmond and Snaith in 1983. Coping strategy adopted by patients were assessed by revised version of the Ways of Coping Checklist developed by Folkman and Lazarus in 1985. Results: Findings of the study showed that depression was universal to all the cancer patients. Majority of cancer patients (66.5% had moderate depression while 13.26% of the cancer patients had severe depression, and only 6.7% of them reported to have low depression. The most effective coping strategy adopted was reappraisal, followed by distancing. There is significant correlation between depression and reappraisal (r=-0.538, p<0.002, and also with depression and acceptance (r=-0.415, p<0.022 strategies. Conclusion: As depression is universal to all cancer patients, use of appropriate coping strategy is very essential to improve their quality of life. The recognition of coping strategies by health team may enable appropriate information and interventions to be provided at optimal times for each individual.

  5. Subscribe to NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... turn Javascript on. Subscribe to NIH MedlinePlus the magazine NIH MedlinePlus the magazine is published quarterly, in print and on the ... up for a free subscription to NIH MedlinePlus Magazine. Librarians may order this magazine in bulk . Please ...

  6. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Winter 2014 Table of Contents From DNA to Beer: Harnessing Nature in Medicine and Industry is an online exhibition created by the National ... consume. The exhibition is called From DNA to Beer: Harnessing Nature in Medicine and Industry. NIH's National Library of Medicine created it with ...

  7. NIH Research Addresses Aging Issues and Disparities in Oral Health | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... maintain oral health. The research is evaluating motivational interviewing, counseling, and oral hygiene skills-building to establish which approach(es) is most effective. We are also in active discussions with NIH ...

  8. Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India

    OpenAIRE

    Georgeena, P; Rajanbabu, Anupama; Vijaykumar, DK; Pavithran, K.; Sundaram, KR; Deepak, KS; Sanal, MR

    2016-01-01

    Objective To evaluate the treatment and survival pattern of patients with advanced epithelial ovarian cancer. Methods and results Retrospective study of all advanced epithelial ovarian cancer patients treated in the department of gynaecologic oncology from an academic centre, in a four year period from 1 January 2008–31 December 2011. Selection criteria All patients with advanced epithelial ovarian cancer (stage III and IV) who underwent surgery from 2008–2011and had a follow-up of at least t...

  9. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial

    OpenAIRE

    Pater, J.; Richardson, H.; Johnston, D.; Goss, Paul E.

    2007-01-01

    Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The ...

  10. Screening mammography. A missed clinical opportunity? Results of the NCI [National Cancer Institute] Breast Cancer Screening Consortium and national health interview survey studies

    International Nuclear Information System (INIS)

    Data from seven studies sponsored by the National Cancer Institute (NCI) were used to determine current rates of breast cancer screening and to identify the characteristics of and reasons for women not being screened. All seven studies were population-based surveys of women aged 50 to 74 years without breast cancer. While over 90% of non-Hispanic white respondents had regular sources of medical care, 46% to 76% had a clinical breast examination within the previous year, and only 25% to 41% had a mammogram. Less educated and poorer women had fewer mammograms. The two most common reasons women gave for never having had a mammogram were that they did not known they needed it and that their physician had not recommended it. Many physicians may have overlooked the opportunity to recommend mammography for older women when performing a clinical breast examination and to educate their patients about the benefit of screening mammography

  11. Comparison of Serum Selenium Levels in Breast Cancer Patients and Healthy People at a Cancer Institute in 2004

    Directory of Open Access Journals (Sweden)

    M Maleki

    2007-01-01

    Full Text Available Introduction: Breast Cancer is one of the most important fatal cancers in women. The mean age of breast cancer in Iran is 48.8 years which is very lower than other countries. Selenium can play an important role in reduction of cancer in several ways, for example selenium increases immunity response and protects cells from oxidation of free radicals and also decreases carcinogenic metabolites. Breast cancer is one of the most important cancers in our country because its incidence is very high and the mean age of patients is very low. Different studies have shown the benefits of selenium in prevention of cancer and since many years selenium has been used as a dietary supplement in advanced countries. Several studies regarding relationship between selenium levels and breast cancer have been done in different countries. We therefore planned a study to evaluate serum selenium levels in breast cancer patients and compare them with a healthy control group. Methods: We selected 45 patients younger than 48 years old and 33 patients older than 48 years old who had not yet received any therapy (surgery, chemotherapy, etc for their cancer as a case group and 46 healthy people who were matched with the patients as a control group and included 23 persons younger and 23 persons older than 48 years old. From each participant, 5cc blood was derived and in several stages, serum selenium levels were evaluated using atomic absorption technology. Data about type of cancer, stage, grade, IHC and cigarette smoking were also collected. Results: The mean Se level was 161.20 μg/l (SD=46.27 μg/l in the patients and 189.13 μg/l (SD=48.75 μg/l in the control group that was statistically significant (P48 years old was 155.39 μg/l (SD=46.68 μg/l that was lower than the control groups. Difference in serum selenium levels between patients and controls in the older group was significant (P=0.007, but in the younger group, it was not statistically significant (P=0

  12. Retrospective assessment of occupational asbestos exposure among 220 patients with respiratory cancer hospitalized at Vilnius University Institute of Oncology

    International Nuclear Information System (INIS)

    No cases of lung cancer or mesothelioma have ever been diagnosed or compensated as asbestos-related in Lithuania. This paper attempts to estimate the proportion of those occupationally exposed to asbestos among respiratory cancer patients. Occupational exposure to asbestos was assessed retrospectively for 218 lung cancer and 2 mesothelioma patients admitted to Institute of Oncology, Vilnius University. The evaluation was based on personal interview data using an internationally established questionnaire. Cumulative exposure to asbestos at work was evaluated in fibre-years. A cumulative asbestos exposure of ≥25 fibre-years was found for 7 patients (3.2%), in further 135 (61.2%) a cumulative exposure from 0.01 to 24.99 fibre-years was assessed. The most common occupations among heavily (≥25 fibre-years) exposed patients were smith, welder or insulator in foundries, construction, shipyard as well as asbestos cement and glass industry. Preliminary findings indicate that a fraction (3.2%) of the respiratory cancer cases could be attributed to occupational exposure to asbestos. Since 1560 or more cases of lung cancer are registered every year in Lithuania, about 50 cases per year could be predicted to be asbestos-related. (author)

  13. 76 FR 37358 - Office of the Director, National Institutes of Health; Notice of Meeting

    Science.gov (United States)

    2011-06-27

    ... p.m. Agenda: To review and evaluate second-level review of NIH Director's Early Independence Awards... HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health... Councils. Date: August 15, 2011. Open: 1 p.m. to 2: p.m. Agenda: Discussion of NIH Director's...

  14. The NIH Intramural Research Loan Repayment Program: Career Outcomes of Participants and Nonparticipants.

    OpenAIRE

    Steven Glazerman; Neil Seftor

    2005-01-01

    For over a decade, the National Institutes of Health has been using repayment of education loans as an incentive to attract and retain first-rate biomedical scientists in its labs and clinics. This report from an evaluation of the NIH Intramural Loan Repayment Programs uses new survey data on recruitment of biomedical researchers and career paths of program participants and nonparticipants to assess the role of these policies in recruiting and retention outcomes. The findings suggest that eli...

  15. Abbreviated report of the NIH/NINDS workshop on sudden unexpected death in epilepsy

    OpenAIRE

    Hirsch, L J; Donner, E.J.; So, E. L.; M. Jacobs; Nashef, L.; Noebels, J.L.; Buchhalter, J.R.

    2011-01-01

    Sudden unexpected death in epilepsy (SUDEP) is a devastating complication of epilepsy and is not rare. The NIH and National Institute of Neurological Disorders and Stroke sponsored a 3-day multidisciplinary workshop to advance research into SUDEP and its prevention. Parallel sessions were held: one with a focus on the science of SUDEP, and the other with a focus on issues related to the education of health care practitioners and people with epilepsy. This report summarizes the discussions and...

  16. Epidemiology and management of breast carcinoma in Egyptian males: Experience of a single Cancer Institute

    International Nuclear Information System (INIS)

    To assess the epidemiological and clinico-pathological features, surgical and reconstructive techniques, adjuvant treatments and clinical outcome of breast carcinoma in males (BCM) at the Egyptian National Cancer Institute (NCI). Patients and methods: Thirty-two males with breast carcinoma presented to NCI between January 2000 and December 2002. They were evaluated by complete history, physical examination, laboratory and radiological investigations. Results: Median age was 59 years. Left sided and retroareolar breast lumps were the commonest presentations. Grade 11 tumors positive for hormone receptors were very common. Stage I, II, 111 and IV disease were encountered in 6.2%, 34.4%, 34.4% and 25.0% of patients, respectively. Curative surgery was done in 22 patients; they received adjuvant hormonal therapy, chemotherapy and radiotherapy in 22,16 and 10 patients, respectively. Eight metastatic patients were treated with palliative measures. Surgery was done in 25 patients; the most common procedure was modified radical mastectomy (40.6%). Primary closure was feasible in 17 patients (68%), local flaps were needed in 4 cases (16%), while myocutaneous flap was done in 3 cases (12%). The commonest complication was development of seroma (9 cases). The overall survival (OS) at 5 years was 65.4%. The disease free survival (DPS) at 5 years was 53.9%. Stage and curative surgery significantly affected OS, while type of surgery was the only variable significantly affecting DPS. Conclusion: Male breast carcinoma occurs at older ages than females, usually in advanced stage. This necessitates directing attention of males and awareness on the prevalence and risk factors for this disease.needed in 4 cases (16%), while myocutaneous flap was done in 3 cases (12%). The commonest complication was development of seroma (9 cases). The overall survival (OS) at 5 years was 65.4%. The disease free survival (DPS) at 5 years was 53.9%. Stage and curative surgery significantly affected OS

  17. 77 FR 27785 - Request for Information Regarding the NIH-Industry Program To Discover New Therapeutic Uses for...

    Science.gov (United States)

    2012-05-11

    ... from the pharmaceutical industry, government, academia, and the non-profit sector ( http://www.ncats... biomedical researchers and the pharmaceutical industry as well as your experiences with drug rescue or... HUMAN SERVICES National Institutes of Health Request for Information Regarding the NIH-Industry...

  18. 78 FR 27974 - Proposed Collection; 60-Day Comment Request: National Cancer Institute (NCI) Alliance for...

    Science.gov (United States)

    2013-05-13

    ... projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written... for Strategic Scientific Initiatives, Office of Cancer Nanotechnology Research, National Cancer... Nanotechnology Research (OCNR), part of the Center for Strategic Scientific Initiatives within NCI. OMB...

  19. Cognition assessment using the NIH Toolbox.

    Science.gov (United States)

    Weintraub, Sandra; Dikmen, Sureyya S; Heaton, Robert K; Tulsky, David S; Zelazo, Philip D; Bauer, Patricia J; Carlozzi, Noelle E; Slotkin, Jerry; Blitz, David; Wallner-Allen, Kathleen; Fox, Nathan A; Beaumont, Jennifer L; Mungas, Dan; Nowinski, Cindy J; Richler, Jennifer; Deocampo, Joanne A; Anderson, Jacob E; Manly, Jennifer J; Borosh, Beth; Havlik, Richard; Conway, Kevin; Edwards, Emmeline; Freund, Lisa; King, Jonathan W; Moy, Claudia; Witt, Ellen; Gershon, Richard C

    2013-03-12

    Cognition is 1 of 4 domains measured by the NIH Toolbox for the Assessment of Neurological and Behavioral Function (NIH-TB), and complements modules testing motor function, sensation, and emotion. On the basis of expert panels, the cognition subdomains identified as most important for health, success in school and work, and independence in daily functioning were Executive Function, Episodic Memory, Language, Processing Speed, Working Memory, and Attention. Seven measures were designed to tap constructs within these subdomains. The instruments were validated in English, in a sample of 476 participants ranging in age from 3 to 85 years, with representation from both sexes, 3 racial/ethnic categories, and 3 levels of education. This report describes the development of the Cognition Battery and presents results on test-retest reliability, age effects on performance, and convergent and discriminant construct validity. The NIH-TB Cognition Battery is intended to serve as a brief, convenient set of measures to supplement other outcome measures in epidemiologic and longitudinal research and clinical trials. With a computerized format and national standardization, this battery will provide a "common currency" among researchers for comparisons across a wide range of studies and populations. PMID:23479546

  20. Gustation assessment using the NIH Toolbox.

    Science.gov (United States)

    Coldwell, Susan E; Mennella, Julie A; Duffy, Valerie B; Pelchat, Marcia L; Griffith, James W; Smutzer, Gregory; Cowart, Beverly J; Breslin, Paul A S; Bartoshuk, Linda M; Hastings, Lloyd; Victorson, David; Hoffman, Howard J

    2013-03-12

    The NIH Toolbox for Assessment of Neurological and Behavioral Function (NIH Toolbox) is a set of brief measures for the assessment of cognitive function, emotional health, motor function, and sensory function for use in clinical trials and in epidemiologic and longitudinal studies. Gustatory perception is assessed as 1 of 6 areas of sensory function. A team of 11 scientists with expertise in taste perception selected 2 gustatory measures, 1 of which can be used in young pediatric populations. The measure selected for young pediatric populations assesses sucrose (sweet) taste preference and can also be used across the age span of 5 to 85 years. For adult populations, the selected measure is a regional test, which assesses variability in perceived intensity of quinine hydrochloride (bitter) when applied to the tongue tip as well as perceived with the whole mouth. The team also recommends the regional test for assessing other tastants, such as sodium chloride (salty). Validation studies have demonstrated that the measures modified for the NIH Toolbox correlate with more traditional assessments, and can identify known population differences in gustation.

  1. 78 FR 39299 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-07-01

    ... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center... of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone...

  2. 76 FR 69747 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2011-11-09

    ... and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001.../NIH/DHHS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892, (301... review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center,...

  3. 75 FR 22816 - National Institute of Mental Health; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-30

    .... Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd..., Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact...

  4. 75 FR 42758 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2010-07-22

    ... review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001..., Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001...: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience...

  5. 76 FR 43333 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2011-07-20

    ... grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard... Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center...: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience...

  6. 78 FR 13358 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-02-27

    ... Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call..., National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606...: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD...

  7. 75 FR 54348 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2010-09-07

    ...: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive..., Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call) Contact...

  8. 78 FR 64227 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2013-10-28

    ...: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive BLVD... Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference...

  9. 76 FR 67468 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2011-11-01

    ... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville... Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center..., Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606, Bethesda, MD 20892-9606, (301)...

  10. 75 FR 19979 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-16

    ... evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive... Review Administrator, Scientific Review Branch, NIH/NINDS/Neuroscience Center, 6001 Executive Blvd....854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated:...

  11. 75 FR 28031 - National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

    Science.gov (United States)

    2010-05-19

    ..., Scientific Review Officer, Scientific Review Branch, National Inst of Dental & Craniofacial Research, NIH...; Teleconference Review of Small Research Grants for Data Analysis and Statistical Methodology (R03) Applications... HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial...

  12. Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an Institute of Medicine workshop.

    Science.gov (United States)

    Balogh, Erin P; Ganz, Patricia A; Murphy, Sharon B; Nass, Sharyl J; Ferrell, Betty R; Stovall, Ellen

    2011-01-01

    The Institute of Medicine's National Cancer Policy Forum recently convened a workshop on patient-centered cancer treatment planning, with the aim of raising awareness about this important but often overlooked aspect of cancer treatment. A primary goal of patient-centered treatment planning is to engage patients and their families in meaningful, thorough interactions with their health care providers to develop an accurate, well-conceived treatment plan, using all available medical information appropriately while also considering the medical, social, and cultural needs and desires of the patient and family. A cancer treatment plan can be shared among the patient, family, and care team in order to facilitate care coordination and provide a roadmap to help patients navigate the path of cancer treatment. There are numerous obstacles to achieving patient-centered cancer treatment planning in practice. Some of these challenges stem from the patient and include patients' lack of assertiveness, health literacy, and numeracy, and their emotional state and concurrent illnesses. Others are a result of physician limitations, such as a lack of time to explain complex information and a lack of tools to facilitate treatment planning, as well as insensitivity to patients' informational, cultural, and emotional needs. Potential solutions to address these obstacles include better training of health care providers and patients in optimal communication and shared decision making, and greater use of support services and tools such as patient navigation and electronic health records. Other options include greater use of quality metrics and reimbursement for the time it takes to develop, discuss, and document a treatment plan. PMID:22128118

  13. A Novel Cross-Disciplinary Multi-Institute Approach to Translational Cancer Research: Lessons Learned from Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC

    Directory of Open Access Journals (Sweden)

    Ashokkumar A. Patel

    2007-01-01

    Full Text Available Background: The Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC, http://www.pcabc.upmc.edu is one of the first major project-based initiatives stemming from the Pennsylvania Cancer Alliance that was funded for four years by the Department of Health of the Commonwealth of Pennsylvania. The objective of this was to initiate a prototype biorepository and bioinformatics infrastructure with a robust data warehouse by developing a statewide data model (1 for bioinformatics and a repository of serum and tissue samples; (2 a data model for biomarker data storage; and (3 a public access website for disseminating research results and bioinformatics tools. The members of the Consortium cooperate closely, exploring the opportunity for sharing clinical, genomic and other bioinformatics data on patient samples in oncology, for the purpose of developing collaborative research programs across cancer research institutions in Pennsylvania. The Consortium’s intention was to establish a virtual repository of many clinical specimens residing in various centers across the state, in order to make them available for research. One of our primary goals was to facilitate the identification of cancer specific biomarkers and encourage collaborative research efforts among the participating centers.Methods: The PCABC has developed unique partnerships so that every region of the state can effectively contribute and participate. It includes over 80 individuals from 14 organizations, and plans to expand to partners outside the State. This has created a network of researchers, clinicians, bioinformaticians, cancer registrars, program directors, and executives from academic and community health systems, as well as external corporate partners - all working together to accomplish a common mission. The various sub-committees have developed a common IRB protocol template, common data elements for standardizing data collections for three organ sites, intellectual

  14. Author Disambiguation in PubMed: Evidence on the Precision and Recall of Author-ity among NIH-Funded Scientists.

    Science.gov (United States)

    Lerchenmueller, Marc J; Sorenson, Olav

    2016-01-01

    We examined the usefulness (precision) and completeness (recall) of the Author-ity author disambiguation for PubMed articles by associating articles with scientists funded by the National Institutes of Health (NIH). In doing so, we exploited established unique identifiers-Principal Investigator (PI) IDs-that the NIH assigns to funded scientists. Analyzing a set of 36,987 NIH scientists who received their first R01 grant between 1985 and 2009, we identified 355,921 articles appearing in PubMed that would allow us to evaluate the precision and recall of the Author-ity disambiguation. We found that Author-ity identified the NIH scientists with 99.51% precision across the articles. It had a corresponding recall of 99.64%. Precision and recall, moreover, appeared stable across common and uncommon last names, across ethnic backgrounds, and across levels of scientist productivity.

  15. Author Disambiguation in PubMed: Evidence on the Precision and Recall of Author-ity among NIH-Funded Scientists.

    Science.gov (United States)

    Lerchenmueller, Marc J; Sorenson, Olav

    2016-01-01

    We examined the usefulness (precision) and completeness (recall) of the Author-ity author disambiguation for PubMed articles by associating articles with scientists funded by the National Institutes of Health (NIH). In doing so, we exploited established unique identifiers-Principal Investigator (PI) IDs-that the NIH assigns to funded scientists. Analyzing a set of 36,987 NIH scientists who received their first R01 grant between 1985 and 2009, we identified 355,921 articles appearing in PubMed that would allow us to evaluate the precision and recall of the Author-ity disambiguation. We found that Author-ity identified the NIH scientists with 99.51% precision across the articles. It had a corresponding recall of 99.64%. Precision and recall, moreover, appeared stable across common and uncommon last names, across ethnic backgrounds, and across levels of scientist productivity. PMID:27367860

  16. From the NIH: A Systems Approach to Increasing the Diversity of the Biomedical Research Workforce.

    Science.gov (United States)

    Valantine, Hannah A; Lund, P Kay; Gammie, Alison E

    2016-01-01

    The National Institutes of Health (NIH) is committed to attracting, developing, and supporting the best scientists from all groups as an integral part of excellence in training. Biomedical research workforce diversity, capitalizing on the full spectrum of skills, talents, and viewpoints, is essential for solving complex human health challenges. Over the past few decades, the biomedical research workforce has benefited from NIH programs aimed at enhancing diversity. However, there is considerable room for improvement, particularly at the level of independent scientists and within scientific leadership. We provide a rationale and specific opportunities to develop and sustain a diverse biomedical research workforce through interventions that promote the successful transitions to different stages on the path toward completion of training and entry into the biomedical workforce.

  17. From the NIH: A Systems Approach to Increasing the Diversity of the Biomedical Research Workforce

    Science.gov (United States)

    Valantine, Hannah A.; Lund, P. Kay; Gammie, Alison E.

    2016-01-01

    The National Institutes of Health (NIH) is committed to attracting, developing, and supporting the best scientists from all groups as an integral part of excellence in training. Biomedical research workforce diversity, capitalizing on the full spectrum of skills, talents, and viewpoints, is essential for solving complex human health challenges. Over the past few decades, the biomedical research workforce has benefited from NIH programs aimed at enhancing diversity. However, there is considerable room for improvement, particularly at the level of independent scientists and within scientific leadership. We provide a rationale and specific opportunities to develop and sustain a diverse biomedical research workforce through interventions that promote the successful transitions to different stages on the path toward completion of training and entry into the biomedical workforce. PMID:27587850

  18. From the NIH: A Systems Approach to Increasing the Diversity of the Biomedical Research Workforce.

    Science.gov (United States)

    Valantine, Hannah A; Lund, P Kay; Gammie, Alison E

    2016-01-01

    The National Institutes of Health (NIH) is committed to attracting, developing, and supporting the best scientists from all groups as an integral part of excellence in training. Biomedical research workforce diversity, capitalizing on the full spectrum of skills, talents, and viewpoints, is essential for solving complex human health challenges. Over the past few decades, the biomedical research workforce has benefited from NIH programs aimed at enhancing diversity. However, there is considerable room for improvement, particularly at the level of independent scientists and within scientific leadership. We provide a rationale and specific opportunities to develop and sustain a diverse biomedical research workforce through interventions that promote the successful transitions to different stages on the path toward completion of training and entry into the biomedical workforce. PMID:27587850

  19. For Distinguished Public Service: Medical Library Association Honors FNLM and NIH MedlinePlus Magazine | NIH ...

    Science.gov (United States)

    ... this page please turn Javascript on. For Distinguished Public Service: Medical Library Association Honors FNLM and NIH MedlinePlus Magazine Past Issues / Summer 2011 Table of Contents MLA President Ruth Holst presented FNLM ... Service Award at the MLA’s recent national conference. ...

  20. NIH Seeks Answers for Endometriosis | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: Endometriosis NIH Seeks Answers for Endometriosis Past Issues / Summer 2016 Table of Contents Dr. ... research. Why is it sometimes difficult to diagnose endometriosis? Several of its symptoms, such as pain and ...

  1. Parkinson's Disease Research at NIH | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: Parkinson's Disease Parkinson's Disease Research at NIH Past Issues / Winter 2014 Table ... areas of its research: MedlinePlus . medlineplus.gov . Type "Parkinson's disease" in the Search box. NIHSeniorHealth —Parkinson's Disease http:// ...

  2. Lung Cancer Surgery Worthwhile for Older Patients

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158689.html Lung Cancer Surgery Worthwhile for Older Patients Study found those ... 2016 THURSDAY, May 5, 2016 (HealthDay News) -- Older lung cancer patients are surviving longer when they have lung ...

  3. Critical appraisal of the suitability of translational research models for performance assessment of cancer institutions

    NARCIS (Netherlands)

    Rajan, A.; Sullivan, R.; Bakker, S.; Harten, van W.H.

    2012-01-01

    Background. Translational research is a complex cumulative process that takes time. However, the operating environment for cancer centers engaged in translational research is now financially insecure. Centers are challenged to improve results and reduce time from discovery to practice innovations. P

  4. Cervical Lymph Node Metastases From Unknown Primary Cancer: A Single-Institution Experience With Intensity-Modulated Radiotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Villeneuve, Hugo, E-mail: hugo.villeneuve@umontreal.ca [Department of Radiation Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Despres, Philippe; Fortin, Bernard; Filion, Edith; Donath, David [Department of Radiation Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Soulieres, Denis [Department of Medical Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Guertin, Louis; Ayad, Tarek; Christopoulos, Apostolos [Department of Head and Neck Surgery, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Nguyen-Tan, Phuc Felix [Department of Radiation Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada)

    2012-04-01

    Purpose: To determine the effectiveness and rate of complications of intensity-modulated radiotherapy (IMRT) in the treatment of cervical lymph node metastases from unknown primary cancer. Methods and Materials: Between February 2005 and November 2008, 25 patients with an unknown primary cancer underwent IMRT, with a median radiation dose of 70 Gy. The bilateral neck and ipsilateral putative pharyngeal mucosa were included in the target volume. All patients had squamous cell carcinoma, except for 1 patient who had adenosquamous differentiation. They were all treated with curative intent. Of the 25 included patients, 20 were men and 5 were women, with a median age of 54 years. Of these patients, 3 had Stage III, 18 had Stage IVa, and 4 had Stage IVb. Of the 25 patients, 18 (72%) received platinum-based chemotherapy in a combined-modality setting. Neck dissection was reserved for residual disease after definitive IMRT. Overall survival, disease-free survival, and locoregional control were calculated using the Kaplan-Meier method. Results: With a median follow-up of 38 months, the overall survival, disease-free survival, and locoregional control rates were all 100% at 3 years. No occurrence of primary cancer was observed during the follow-up period. The reported rates of xerostomia reduced with the interval from the completion of treatment. Nine patients (36%) reported Grade 2 or greater xerostomia at 6 months, and only 2 (8%) of them reported the same grade of salivary function toxicity after 24 months of follow-up. Conclusion: In our institution, IMRT for unknown primary cancer has provided good overall and disease-free survival in all the patients with an acceptable rate of complications. IMRT allowed us to address the bilateral neck and ipsilateral putative pharyngeal mucosa with minimal late salivary function toxicity. The use of concurrent chemotherapy and IMRT for more advanced disease led to good clinical results with reasonable toxicities.

  5. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.

    Science.gov (United States)

    Ambe, Chenwi M; Mahipal, Amit; Fulp, Jimmy; Chen, Lu; Malafa, Mokenge P

    2016-01-01

    Observational studies have demonstrated that metformin use in diabetic patients is associated with reduced cancer incidence and mortality. Here, we aimed to determine whether metformin use was associated with improved survival in patients with resected pancreatic cancer. All patients with diabetes who underwent resection for pancreatic adenocarcinoma between 12/1/1986 and 4/30/2013 at our institution were categorized by metformin use. Survival analysis was done using the Kaplan-Meier method, with log-rank test and Cox proportional hazards multivariable regression models. For analyses of our data and the only other published study, we used Meta-Analysis version 2.2. We identified 44 pancreatic cancer patients with diabetes who underwent resection of the primary tumor (19 with ongoing metformin use, 25 never used metformin). There were no significant differences in major clinical and demographic characteristics between metformin and non-metformin users. Metformin users had a better median survival than nonusers, but the difference was not statistically significant (35.3 versus 20.2 months; P = 0.3875). The estimated 2-, 3-, and 5-year survival rates for non-metformin users were 42%, 28%, and 14%, respectively. Metformin users fared better with corresponding rates of 68%, 34%, and 34%, respectively. In our literature review, which included 111 patients from the two studies (46 metformin users and 65 non-users), overall hazard ratio was 0.668 (95% CI 0.397-1.125), with P = 0.129. Metformin use was associated with improved survival outcomes in patients with resected pancreatic cancer, but the difference was not statistically significant. The potential benefit of metformin should be investigated in adequately powered prospective studies.

  6. Precision Medicine: Healthcare Tailored to You | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: NIH Precision Medicine Initiative Precision Medicine: Healthcare Tailored to You Past Issues / Fall 2015 ... NIH researchers and fellow scientists working on precision medicine efforts gather on the NIH campus in Bethesda, ...

  7. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology

    Directory of Open Access Journals (Sweden)

    Rais Ghizlane

    2012-10-01

    Full Text Available Abstract Background Triple-negative breast cancer (TNBC is defined by the lack of estrogen receptor (ER, progesterone receptor (PR, and human epidermal growth factor receptor 2 (HER-2 expression. This is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. The aim of this study is to determine the clinicopathological, therapeutic features and outcomes associated with this type of breast cancer. Methods This is a retrospective study of confirmed triple negative breast cancer females collected at the National institute of oncology of Rabat in Morocco, between January 2007 and December 2008. Epidemiological, clinical, histological, therapeutic and evolutive data were analyzed. OS and DFS rates were estimated by Kaplan-Meier analysis. Results A total of one 152 patients with breast cancer, were identified as having triple-negative breast cancer (16,5%. The median age at diagnosis was 46 years. 130 patients (86% had infiltrating ductal carcinoma and thirteen had medullar carcinoma (9%. 84 cases (55% were grade III Scarff-Bloom-Richardson (SBR. 48 % had positive lymph nodes, and 5 % had distant metastases at diagnosis. According TNM staging, 12 patients (8% had stage I, 90 patients (60% had stage II and the 43(28% had stage III. 145 patients received surgery. 41 (28% had conservative surgery and 104 (72% received radical mastectomy with axillary lymph nodes dissection. 14 patients with advanced tumors or inflammatory breast cancer have received neoadjuvant chemotherapy and four patients (28% had complete pathologic response. From 131 patients how received adjuvant chemotherapy, 99 patients (75,5% had Anthracycline based chemotherapy and 27 patients (20,6% had sequential Anthracycline and docetaxel,. Seven patients with metastatic disease received anthracycline-based regimen in the first line metastatic chemotherapy. The median follow-up time was 46 months (range 6,1 -60 months. Overall survival at 5 years

  8. A simple technique for the generation of institution-specific nomograms for permanent prostate cancer brachytherapy

    OpenAIRE

    Lafata, Kyle J.; Bushe, Harry; Aronowitz, Jesse N.

    2014-01-01

    Purpose Nomograms once had a vital role in prostate brachytherapy practice. Although some of their functions have been assumed by computerized dosimetry, many programs still find them useful to determine the number and strength of seeds to be ordered in advance of the implant. As it has been demonstrated that brachytherapists differ in their implant practices and preferences (in regard to seed distribution and total implanted activity), we propose a simple technique for generating institution...

  9. NIH study finds that coffee drinkers have lower risk of death

    Science.gov (United States)

    Older adults who drank coffee -- caffeinated or decaffeinated -- had a lower risk of death overall than others who did not drink coffee, according a study by researchers from the National Cancer Institute (NCI), part of the National Institutes of Health,

  10. 78 FR 24221 - National Institute of Neurological Disorders and Stroke

    Science.gov (United States)

    2013-04-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke... Advisor, Officer of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31...

  11. 78 FR 77475 - National Institute of Neurological Disorders and Stroke

    Science.gov (United States)

    2013-12-23

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke..., Officer of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31 Center...

  12. Prostate cancer - resources

    Science.gov (United States)

    Resources - prostate cancer ... The following organizations are good resources for information on prostate cancer : American Cancer Society -- www.cancer.org/cancer/prostatecancer/index National Cancer Institute -- www.cancer.gov/cancertopics/ ...

  13. A long-term survival pattern for breast cancer treated in a single institution

    Directory of Open Access Journals (Sweden)

    T Gokce

    2011-01-01

    Full Text Available Aim: This paper presents a 14-year retrospective study evaluating the survival rates and prognostic factors of breast carcinoma patients treated in private treatment center in the west coast of Turkey. Materials and Methods: The survival rates of breast cancer patients (n = 1746 who have been treated from 1995 until 2008 were analyzed. The clinical data include age, menopausal stage, oestrogen (ER and progesterone (PR receptor status, and C-erbB-2 status as well as histopathological evaluation. AJCC (2002 was used for clinical tumor staging. Survival rates were computed using standard Kaplan-Meier methods, and the difference in survival curves was analyzed with the log-rank test. Results: The 14-year overall survival, disease-free survival, local failure-free survival, and distant failure-free survival rates were 77%, 95%, 77%, and 94%, respectively. Early-stage patients had higher overall survival rates compared to advanced-stage patients (stage IIIb and IIIc, AJCC 2002, and early-stage patients had higher survival rates than advanced-stage patients for disease-free survival, local failure-free survival, and distant failure-free survival. The risk for cancer development increases significantly for advanced-stage patients with positive ER and PR receptor as well as C-erbB-2 receptor. Conclusions: The incidence of breast cancer in Turkey is smaller compared to other European countries. Low advanced-stage patient numbers compared to high early-stage patient numbers; and very high median survival times could possibly be the result of the improvement of detection and treatment of breast cancer over the years.

  14. Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan

    Energy Technology Data Exchange (ETDEWEB)

    Jingu, Keiichi, E-mail: kjingu-jr@rad.med.tohoku.ac.jp [Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan); Tanabe, Takaya [Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan); Nemoto, Kenji [Department of Radiation Oncology, Yamagata University School of Medicine, Yamagata (Japan); Ariga, Hisanori; Umezawa, Rei; Ogawa, Yoshihiro; Takeda, Ken; Koto, Masashi; Sugawara, Toshiyuki; Kubozono, Masaki; Shimizu, Eiji; Abe, Keiko; Yamada, Shogo [Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan)

    2012-07-15

    Purpose: To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy ({+-} EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials: Records for 322 patients with pancreatic cancer treated by IORT {+-} EBRT in Tohoku University Hospital between 1980 and 2009 were reviewed. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled in the present study. Results: Eighty-three patients underwent gross total resection (R0: 48 patients, R1: 35 patients), and 109 patients underwent only biopsy or palliative resection. Fifty-five patients underwent adjuvant EBRT, and 124 underwent adjuvant chemotherapy. The median doses of IORT and EBRT were 25 and 40 Gy, respectively. The median follow-up period was 37.5 months. At the time of the analysis, 166 patients had disease recurrence, and 35 patients had local failure. The 2-year local control (LC) and overall survival (OS) rates were 71.0% and 16.9%, respectively. Comparison of the results for each decade showed that OS was significantly improved decade by decade (2-year: 25.0% vs. 18.8% vs. 4.2%, p < 0.001). Multivariate analysis showed that degree of resection (R0-1 vs. R2, hazard ratio = 1.97, p = 0.001) and adjuvant chemotherapy (yes vs. no, hazard ratio = 1.54, p = 0.028) had significant impacts on OS. Late gastrointestinal morbidity of Common Terminology Criteria for Adverse Events version 3.0 grade 4 or 5 was observed in four patients. Conclusion: Excellent local control for pancreatic cancer with few cases of severe late toxicity was achieved by using IORT. OS of patients with pancreatic cancer treated by IORT {+-} EBRT improved significantly decade by decade. Multivariate analysis showed that degree of resection and adjuvant chemotherapy had significant impacts on OS.

  15. Radiotherapy in the cavum cancer: analysis of 30 cases treated in our institution in Beirut

    International Nuclear Information System (INIS)

    The authors describe the results obtained for nasopharyngeal cancers treated by irradiation, exclusively or in combination with chemotherapy. They also assess the impact of the different pathological and clinic variables on survival without relapse. The study is based on a sample of 30 patients treated between 1999 and 2009. Local control, metastatic dissemination, and toxicity are analysed and discussed. A ganglionary extension seems to be the worst prognostic factor. Short communication

  16. CPRIT/Johnson Space Center, September, 2011 (Cancer Prevention and Research Institute of Texas)

    Science.gov (United States)

    Davis, Jeffrey; Lane, Helen; Baker, Tracey; Cucinotta, Francis; Wu, Honglu

    2011-01-01

    JSC researchers study carcinogenesis, cancer prevention and treatment along with epidemiological (primarily retrospective and longitudinal) studies, modeling, and interactions with the environment such as radiation, nutritional, and endocrine changes related to space flight along with behaviors such as smoking. Cancer research is a major focus for human space flight due to the exposure to space radiation which consists of particles of varying charges and energies, and secondary neutrons. The JSC laboratories collaborate with investigators from the U.S. as well as our European and Japanese partners. We use accelerator facilities at the Brookhaven National Laboratory, Loma Linda University and Los Alamos National Laboratory that generate high energy charged particles and neutrons to simulate cosmic radiation and solar particle events. The research using cultured cells and animals concentrates on damage and repair from the level of DNA to organ tissues, due to exposure to simulated space radiation exposure, that contribute to the induction of leukemia and solid tumors in most major tissues such as lung, colon, liver and breast. The goal of the research is to develop a mathematical model that can predict cancer morbidity and mortality risks with sufficient accuracy for a given space mission.

  17. Lung Cancer in Homeless People: Clinical Outcomes and Cost Analysis in a Single Institute

    Directory of Open Access Journals (Sweden)

    Koung Jin Suh

    2016-01-01

    Full Text Available Introduction. To characterize the demographic and clinical features, outcomes, and treatment costs of lung cancer in homeless people. Methods. Medical records of 22 homeless patients with lung cancer at Seoul National University Boramae Medical Center in Seoul, South Korea, were retrospectively analyzed. Results. All patients were men (median age, 62 years. Most patients (78% had advanced disease (stage IIIB, n=2; stage IV, n=15. Seven died during initial hospitalization (median survival, 1.5 months. Six were lost to follow-up after initial outpatient visits or discharges from initial admission (median follow-up, 13 days. Only 4 received appropriate treatment for their disease and survived for 1, 15, 19, and 28 months, respectively. Conversely, 4 of 5 patients with early stage disease (stage I, n=4; stage IIA, n=1 received curative surgery (median follow-up 25.5 months. The median treatment cost based on 29 days of hospitalization and 2 outpatient visits was $12,513, constituting 47.3% of the 2013 per capita income. Inpatient treatment accounted for 90% of the total costs. The National Health Insurance Service paid 82% of the costs. Conclusion. Among the homeless, lung cancer seems to be associated with poor prognosis and substantial costs during a relatively short follow-up and survival period.

  18. 76 FR 49778 - National Institutes of Health National Institute of Environmental Health Sciences; Notice of Meeting

    Science.gov (United States)

    2011-08-11

    ....), notice is hereby given of a meeting of the Interagency Breast Cancer and Environmental Research... Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee. Date: September 26... NIH & other Federal agencies on how to improve existing research programs related to breast...

  19. The National Institutes of Health Affordable Cancer Technologies Program: Improving Access to Resource-Appropriate Technologies for Cancer Detection, Diagnosis, Monitoring, and Treatment in Low- and Middle-Income Countries

    Science.gov (United States)

    Divi, Rao; Gwede, Michael; Tandon, Pushpa; Sorg, Brian S.; Ossandon, Miguel R.; Agrawal, Lokesh; Pai, Vinay; Baker, Houston; Lash, Tiffani Bailey

    2016-01-01

    Point-of-care (POC) technologies have proved valuable in cancer detection, diagnosis, monitoring, and treatment in the developed world, and have shown promise in low-and-middle-income countries (LMIC) as well. Despite this promise, the unique design constraints presented in low-resource settings, coupled with the variety of country-specific regulatory and institutional dynamics, have made it difficult for investigators to translate successful POC cancer interventions to the LMIC markets. In response to this need, the National Cancer Institute has partnered with the National Institute of Biomedical Imaging and Bioengineering to create the National Institutes of Health Affordable Cancer Technologies (ACTs) program. This program seeks to simplify the pathway to market by funding multidisciplinary investigative teams to adapt and validate the existing technologies for cancer detection, diagnosis, and treatment in LMIC settings. The various projects under ACTs range from microfluidic cancer diagnostic tools to novel treatment devices, each geared for successful clinical adaptation to LMIC settings. Via progression through this program, each POC innovation will be uniquely leveraged for successful clinical translation to LMICs in a way not before seen in this arena. PMID:27730015

  20. An Institutional Retrospective Analysis of 93 Patients with Brain Metastases from Breast Cancer: Treatment Outcomes, Diagnosis-Specific Prognostic Factors

    Directory of Open Access Journals (Sweden)

    Delphine Antoni

    2012-12-01

    Full Text Available To evaluate the prognostic factors and indexes of a series of 93 patients with breast cancer and brain metastases (BM in a single institution. Treatment outcomes were evaluated according to the major prognostic indexes (RPA, BSBM, GPA scores and breast cancer subtypes. Independent prognostic factors for overall survival (OS were identified. The median OS values according to GPA 0–1, 1.5–2, 2.5–3 and 3.5–4, were 4.5, 9.5, 14.2 and 19.1 months, respectively (p < 0.0001 and according to genetic subtypes, they were 5, 14.2, 16.5 and 17.1 months for basal-like, luminal A and B and HER, respectively (p = 0.04. Using multivariate analysis, we established a new grading system using the six factors that were identified as indicators of longer survival: age under 60 (p = 0.001, high KPS (p = 0.007, primary tumor control (p = 0.05, low number of extracranial metastases and BM (p = 0.01 and 0.0002, respectively and triple negative subtype (p = 0.002. Three groups with significantly different median survival times were identified: 4.1, 9.5 and 26.3 months, respectively (p < 0.0001. Our new grading system shows that prognostic indexes could be improved by using more levels of classification and confirms the strength of biological prognostic factors.

  1. Skin Sparing Mastectomy and Immediate Breast Reconstruction (SSMIR for early breast cancer: Eight years single institution experience

    Directory of Open Access Journals (Sweden)

    Bobin Jean

    2008-04-01

    Full Text Available Abstract Background Skin Sparing Mastectomy (SSM and immediate breast reconstruction has become increasingly popular as an effective treatment for patients with breast carcinoma. The aim of this study was to evaluate the clinical outcome of skin sparing mastectomy in early breast cancer at a single population-based institution. Methods Records of ninety-five consecutive patients with operable breast cancer who had skin-sparing mastectomy and immediate breast reconstructions between 1995 and 2003 were reviewed. Patient and tumor characteristic, type of reconstruction, postoperative complications, aesthetic results and incidence of recurrence were analyzed. Results Mean age of the patients was 51.6(range 33–72 years. The AJCC pathologic stages were 0 (n = 51, 53.7%, I (n = 20, 21.1%, and II (n = 2, 2.1%. Twenty of the patients had recurrent disease (21.1%. The immediate breast reconstructions were performed with autologus tissue including latissimus dorsi musculocutaneous flap in 63 (66.3% patients and transverse rectus abdominis myocutaneous (TRAM flap in 4 (4.2% patients. Implants were used in 28 (29.4% patients. The average hospital stay was 7.7 days. Flap complication occurred in seven (10.4% patients resulting in four (6% re-operations and there were no delay in accomplishing postoperative adjuvant therapy. At a median follow-up of 69 months (range 48 to 144, local recurrence was seen in one patient (1.1% and systemic recurrence was seen in two patients (2.1%. Conclusion Skin sparing mastectomy and immediate breast reconstruction for early breast cancer is associated with low morbidity and low rate of local recurrence.

  2. Engineering behaviour change in an epidemic: the epistemology of NIH-funded HIV prevention science.

    Science.gov (United States)

    Green, Adam; Kolar, Kat

    2015-05-01

    Social scientific and public health literature on National Institutes of Health-funded HIV behavioural prevention science often assumes that this body of work has a strong biomedical epistemological orientation. We explore this assumption by conducting a systematic content analysis of all NIH-funded HIV behavioural prevention grants for men who have sex with men between 1989 and 2012. We find that while intervention research strongly favours a biomedical orientation, research into the antecedents of HIV risk practices favours a sociological, interpretive and structural orientation. Thus, with respect to NIH-funded HIV prevention science, there exists a major disjunct in the guiding epistemological orientations of how scientists understand HIV risk, on the one hand, and how they engineer behaviour change in behavioural interventions, on the other. Building on the extant literature, we suggest that the cause of this disjunct is probably attributable not to an NIH-wide positivist orientation, but to the specific standards of evidence used to adjudicate HIV intervention grant awards, including randomised controlled trials and other quantitative measures of intervention efficacy.

  3. Executive function in children with attention deficit/hyperactivity disorder: the NIH EXAMINER battery.

    Science.gov (United States)

    Schreiber, Jane E; Possin, Katherine L; Girard, Jonathan M; Rey-Casserly, Celiane

    2014-01-01

    Theories of attention deficit/hyperactivity disorder (ADHD) increasingly highlight the role of neuropsychological impairment in ADHD; however, a consistent and identifiable pattern of performance on tests is not well established. The National Institutes of Health (NIH) Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) battery provides measures of common variance across multiple executive function tests within specific domains and was used to characterize which executive functions are most affected in children with ADHD. Thirty-two children (24 male), ages 8-15 years (M = 12.02; SD = 2.29), diagnosed with ADHD and no comorbid disorder completed the NIH EXAMINER battery. Sixty age and gender matched healthy controls were chosen from a database of participants enrolled in the NIH EXAMINER multi-site study. Children with ADHD performed worse on the working memory score compared with the controls. No differences were found on the cognitive control or fluency scores. For children with ADHD, poorer working memory performance predicted parent report of child learning problems. Cognitive control and fluency scores did not predict learning problems. In summary, working memory emerges as a primary impairment in children with ADHD who have no comorbid disorders. Furthermore, working memory weaknesses may underlie the academic problems often seen in children with ADHD.

  4. Executive function in children with attention deficit/hyperactivity disorder: the NIH EXAMINER battery.

    Science.gov (United States)

    Schreiber, Jane E; Possin, Katherine L; Girard, Jonathan M; Rey-Casserly, Celiane

    2014-01-01

    Theories of attention deficit/hyperactivity disorder (ADHD) increasingly highlight the role of neuropsychological impairment in ADHD; however, a consistent and identifiable pattern of performance on tests is not well established. The National Institutes of Health (NIH) Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) battery provides measures of common variance across multiple executive function tests within specific domains and was used to characterize which executive functions are most affected in children with ADHD. Thirty-two children (24 male), ages 8-15 years (M = 12.02; SD = 2.29), diagnosed with ADHD and no comorbid disorder completed the NIH EXAMINER battery. Sixty age and gender matched healthy controls were chosen from a database of participants enrolled in the NIH EXAMINER multi-site study. Children with ADHD performed worse on the working memory score compared with the controls. No differences were found on the cognitive control or fluency scores. For children with ADHD, poorer working memory performance predicted parent report of child learning problems. Cognitive control and fluency scores did not predict learning problems. In summary, working memory emerges as a primary impairment in children with ADHD who have no comorbid disorders. Furthermore, working memory weaknesses may underlie the academic problems often seen in children with ADHD. PMID:24103310

  5. Multidisciplinary Service Utilization Pattern by Advanced Head and Neck Cancer Patients: A Single Institution Study

    Science.gov (United States)

    Junn, Jacqueline C.; Kim, Irene A.; Zahurak, Marianna L.; Tan, Marietta; Fan, Katherine Y.; Lake, Spencer T.; Zaboli, David; Messing, Barbara P.; Ulmer, Karen; Harrer, Karen B.; Gold, Dorothy; Ryniak, Keri L.; Zinreich, Eva S.; Tang, Mei; Levine, Marshall A.; Blanco, Ray G.; Saunders, John R.; Califano, Joseph A.; Ha, Patrick K.

    2012-01-01

    Purpose. To analyze the patterns and associations of adjunctive service visits by head and neck cancer patients receiving primary, concurrent chemoradiation therapy. Methods. Retrospective chart review of patients receiving adjunctive support during a uniform chemoradiation regimen for stages III-IV head and neck squamous cell carcinoma. Univariate and multivariate models for each outcome were obtained from simple and multivariate linear regression analyses. Results. Fifty-two consecutive patients were assessed. Female gender, single marital status, and nonprivate insurance were factors associated with an increased number of social work visits. In a multivariate analysis, female gender and marital status were related to increased social work services. Female gender and stage IV disease were significant for increased nursing visits. In a multivariate analysis for nursing visits, living greater than 20 miles between home and hospital was a negative predictive factor. Conclusion. Treatment of advanced stage head and neck cancer with concurrent chemoradiation warrants a multidisciplinary approach. Female gender, single marital status, and stage IV disease were correlated with increased utilization of social work and nursing services. Distance over 20 miles from the center was a negative factor. This information may help guide the treatment team to allocate resources for the comprehensive care of patients. PMID:23118755

  6. Multidisciplinary Service Utilization Pattern by Advanced Head and Neck Cancer Patients: A Single Institution Study

    Directory of Open Access Journals (Sweden)

    Jacqueline C. Junn

    2012-01-01

    Full Text Available Purpose. To analyze the patterns and associations of adjunctive service visits by head and neck cancer patients receiving primary, concurrent chemoradiation therapy. Methods. Retrospective chart review of patients receiving adjunctive support during a uniform chemoradiation regimen for stages III-IV head and neck squamous cell carcinoma. Univariate and multivariate models for each outcome were obtained from simple and multivariate linear regression analyses. Results. Fifty-two consecutive patients were assessed. Female gender, single marital status, and nonprivate insurance were factors associated with an increased number of social work visits. In a multivariate analysis, female gender and marital status were related to increased social work services. Female gender and stage IV disease were significant for increased nursing visits. In a multivariate analysis for nursing visits, living greater than 20 miles between home and hospital was a negative predictive factor. Conclusion. Treatment of advanced stage head and neck cancer with concurrent chemoradiation warrants a multidisciplinary approach. Female gender, single marital status, and stage IV disease were correlated with increased utilization of social work and nursing services. Distance over 20 miles from the center was a negative factor. This information may help guide the treatment team to allocate resources for the comprehensive care of patients.

  7. 75 FR 11187 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2010-03-10

    ... evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive..., Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive... Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive...

  8. 76 FR 38406 - National Institute of Neurological Disorders and Stroke Notice of Closed Meetings

    Science.gov (United States)

    2011-06-30

    ... Research, NINDS/ NIH/DHHS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD... applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville... Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience...

  9. 75 FR 13768 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2010-03-23

    ... evaluate grant applications. Place: National Institutes of Health Neuroscience Center, 6001 Executive.../NIH/NINDS/DER/SRB, 6001 Executive Boulevard; MSC 9529, Neuroscience Center; Room 3203, Bethesda, MD..., PhD., Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience...

  10. 76 FR 61722 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2011-10-05

    ..., DHHS/NIH/NINDS/DER/SRB, 6001 Executive Boulevard, MSC 9529, Neuroscience Center, Room 3208, Bethesda...., Scientific Review Officer, DHHS/NIH/NINDS/DER/SRB, 6001 Executive Boulevard, MSC 9529, Neuroscience Center... Neurosciences, National Institutes of Health, HHS) Dated: September 27, 2011. Jennifer S. Spaeth,...

  11. 75 FR 81283 - Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting

    Science.gov (United States)

    2010-12-27

    ... Plan Presentation; (3) NIH Peer Review Enhancement Update, (4) NIH Support for Human Embryonic Stem Cell Research Update. Place: National Institutes of Health, Building 31, 31 Center Drive, C-Wing... Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center...

  12. The History of Art Therapy at the National Institutes of Health

    Science.gov (United States)

    Robb, Megan

    2012-01-01

    The National Institutes of Health (NIH) Clinical Research Center is a government facility that has a long history of groundbreaking research. Art therapy research began at NIH in 1958 with Hanna Kwiatkowska, whose work contributed to the foundation of art therapy with families, and with Harriet Wadeson, who conducted psychodynamic art therapy…

  13. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium.

    OpenAIRE

    van der Lei, J.; Rudolph, A; Moysich, KB; Behrens, S; Goode, EL.; Bolla, MK; Dennis, J; Dunning, AM; Easton, DF; Wang, Q.; Benitez, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A

    2015-01-01

    Funding for the iCOGS infrastructure came from: the European Community?s Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (NIH, CA128978, CA122443) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112?the GAME-ON initiative), the Department of Defence (W81...

  14. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium

    OpenAIRE

    Lei, Jieping; Rudolph, Anja; Kirsten B Moysich; Behrens, Sabine; Goode, Ellen L.; Bolla, Manjeet K; Dennis, Joe; Dunning, Alison M; Easton, Douglas F.; Wang, Qin; Benitez, Javier; John L. Hopper; Southey, Melissa C.; Schmidt, Marjanka K.; Broeks, Annegien

    2015-01-01

    Funding for the iCOGS infrastructure came from: the European Community?s Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (NIH, CA128978, CA122443) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112?the GAME-ON initiative), the Department of Defence (W81...

  15. Skin Diseases: NIH Research to Results

    Science.gov (United States)

    ... are focusing on new treatments, including biologic agents, fatty acid supplements, and new forms of phototherapy. Skin cancer —New ways of working with the immune system to fight cancer are being studied. Researchers are ...

  16. La gigantomastie gravidique à l'Institut du Cancer de Dakar: à propos de 2 cas

    Science.gov (United States)

    Ka, Sidy; Thiam, Jaafar; Mane, Maimouna; Some, Rolland; Niang, Rokhaya; Goudiaby, Céline; Dem, Ahmadou

    2015-01-01

    La gigantomastie gravidique est une augmentation exagérée et invalidante de la taille des seins survenant pendant la grossesse chez une patiente aux seins préalablement normaux. Sa physiopathologie est mal cernée. Elle pose localement des problèmes trophiques et rend difficile la grossesse. Le traitement est médical anti hormonal et chirurgical sur la base d'une réduction mammaire. Il est difficile et peut compromettre l'avenir esthétique et fonctionnel de la glande mammaire. Nous rapportons 2 cas de gigantomasties gravidiques suivies et traitées à l'Institut Joliot Curie de Dakar. PMID:26977223

  17. Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan

    Institute of Scientific and Technical Information of China (English)

    Toshihiro Saito; Yasuo Kitamura; Shuichi Komatsubara; Yasuo Matsumoto; Tadashi Sugita; Noboru Hara

    2006-01-01

    Aim: To investigate the outcomes for Asian populations with locally advanced/clinical stage Ⅲ prostate cancer (Pca)treated with currently prevailing modalities. Methods: We reviewed the record of 209 patients with clinical stage Ⅲ Pca, who were treated at Niigata Cancer Center Hospital between 1992 and 2003. Treatment options included hormone therapy-combined radical prostatectomy (RP+HT), hormone therapy-combined external beam irradiation (EBRT+HT) and primary hormone therapy (PHT). Results: The 5- and 10-year overall survival rates were 80.3%and 46.1% in all cohorts, respectively. The survival rates were 87.3% and 66.5% in the RP+HT group, 94.9% and 70.0% in the EBRT+HT group and 66.1% and 17.2% in the PHT group, respectively. A significant survival advantage was found in the EBRT+HT group compared with that in the PHT group (P < 0.0001). Also, the RP+HT group had better survival than the PHT group (P = 0.0107). The 5- and 10-year disease-specific survival rates for all cases were 92.5% and 80.0%, respectively. They were 93.8% and 71.4% in the RP+HT group, 96.6% and 93.6% in the EBRT+HT group and 88.6% and 62.3% in the PHT group, respectively. A survival advantage was found in the EBRT+HT group compared with the PHT group (P = 0.029). No significant difference was found in disease-specific survival between the EBRT+HT and RP+HT groups or between the RP+HT and PHT groups. Conclusion: Although our findings indicate that radiotherapy plus HT has a survival advantage in this stage of Pca, we recommend therapies that take into account the patients' social and medical conditions for Asian men with clinical stage Ⅲ PCa.

  18. The costs of breast cancer in a Mexican public health institution

    Directory of Open Access Journals (Sweden)

    Jacobo Alejandro Gómez-Rico

    2008-11-01

    Full Text Available Jacobo Alejandro Gómez-Rico1, Marina Altagracia-Martínez1, Jaime Kravzov-Jinich1, Rosario Cárdenas-Elizalde1, Consuelo Rubio-Poo21Universidad Autónoma Metropolitano–Xochimilco (UAM-X, Departments: Biological Systems and Healthcare, Biological and Health Sciences Division (DCBS; 2Universidad Nacional Autónoma de México (UNAM, Faculty of Professional Studies-Zaragoza (FES-ZaragozaAbstract: Breast cancer (BC is the second leading cause of death as a result of neoplasia in Mexico. This study aimed to identify the direct and indirect costs of treating female outpatients diagnosed with BC at a Mexican public hospital. A cross-sectional, observational, analytical study was conducted. A total of 506 medical records were analyzed and 102 were included in the cost analysis. The micro-costing process was used to estimate treatment costs. A 17-item questionnaire was used to obtain information on direct and indirect costs. Of the 102 women with BC included in the study, 92.2% (94 were at Stage II, and only 7.8% at Stage I. Total direct costs over six months for the 82 women who had modified radical mastectomy (MRM surgury were US$733,821.15. Total direct costs for the 15 patients with conservative surgery (CS were US$138,190.39. We found that the total economic burden in the study population was much higher for patients with MRM than for patients with CS.Keywords: breast cancer, Mexican women, direct and indirect costs

  19. Security and privacy requirements for a multi-institutional cancer research data grid: an interview-based study

    Directory of Open Access Journals (Sweden)

    Weems William A

    2009-06-01

    Full Text Available Abstract Background Data protection is important for all information systems that deal with human-subjects data. Grid-based systems – such as the cancer Biomedical Informatics Grid (caBIG – seek to develop new mechanisms to facilitate real-time federation of cancer-relevant data sources, including sources protected under a variety of regulatory laws, such as HIPAA and 21CFR11. These systems embody new models for data sharing, and hence pose new challenges to the regulatory community, and to those who would develop or adopt them. These challenges must be understood by both systems developers and system adopters. In this paper, we describe our work collecting policy statements, expectations, and requirements from regulatory decision makers at academic cancer centers in the United States. We use these statements to examine fundamental assumptions regarding data sharing using data federations and grid computing. Methods An interview-based study of key stakeholders from a sample of US cancer centers. Interviews were structured, and used an instrument that was developed for the purpose of this study. The instrument included a set of problem scenarios – difficult policy situations that were derived during a full-day discussion of potentially problematic issues by a set of project participants with diverse expertise. Each problem scenario included a set of open-ended questions that were designed to elucidate stakeholder opinions and concerns. Interviews were transcribed verbatim and used for both qualitative and quantitative analysis. For quantitative analysis, data was aggregated at the individual or institutional unit of analysis, depending on the specific interview question. Results Thirty-one (31 individuals at six cancer centers were contacted to participate. Twenty-four out of thirty-one (24/31 individuals responded to our request- yielding a total response rate of 77%. Respondents included IRB directors and policy-makers, privacy and

  20. Pazopanib in metastatic renal cancer: a “real-world” experience at National Cancer Institute “Fondazione G. Pascale”

    Directory of Open Access Journals (Sweden)

    Sabrina Chiara Cecere

    2016-08-01

    Full Text Available Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective, observational nature and the unselected population, our experience can be defined a real-world study. The medical records of 38 mRCC patients treated with front-line pazopanib were retrospectively reviewed and analyzed. The progression free survival (PFS and the overall survival (OS were the primary endpoints, while secondary objectives included Objective Response Rate (ORR, Disease Control Rate (DCR, and treatment tolerability. Pazopanib achieved a median PFS (mPFS of 12.7 months (95% CI, 6.9-18.5 months. The median OS (mOS was 26.2 months (95% CI, 12.6-39.9 months; the observed ORR and DCR were 30.3% and 72.7%, respectively, with a median duration of response of 11 weeks. mPFS appeared not to be influenced by number of co-morbidities (3, gender, Fuhrman grade and age. Conversely, the ORR and the DCR positively affect the mPFS (HR=0.05 [95% CI, 0.05-055], p=0.01; HR=0.10 [95% CI, 0.02-0.43], p=0.002 respectively. A worse outcome was associated with a lower mPFS in patients with liver metastases (p= 0.2 and with a high tumor burden (number of metastatic sites 6 (p= 0.08. Worst OS was observed in patients age >70 years old (HR=6.91 [95% CI, 1.49-31.91], p=0.01. The treatment was well tolerated: no grade 4 adverse events, nor discontinuation due to toxicities was reported. Grade 3 hypertension affected positively the OS reaching the statistical significance (HR=0.22 [95% CI, 0.05-0.8], p=0.03 and thyroid dysfunction (hypo and hyperthyroidism seems to correlate with better outcome in terms of a longer mPFS (HR=0.12 [95% CI, 0.02-0.78], p=0.02. Our results are consistent with those reported in prospective phase III trials and the published retrospective

  1. ExCEL in Social Work: Excellence in Cancer Education & Leadership: An Oncology Social Work Response to the 2008 Institute of Medicine Report.

    Science.gov (United States)

    Otis-Green, Shirley; Jones, Barbara; Zebrack, Brad; Kilburn, Lisa; Altilio, Terry A; Ferrell, Betty

    2015-09-01

    ExCEL in Social Work: Excellence in Cancer Education & Leadership was a multi-year National Cancer Institute (NCI)-funded grant for the development and implementation of an innovative educational program for oncology social workers. The program's curriculum focused upon six core competencies of psychosocial-spiritual support necessary to meet the standard of care recommended by the 2008 Institute of Medicine (IOM) Report: Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. The curriculum was delivered through a collaborative partnership between the City of Hope National Medical Center and the two leading professional organizations devoted exclusively to representing oncology social workers--the Association of Oncology Social Work and the Association of Pediatric Oncology Social Workers. Initial findings support the feasibility and acceptability of this tailored leadership skills-building program for participating oncology social workers.

  2. Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

    Science.gov (United States)

    Cecere, Sabrina C.; Rossetti, Sabrina; Cavaliere, Carla; Della Pepa, Chiara; Di Napoli, Marilena; Crispo, Anna; Iovane, Gelsomina; Piscitelli, Raffaele; Sorrentino, Domenico; Ciliberto, Gennaro; Maiolino, Piera; Muto, Paolo; Perdonà, Sisto; Berretta, Massimiliano; Pignata, Sandro; Facchini, Gaetano; D'Aniello, Carmine

    2016-01-01

    Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective, observational nature and the unselected population, our experience can be defined a “real-world” study. The medical records of 38 mRCC patients treated with front-line pazopanib were retrospectively reviewed and analyzed. The progression free survival (PFS) and the overall survival (OS) were the primary endpoints, while secondary objectives included objective response rate (ORR), disease control rate (DCR), and treatment tolerability. Pazopanib achieved a median PFS (mPFS) of 12.7 months (95% CI, 6.9–18.5 months). The median OS (mOS) was 26.2 months (95% CI, 12.6–39.9 months); the observed ORR and DCR were 30.3 and 72.7%, respectively, with a median duration of response of 11 weeks. mPFS appeared not to be influenced by number of co-morbidities (< 3 vs. ≥3), gender, Fuhrman grade and age. Conversely, the ORR and the DCR positively affect the mPFS (HR = 0.05 [95% CI, 0.05–0.55], p = 0.01; HR = 0.10 [95% CI, 0.02–0.43], p = 0.002, respectively). A worse outcome was associated with a lower mPFS in patients with liver metastases (p = 0.2) and with a high tumor burden (number of metastatic sites < 6 vs. ≥6) (p = 0.08). Worst OS was observed in patients aged ≥70 years old (HR = 6.91 [95% CI, 1.49–31.91], p = 0.01). The treatment was well-tolerated: no grade 4 adverse events, nor discontinuation due to toxicities was reported. Grade 3 hypertension affected positively the OS reaching the statistical significance (HR = 0.22 [95% CI, 0.05–0.8], p = 0.03). Thyroid dysfunction (hypo and hyperthyroidism) seems to correlate with better outcome in terms of a longer mPFS (HR = 0.12 [95% CI, 0.02–0.78], p = 0.02). Our results are consistent with those reported in

  3. Online Bioinformatics Tutorials | Office of Cancer Genomics

    Science.gov (United States)

    Bioinformatics is a scientific discipline that applies computer science and information technology to help understand biological processes. The NIH provides a list of free online bioinformatics tutorials, either generated by the NIH Library or other institutes, which includes introductory lectures and "how to" videos on using various tools.

  4. Community resources and technologies developed through the NIH Roadmap Epigenomics Program.

    Science.gov (United States)

    Satterlee, John S; Beckel-Mitchener, Andrea; McAllister, Kim; Procaccini, Dena C; Rutter, Joni L; Tyson, Frederick L; Chadwick, Lisa Helbling

    2015-01-01

    This chapter describes resources and technologies generated by the NIH Roadmap Epigenomics Program that may be useful to epigenomics researchers investigating a variety of diseases including cancer. Highlights include reference epigenome maps for a wide variety of human cells and tissues, the development of new technologies for epigenetic assays and imaging, the identification of novel epigenetic modifications, and an improved understanding of the role of epigenetic processes in a diversity of human diseases. We also discuss future needs in this area including exploration of epigenomic variation between individuals, single-cell epigenomics, environmental epigenomics, exploration of the use of surrogate tissues, and improved technologies for epigenome manipulation.

  5. CYP17 genetic variation and risk of breast and prostate cancer from the national Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

    NARCIS (Netherlands)

    Setiawan, Veronica Wendy; Schumacher, Fredrick R.; Haiman, Christopher A.; Stram, Daniel O.; Albanes, Demetrius; Altshuler, David; Berglund, Gran; Buring, Julie; Calle, Eugenia E.; Clavel-Chapelon, Francoise; Cox, David G.; Gaziano, J. Michael; Hankinson, Susan E.; Hayes, Richard B.; Henderson, Brian E.; Hirschhorn, Joel; Hoover, Robert; Hunter, David J.; Kaaks, Rudolf; Kolonel, Laurence N.; Kraft, Peter; Ma, Jing; Le Marchand, Loic; Linseisen, Jakob; Lund, Eiliv; Navarro, Carmen; Overvad, Kim; Palli, Domenico; Peeters, Petra H. M.; Pike, Malcolm C.; Riboli, Elio; Stampfer, Meir J.; Thun, Michael J.; Travis, Ruth; Trichopoulos, Dimitrios; Yeager, Meredith; Ziegler, Regina G.; Feigelson, Heather Spencer; Chanock, Stephen J.

    2007-01-01

    CYP17 encodes cytochrome p450c17 alpha, which mediates activities essential for the production of sex steroids. Common germ line variation in the CYP17 gene has been related to inconsistent results in breast and prostate cancer, with most studies focusing on the nonsynonymous single nucleotide polym

  6. The costs of breast cancer in a Mexican public health institution

    Science.gov (United States)

    Gómez-Rico, Jacobo Alejandro; Altagracia-Martínez, Marina; Kravzov-Jinich, Jaime; Cárdenas-Elizalde, Rosario; Rubio-Poo, Consuelo

    2008-01-01

    Breast cancer (BC) is the second leading cause of death as a result of neoplasia in Mexico. This study aimed to identify the direct and indirect costs of treating female outpatients diagnosed with BC at a Mexican public hospital. A cross-sectional, observational, analytical study was conducted. A total of 506 medical records were analyzed and 102 were included in the cost analysis. The micro-costing process was used to estimate treatment costs. A 17-item questionnaire was used to obtain information on direct and indirect costs. Of the 102 women with BC included in the study, 92.2% (94) were at Stage II, and only 7.8% at Stage I. Total direct costs over six months for the 82 women who had modified radical mastectomy (MRM) surgury were US$733,821.15. Total direct costs for the 15 patients with conservative surgery (CS) were US$138,190.39. We found that the total economic burden in the study population was much higher for patients with MRM than for patients with CS. PMID:22312199

  7. Lifestyle and cancer prevention in female employees at a health institution

    Directory of Open Access Journals (Sweden)

    Gladys Eugenia Canaval

    2011-06-01

    Full Text Available Objective: To establish the relationship between lifestyle for prevention of cervix and breast cancer and perceptual cognitive factors from the Pender model in working women. Materials and methods: Correlation and cross-sectional study with a random sample of 143 working women. The Lifestyle index is the total score of 5 variables: Papanicolau test, breast self-exam, physical activity, body mass index, and cigarette smoking. Results: The mean age for the sample was 44.4 + 6.2; 87% of the women had higher education and 85% were working in health care services. A total of 89% of the women had unhealthy lifestyles because of the lack of regular physical activity, not having a Papanicolau test according to the norm, not practicing breast self-exams, and having an altered body mass index. There was significant correlation between lifestyle and occupation, and also with self-efficacy perception for breast self-examination. Conclusion: The lifestyles for most of the women sampled were unhealthy. Recommendations: It is also recommend conducting culturally sensitive healthcare campaigns in addition to setting up flexible attention schedules for women.

  8. Lifestyle and cancer prevention in female employees at a health institution

    Directory of Open Access Journals (Sweden)

    Gladys Eugenia Canaval

    2011-06-01

    Full Text Available Objective: To establish the relationship between lifestyle for prevention of cervix and breast cancer and perceptual cognitive factors from the Pender model in working women.Materials and methods: Correlation and cross-sectional study with a random sample of 143 working women. The Lifestyle index is the total score of 5 variables: Papanicolau test, breast self-exam, physical activity, body mass index, and cigarette smoking.Results: The mean age for the sample was 44.4 + 6.2; 87% of the women had higher education and 85% were working in health care services. A total of 89% of the women had unhealthy lifestyles because of the lack of regular physical activity, not having a Papanicolau test according to the norm, not practicing breast self-exams, and having an altered body mass index. There was significant correlation between lifestyle and occupation, and also with self-efficacy perception for breast self-examination.Conclusion: The lifestyles for most of the women sampled were unhealthy.Recommendations: It is recommend the reorientation of health services based on health promotion, which permit planning and executing health care, health education and nursing care programs specifically for working women. It is also recommend conducting culturally sensitive.

  9. Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience

    Directory of Open Access Journals (Sweden)

    Gary W. Nace

    2011-01-01

    Full Text Available Purpose. We sought to evaluate our experience using yttrium-90 (90Y resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC. Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first 90Y treatment was 10.2 months (95% CI = 7.5–13.0. The absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4–27.6, compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95% CI = 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status.

  10. Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China

    Institute of Scientific and Technical Information of China (English)

    ZHOU Jian; HE Yi-feng; YANG Guo-huan; SONG Kang; YUAN Zhou; WANG Yu-qi; TANG Zhao-you; FAN Jia; WU Zhi-quan; QIU Shuang-jian; HUANG Xiao-wu; YU Yao; WANG Zheng; SUN Jian; XIAO Yong-sheng

    2005-01-01

    Background Selection of patients with hepatocellular carcinoma (HCC) for orthotopic liver transplantation (OLT) remains controversial. Since there is a trend to expand the transplant criteria for HCC patients, we reviewed the data of patients with HCC who had received OLT at our institute to determine their survival and prognostic factors.Methods A total of 67 patients with HCC who had undergone OLT from April 2001 through December 2003 were reviewed retrospectively. Selection OLT candidates with HCC was dependent on the anatomical characteristics and/or the severity of underlying liver cirrhosis. The 67 patients were followed up for more than 6 months after transplantation. Their survival rate was calculated by the Kaplan-Meier method. Univariate and multivariate analyses using the Cox proportional hazards regression model were performed to reveal the factors affecting the survival rate.Results No perioperative death occurred in this series. The 1- and 2-year cumulative survival rates were 90.0% and 65.6%, and the disease-free survival (DFS) rates were 77.5% and 62.5% respectively. Univariate analysis revealed the tumor size, portal vein tumor thrombus (PVTT), serum alpha-fetoprotein level, bilobular distribution of tumors, pTNM stage and histological differentiation were statistically significant factors affecting the DFS (P<0.05). Multivariate analysis showed tumor size and PVTT were independent and statistically significant factors affecting the DFS (P=0.005 and 0.010, respectively). In this series, all but 2 received systemic chemotherapy, among them 13 had tumor recurrence within 8 months after OLT.Conclusions OLT is indicated for patients with HCC, even for some patients with end-stage liver disease who may survive longer without tumor recurrence. Adjuvant chemotherapy may decrease the recurrence of HCC after OLT.

  11. Cancer risk among Italian veterans from the Balkans: the activities of the Italian National Institute of Health

    International Nuclear Information System (INIS)

    In recent years, cases of cancer have been reported among Italian troops involved in the peace-keeping mission in Bosnia and Kosovo. By the end of 2000, the Italian Minister of Defence appointed a Committee of Enquiry to gain a scientifically sound, reliable picture of the health consequences of the exposure of military personnel to Depleted Uranium (DU) and to assess the possible etiologic role DU may have played in the occurrence of specific pathologies. The Committee found a statistically significant excess of Hodgkin's lymphomas, but up to now the lack of thorough knowledge about internal uranium exposure and its potential effects has prevented us from determining whether lymphatic cancers are correlated with DU exposure. The Committee of Enquiry issued several recommendations, in particular: 1) to follow up the cohort of military personnel deployed in Bosnia and Kosovo and monitor the incidence of tumours and the evolution of the ensuing epidemiological scenario, and 2) to list the individuals that could have been exposed to DU for different reasons and enrol them in a long-term programme of medical surveillance. A decision was also made to quantify levels of U and other potentially toxic elements - as well as to measure the isotopic ratio 235U/238U for the assessment of DU - in biological samples of soldiers deployed in war theatres where presumably DU weapons were used, together with tentative indexes of contact with possible genotoxic factors. In this paper a general description is given of the activities carried out by the Italian National Institute of Health (ISS, in the Italian acronym) in compliance with both the recommendations of the Committee of Enquiry and the decision to quantify potential exposures. (author)

  12. Multi-institutional analysis of bioimpedance spectroscopy in the early detection of breast cancer related lymphedema

    Directory of Open Access Journals (Sweden)

    Vicini FA

    2013-03-01

    Full Text Available Background: The purpose of this study was to evaluate bioelectrical impedance spectroscopy’s (BIS ability to detect and monitor extracellular fluid accumulation of the upper limb as it relates to the extent of loco-regional therapy. Methods: A total of 125 patients with breast cancer from 4 clinical practices were evaluated with BIS at baseline and following loco-regional procedures. In order to assess the ability of BIS to detect subclinical changes by treatment modality, the change in L-Dex score from baseline to measurements taken within 180 days following surgery were calculated. Results: Mean age was 55 years with 68 patients (54.4% undergoing sentinel lymph node (SLN sampling while 57 (45.6% underwent an axillary dissection (ALND. Sixty-five patients (52% underwent radiation therapy (RT. Patients receiving RT had a significantly increased change in L-Dex score (0.8 v.-2.5, p=0.03 compared with those patients not receiving RT. For all patients, ALND was associated with a significantly increased change in L-Dex score (5.0 v. 0.3, p=0.003 compared with SLN. When stratifying by the number of nodes removed, a statistically significant increase in the change in L-Dex score was noted (0.4 v. 0.4 v. 4.3 v. 6.4, p=0.04 for 0-3, 4-6, 7-10 and greater than 10 lymph nodes removed. Conclusions: In this limited analysis, L-Dex scores paralleled the extent of axillary sampling and the addition of radiation therapy; these results demonstrate that BIS can be used to monitor patients for the early onset of edema as differences emerged within 180 days of surgery.

  13. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model

    OpenAIRE

    Meixensberger Jürgen; Gebhardt Rolf; Hengstler Jan; Hermes Matthias; Geiger Kathrin D; Fuchs Beate; Zemitzsch Nadine; Renner Christof; Gaunitz Frank

    2010-01-01

    Abstract Background It was previously demonstrated that the dipeptide carnosine inhibits growth of cultured cells isolated from patients with malignant glioma. In the present work we investigated whether carnosine also affects tumor growth in vivo and may therefore be considered for human cancer therapy. Results A mouse model was used to investigate whether tumor growth in vivo can be inhibited by carnosine. Therefore, NIH3T3 fibroblasts, conditionally expressing the human epidermal growth fa...

  14. 78 FR 56902 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other..., kellya2@nidcd.nih.gov . Name of Committee: National Institute on Deafness and Other...

  15. 76 FR 9031 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2011-02-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  16. 78 FR 10621 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2013-02-14

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  17. 76 FR 12744 - National Institute On Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2011-03-08

    ... HUMAN SERVICES National Institutes of Health National Institute On Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  18. 77 FR 59405 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-27

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  19. 76 FR 65517 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2011-10-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA R13 Conference Grant Review. Date... Affairs, National Institute on Drug Abuse, NIH, 6001 Executive Blvd., Room 4226, MSC 9550, Bethesda,...

  20. 78 FR 27411 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2013-05-10

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... of Committee: National Institute on Drug Abuse Special Emphasis Panel; Medication Ingestion... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  1. 77 FR 47654 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-08-09

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Collaborative Clinical Trials in Drug... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  2. 76 FR 3913 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-01-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... and projects conducted by the National Institute on Drug Abuse, including consideration of personnel... Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD...

  3. 76 FR 31967 - National Institute On Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-06-02

    ... HUMAN SERVICES National Institutes of Health National Institute On Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA R13 Conference Grant Review. Date... Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4226, MSC 9550, 6001 Executive...

  4. 77 FR 75179 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2012-12-19

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... of Committee: National Institute on Drug Abuse Special Emphasis Panel; Collaborative Clinical Trials..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  5. 75 FR 21006 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; R25 Review (PAR-07-221). Date: April 29... Institute on Drug Abuse, NIH, 6101 Executive Blvd., Rm. 213, MSC 8401, Bethesda, MD 20892,...

  6. 76 FR 35226 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-06-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, 2011 NIDA Avant-Garde Award Program for... Institute on Drug Abuse, NIH, DHHS, Room 4229, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,...

  7. 77 FR 27075 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-05-08

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Grand Opportunity in Medications... of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  8. 78 FR 58320 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-23

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel GOMED: Grand Opportunity in Medications... of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  9. 76 FR 81952 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-12-29

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Training and Career Development..., National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive Blvd., Bethesda, MD...

  10. 78 FR 63994 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-10-25

    ... Committee: National Institute on Drug Abuse Special Emphasis Panel; Substance Use Disorders and Molecular... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC...

  11. 77 FR 22581 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2012-04-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Multi-site Trials. Date: May 22, 2012... Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4226, MSC 9550,...

  12. 77 FR 58855 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2012-09-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Phased Services Research Studies of Drug... Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001...

  13. 77 FR 54919 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-06

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Grand Opportunities in Medications..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  14. 76 FR 31967 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-06-02

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; N01DA-11-7777: Synthesis and..., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room...

  15. 77 FR 27075 - National Institute on Drug Abuse Notice of Closed Meeting

    Science.gov (United States)

    2012-05-08

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Regulatory Affairs Support (8902). Date... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive...

  16. 78 FR 73866 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-12-09

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Center for Genetics Studies (7789... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive...

  17. 76 FR 22715 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-04-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Blending Research and Practice... Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH,...

  18. 78 FR 63995 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-10-25

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel R13 Conference Grant Review (PA12-212..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd.,...

  19. 78 FR 25460 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-01

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA I/START Small Grant Review. Date... Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,...

  20. 77 FR 75179 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-12-19

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; N43DA13-4417: Video Gaming Targeting..., rogersn2@nida.nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;...

  1. 77 FR 69640 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-11-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel CEBRA Review. Date: November 29, 2012... Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892- 9550,...

  2. 75 FR 9606 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-03

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Web-Enabled Cognitive/Neuropsychological... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive...

  3. 75 FR 3239 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-01-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Rapid Assessment for Drug Abuse and... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive...

  4. 75 FR 42104 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-07-20

    ... Committee: National Institute on Drug Abuse Special Emphasis Panel Systems Biology, HIV/AIDS, and Substance... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda,...

  5. 77 FR 47654 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2012-08-09

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Clinical Trials Research Coordination... of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550,...

  6. 76 FR 3916 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-01-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA B/START R03 Small Grant Review... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4238, MSC 9550, 6001 Executive Blvd.,...

  7. 75 FR 42102 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Research Dissemination (1143). Date..., Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,...

  8. 76 FR 31968 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-06-02

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Technical Conference Support for DPMCDA... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive...

  9. 76 FR 35227 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-06-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, SecuRX: Preventing Prescription Drug..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, ]...

  10. 76 FR 11252 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-03-01

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Initial Review Group; Training and Career Development... Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,...

  11. 78 FR 43890 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-07-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Pharmacokinetic Analysis Resource Center..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  12. 78 FR 33853 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-06-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; PAR 11-109 Grand Opportunity in...@nida.nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;...

  13. 75 FR 36429 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-06-25

    ... Committee: National Institute on Drug Abuse Special Emphasis Panel, Medications Development for Substance... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting...@nida.nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel,...

  14. 78 FR 64960 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-10-30

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; R25 and T32 AIDS Applications. Date... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive...

  15. 77 FR 22579 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-04-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel E-Technology Tools for Extending the... Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-9550,...

  16. 75 FR 63491 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2010-10-15

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA Basic Science Conference Grant (R13..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive, Blvd., Bethesda, MD...

  17. 76 FR 59415 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-09-26

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Multisites Applications (R01) Review... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive...

  18. 75 FR 6042 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-02-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Rapid Assessments Tools of Sexual and... Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC...

  19. 75 FR 71712 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-11-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Cutting-Edge Basic Research Awards..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD...

  20. 77 FR 33472 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-06-06

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Training and Career Development... Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC...

  1. 75 FR 14175 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Substance Abuse Treatment Referral..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda,...

  2. 75 FR 80512 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2010-12-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Cutting-Edge Basic Research Award..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401,...

  3. 76 FR 65517 - National Institute on Drug Abuse Notice of Closed Meeting

    Science.gov (United States)

    2011-10-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meeting... projects conducted by the National Institute on Drug Abuse, including consideration of personnel..., National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD 21223. Contact...

  4. 78 FR 27410 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-05-10

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; R13 Conference Grant Review. Date: June... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4226, MSC...

  5. 75 FR 54348 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2010-09-07

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA Clinical Science Conference Grant... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd.,...

  6. 76 FR 59414 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-09-26

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, I/START Review Committee. Date: October..., National Institute on Drug Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., Bethesda, MD...

  7. 78 FR 56238 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-12

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Multisite Clinical Trials. Date... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive...

  8. 78 FR 55265 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-09-10

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... projects conducted by the National Institute on Drug Abuse, including consideration of personnel... Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD...

  9. 78 FR 6122 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-01-29

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Research ``Center of Excellence..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550,...

  10. 75 FR 71711 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2010-11-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel E-Technology tools for Extending the... Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room...

  11. 77 FR 44640 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2012-07-30

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Rodent Testing to Identify... Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room...

  12. 78 FR 23772 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-04-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Drugged Driving: Future Research... of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550,...

  13. 75 FR 9420 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-02

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Web-Enabled Cognitive/Neuropsychological... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive...

  14. 78 FR 69858 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-11-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Revision Applications to Promote CRAN... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  15. 76 FR 51381 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-08-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel SEDAPA R25. Date: September 22, 2011..., gm145a@nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel,...

  16. 76 FR 70463 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-11-14

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Preclinical Medications Discovery and... Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC...

  17. 75 FR 13136 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Loan Repayment. Date: March 22, 2010..., Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH. DHHS,...

  18. 78 FR 70065 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

    Science.gov (United States)

    2013-11-22

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis...@niaid.nih.gov . Name of Committee: National Institute of Allergy and Infectious Diseases...

  19. 77 FR 16845 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

    Science.gov (United States)

    2012-03-22

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis..., lr228v@nih.gov . Name of Committee: National Institute of Allergy and Infectious Diseases...

  20. 78 FR 76847 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

    Science.gov (United States)

    2013-12-19

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis....nih.gov . Name of Committee: National Institute of Allergy and Infectious Diseases Special...

  1. ZBIRKA MATEMATIČNIH IGER ZA PREDŠOLSKO OBDOBJE

    OpenAIRE

    Florjančič, Jasmina

    2011-01-01

    POVZETEK Diplomsko delo z naslovom Zbirka matematičnih iger za predšolsko obdobje predstavlja uporabnost in pestrost možnosti izdelave in uporabe matematičnih iger v predšolskem obdobju. Namen in cilj diplomskega dela je bil predstaviti in opisati čimveč različnih oblik matematičnih iger, ki jih lahko uporabimo pri delu in dejavnostih s predšolskimi otroki. Prav tako pa tudi preučiti v kolikšni meri in na kakšen način lahko igre, kot matematično vsebino, uporabljamo in vpletamo v druga vs...

  2. The UC Davis/NIH NeuroMab Facility

    Data.gov (United States)

    Federal Laboratory Consortium — The mission of the UC Davis/NIH NeuroMab facility is to generate and distribute high quality, validated mouse monoclonal antibodies against molecular targets found...

  3. Welcome to NIH MedlinePlus, the magazine

    Science.gov (United States)

    ... Past Issues Welcome to NIH Medline Plus , the magazine Past Issues / Summer 2006 Table of Contents For ... MedlinePlus Web site. Your physician has made this magazine available to you as a free health resource; ...

  4. The Zika Virus | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... please turn JavaScript on. Feature: Infectious Diseases The Zika Virus Past Issues / Spring 2016 Table of Contents A ... Photo Courtesy of NIH "You could have a Zika virus vaccine in large-scale clinical trials in 2017, ...

  5. Diabetes Complications | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Diabetes Complications Tailoring Diabetes Treatment to the Patient Past Issues / Fall 2012 ... been reported for the treatment of type 2 diabetes. How was the NIH involved? These are guidelines ...

  6. V. NIH Toolbox Cognition Battery (CB): measuring working memory.

    Science.gov (United States)

    Tulsky, David S; Carlozzi, Noelle E; Chevalier, Nicolas; Espy, Kimberly A; Beaumont, Jennifer L; Mungas, Dan

    2013-08-01

    This chapter focuses on the NIH Toolbox List Sorting Working Memory Test, which was developed to assess processing speed within the NIH Toolbox Cognition Battery (CB). This test is a sequencing task requiring children and adults to process stimuli (presented both visually and auditorily) and sequence the stimuli according to size. We describe the development of the NIH Toolbox List Sorting Working Memory Test, highlighting its utility in children. We examine descriptive data, test-retest reliability, and convergent and discriminant validity. Results indicated that List Sorting performance was positively correlated with age indicating that performance on the task improved throughout childhood and early adolescence. Further, test-retest reliability coefficients were high and there was support for both convergent and discriminant validity. These data suggest that the NIH Toolbox List Sorting Working Memory Test is reliable and shows evidence of construct validity.

  7. Precision Medicine In Action | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: NIH Precision Medicine Initiative Precision Medicine In Action Past Issues / Fall 2015 Table of ... Dishman "I am totally motivated to support precision medicine because I am one of the early prototype ...

  8. Better Lung Cancer Survival? There's an App for That

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_159289.html Better Lung Cancer Survival? There's an App for That Study found ... HealthDay News) -- A new smartphone app may help lung cancer patients live longer and better by monitoring their ...

  9. Only Half of Rectal Cancer Patients Get Recommended Treatment

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158339.html Only Half of Rectal Cancer Patients Get Recommended Treatment: ... therapy for rectal cancer in the United States, only slightly more than half of patients receive it, ...

  10. GRADNJA DOMENSKO SPECIFIČNIH JEZIKOV V PROGRAMSKEM JEZIKU SCALA

    OpenAIRE

    Kokol, Primož

    2012-01-01

    Scala je razmeroma nov, splošno namenski, statično tipiziran programski jezik, ki združuje principe objektnega in funkcijskega programiranja. Predvsem principi funkcijskega programiranja namigujejo na to, da bi omenjen jezik lahko predstavljal dobro alternativo za implementacijo domensko specifičnih jezikov. V sklopu diplomskega dela smo preučili ustreznost omenjenega programskega jezika za implementacijo domensko specifičnih programskih jezikov na primeru jezika FDL (ang. Feature Description...

  11. Latest Research from NIH's National Institute of Dental and Craniofacial Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... engineering, as well as periodontal (gum) disease and tooth decay. NIDCR-supported scientists are designing specialized instruments that ... are focused on comparing DNA from people with tooth decay to those without it to look for genetic ...

  12. Latest Research from NIH's National Institute of Dental and Craniofacial Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... communicate with one another in the plaque or biofilm, the complex community in which they live. Such ... its Centers for Research to Reduce Disparities in Oral Health, NIDCR continues to identify effective and culturally ...

  13. Monitoring of people and workers exposure to the electric, magnetic and electromagnetic fields in an Italian national cancer Institute

    Directory of Open Access Journals (Sweden)

    Palomba Raffaele

    2008-07-01

    Full Text Available Abstract Background The paper reports the electric, magnetic and electromagnetic fields (emf measurements carried out in the Regina Elena National Cancer Institute (NCI. Several devices, used in diagnostics and in medical cures, can represent sources of emf for the workers and for the public subjected to the treatments. The aim is to evaluate their exposition, in order to assess the compliance with the law. Methods The investigations have been carried out in the departments of: intensive care, physiotherapy, MR presstherapy and in the surgical rooms. The measurements have been performed using broad band probes in the frequency ranges 5 Hz÷30 kHz and 100 kHz-3 GHz. Results The variability of the magnetic induction (B(μT levels is between 0,05 μT and 80 μT. The statistical distribution shows that most of the measurements are in the range 0,05 Conclusion The measurement of the emf levels in the NCI is recommended because of the presence of the oncological patients; their long stay near the equipments and their day-long exposure represent additional risk factors for which a prudent avoidance strategy have to de adopted.

  14. ONE STEP NUCLEIC ACID AMPLIFICATION IN BREAST CANCER SENTINEL LYMPH NODE.A SINGLE INSTITUTIONAL EXPERIENCE AND A SHORT REVIEW.

    Directory of Open Access Journals (Sweden)

    Tatiana eBrambilla

    2015-06-01

    Full Text Available Sentinel lymph node (SLN examination is a standard in breast cancer patients, with several methods employed along its 20-years history, the last one represented by OSNA. The latter is a intra-operative molecular assay searching for CK19 mRNA as a surrogate of metastatic cells. Our 3-years experience with OSNA (1122 patients showed results overlapping those recorded in the same Institution with a morphological evaluation (930 patients of SLN. In detail the data of OSNA were almost identical to those observed with standard post-operative procedure in terms of patients with positive SLN (30% and micrometastatic/macrometastatic involvement of SLN (respectively 38-45% and 62-55%. By contrast when OSNA was compared to the standard intra-operatory procedure it was superior in terms of accuracy, prompting the use of this molecular assay as a very valid and reproducible for intra-operative evaluation of SLN.Further possibilities prompting the use of OSNA range from adhesion to quality control programs, saving of medical time, ability to predict, during surgery, additional nodal metatastis and molecular bio-banking.

  15. Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology

    Directory of Open Access Journals (Sweden)

    Aguinaldo Cesar Nardi

    2012-04-01

    Full Text Available OBJECTIVE: To describe the epidemiological features and patterns of initial care for prostate cancer at public and private institutions in the State of Sao Paulo, Brazil. MATERIALS AND METHODS: A total of 1,082 physicians affiliated to the Sao Paulo Section of the Brazilian Society of Urology were invited to participate in this cross-sectional, web-based survey. Between September 2004 and September 2005, participating urologists entered data on demographic, clinical and pathological characteristics of patients diagnosed with prostate cancer in their practice. Data on patients attended at public institutions were analyzed and compared with those patients attended at private practice. RESULTS: One hundred and ten society members contributed with data from 1915 patients, 1026 (53.6% of whom from public institutions. When compared with patients attended at private institutions, those attended at public institutions were older and more likely to be black, had higher serum prostate specific antigen (PSA levels, had a higher probability of being diagnosed with metastatic disease, but were less likely to undergo prostatectomy (all P < 0.001. In multivariate analysis, age, biopsy Gleason score, and being attended at a public institution were independently associated with metastatic disease upon diagnosis. The significant predictors of nonsurgical treatment were age, black race, and higher serum levels of PSA. CONCLUSIONS: A statewide registry provides valuable information regarding patient demographics, clinical features, and patterns of care. The results of this study suggest that significant disparities exist for patients with prostate cancer attended at different health-care systems. The relative contribution of biological versus socioeconomic features remains uncertain.

  16. The NIH Extracellular RNA Communication Consortium

    Directory of Open Access Journals (Sweden)

    Alexandra M. Ainsztein

    2015-08-01

    Full Text Available The Extracellular RNA (exRNA Communication Consortium, funded as an initiative of the NIH Common Fund, represents a consortium of investigators assembled to address the critical issues in the exRNA research arena. The overarching goal is to generate a multi-component community resource for sharing fundamental scientific discoveries, protocols, and innovative tools and technologies. The key initiatives include (a generating a reference catalogue of exRNAs present in body fluids of normal healthy individuals that would facilitate disease diagnosis and therapies, (b defining the fundamental principles of exRNA biogenesis, distribution, uptake, and function, as well as development of molecular tools, technologies, and imaging modalities to enable these studies, (c identifying exRNA biomarkers of disease, (d demonstrating clinical utility of exRNAs as therapeutic agents and developing scalable technologies required for these studies, and (e developing a community resource, the exRNA Atlas, to provide the scientific community access to exRNA data, standardized exRNA protocols, and other useful tools and technologies generated by funded investigators.

  17. Nove konstrukcije velikih montažnih lučnih mostova

    OpenAIRE

    Čandrlić, Vinko; Mrakovčić, Silvija; Skazlić, Marijan

    2003-01-01

    Opisani su konstrukcijski i tehnološki aspekti gradnje velikih lučnih mostova s montažnim odsječcima primjenom betona od reaktivnog praha. Odsječci se izrađuju betoniranjem sukladnih sljubnica, spajaju epoksidnim smolama i potom prednapinju vanjskim čeličnim šipkama samo na dijelu spojnica. Lukovi se izvode zrakastim ovješenjem konzola preko petnih stupova, a grede obostranim potiskivanjem bez klasičnog kljuna s istodobnim postavljanjem stupova s grede i reguliranjem visine nivelete.

  18. PRESOJANJE BONITETE PODJETJA Z UPORABO FINANČNIH IN NEFINANČNIH KAZALNIKOV

    OpenAIRE

    Platovšek, Boštjan

    2010-01-01

    Poznavanje poslovnega partnerja in njegove bonitete je eden ključnih načinov za zmanjševanje informacijske asimetrije ter tveganj, ki izvirajo iz nje. Preverjanje bonitete podjetja postaja poslovna praksa, ki se je izkazala za zelo učinkovito doma in v svetu. Prav tako pomeni mnogo lažji in predvsem hitrejši način dostopa do kakovostnih informacij, ki jih za učinkovito presojo potrebujemo o določenem poslovnem subjektu. S tem zmanjšujemo nepotrebno izgubo časa, energije, volje, interesa za fi...

  19. 75 FR 61157 - National Institute on Aging; Notice of Closed Meetings

    Science.gov (United States)

    2010-10-04

    ...: National Institute on Aging Special Emphasis Panel, Restless Leg Syndrome. Date: November 22, 2010. Time: 1...@nia.nih.gov . (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research,...

  20. 76 FR 16432 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

    Science.gov (United States)

    2011-03-23

    ... review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001... Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/ NIH/DHHS/Neuroscience... to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences,...